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CHAPTER I 
 
 
INTRODUCTION 
 
 
 Endometriosis was first described in the scientific literature in 1860, by Austrian 
pathologist Karl Freiherr von Rokitansky, who referred to the disease in his writings as 
simply "an adenomyoma" (http://www.endocenter.org/womenshealthmarch.html).  It was 
not until 1927 that John Sampson introduced the term “endometriosis,” postulating that 
retrograde menstrual flow transported desquamated endometrial cells into the peritoneal 
cavity, and that viable cells subsequently implanted and grew (1).  His theory has 
remained paramount, however other theories, including coelomic metaplasia, exposure to 
toxins, and genomic alterations, are believed to have roles as well.  Although 
endometriosis has remained an enigmatic disease, there has been an explosion in clinical 
and basic science information in the last five years, with research predominantly in the 
disciplines of genetics, environmental science, cancer biology, and immunology (2).   
 It is likely that heritable genetic factors contribute to the development of 
endometriosis.  Although the genetic risk may be due to a single gene, it is probably due 
to activation of a number of genes, each responsible for a small incremental increase in 
risk (3).  Several large-scale studies aimed at identifying disease susceptibility genes are 
currently underway.  Both the Oxford Endometriosis Gene (OXEGENE) study and an 
Australian collaborative study are using affected sibling pairs and positional cloning 
2 
techniques to identify regions of chromosomes that may harbor susceptibility genes for 
endometriosis (4).   
 The investigation of gene expression in the past has been limited by the inability 
to study more than one gene at a time.  The introduction of deoxyribonucleic acid (DNA) 
microarray technology has made it possible to examine the expression of thousands of 
genes at a time.  Recently, DNA microarray analysis was found to be an effective tool for 
the identification of differentially expressed genes between uterine and ectopic 
endometrium.  This study found that the expression of eight genes, from a total of 4,133 
genes on the DNA microarray, was increased in endometriotic implants compared with 
uterine endometrium (5).  However, no endometrial samples were tested from patients 
who did not have endometriosis.  If the uterine endometrium of patients with 
endometriosis exhibits defective or altered gene expression, which is subsequently 
involved in the ability of endometrial tissue to implant in the abdomen, then this study 
would have missed that gene expression change. 
 Another recent study utilizing DNA microarray technology compared gene 
expression in the eutopic endometrium of women with or without endometriosis.  This 
group utilized a human microarray containing with a total of 9,600 genes.  While a 
difference in gene expression was found between the two types of eutopic endometrium, 
the study did not test any endometriotic tissue (6).  As a result, there is still a need for 
gene expression analysis involving normal eutopic endometrium in women with and 
without endometriosis, as well as of ectopic endometriotic lesions throughout all stages 
of endometriosis.   
 Women with endometriosis have significantly more peritoneal macrophages and 
oviductal macrophages compared to normal fertile controls.  Peritoneal macrophages 
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from women with endometriosis demonstrate increased phagocytosis, secretion of 
cytokines, prostaglandins, growth factors, and enzymes (7).  Peritoneal fluid containing 
immune-related cells is often seen in the vesicouterine cavity or pouch of Douglas during 
gynecologic surgery and bathes the pelvic cavity, uterus, fallopian tubes, and ovaries.  It 
may be a major factor controlling the peritoneal microenvironment, influencing the 
development and progression of endometriosis and endometriosis-associated infertility 
(8).  Peritoneal macrophages have reduced capacity to destroy endometrial cells and 
ectopic endometrial cells have increased resistance to macrophage-mediated cytolysis.  
The many growth factors secreted by macrophages in patients with endometriosis provide 
a vehicle by which endometrial cellular proliferation can be promoted (9).  Peritoneal 
macrophages from women with endometriosis also have increased ability to phagocytize 
and kill normal sperm in vitro, due in part to increased concentrations of nitric oxide 
(NO).  The presence of NO-producing peritoneal macrophages in women with 
endometriosis may be one reason for reduced fertility in this disease (7).  The direct 
effects of peritoneal macrophages on endometriotic implant development and infertility 
have yet to be elucidated.  Examination into the differential gene expression of peritoneal 
macrophages in women who have developed endometriosis versus those who do not 
exhibit disease would assist in increased understanding of macrophage mechanisms of 
action in this disease. 
  
Statement of the Problem 
 
To observe the differences in gene expression in eutopic endometrial tissue and 
normal pelvic peritoneum in women with and without endometriosis, and to observe the 
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differences and/or possible progression in gene expression throughout all four stages of 
endometriosis.   
 
Purpose of the Study 
 
 The purpose of this study was to conduct a more thorough examination of gene 
expression in women with and without endometriosis than has been performed to date.  
This allows for a more complete identification of the genes up-regulated and down-
regulated in the eutopic endometrium and normal pelvic peritoneum of women with 
endometriosis versus those without.   
 
Significance of the Study 
 
The benefits of this study include gaining a deeper knowledge of the genetic basis 
of endometriosis.  Previous studies have already discovered that there is a difference in 
gene expression between normal endometrium and ectopic tissue in women with 
endometriosis, as well as a difference in eutopic endometrium of women with and 
without endometriosis.  This study’s aim was to provide analyses not only on a larger 
scale (i.e. more normal subjects and diseased patients), but also using human cDNA 
microarrays that will allow for inspection of approximately 23,000 genes.  This will 
allow for a greater understanding of how gene expression affects disease expression, 
which may lead to subsequent studies of specific genes that have a role in the 
pathogenesis of endometriosis.   Studies such as this one may help in predicting and 
potentially preventing disease development and/or progression in women with a family 
history of disease and may lead to screening practices for all women.  In addition, this 
5 
information could lead to more specific treatments, including refined surgical procedures, 
pharmaceutical regimens, and other therapies designed for patients suffering from 
endometriosis and associated pelvic pain and infertility. 
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Endometriosis: The Disease 
 
 
What is Endometriosis? 
 
 Endometriosis is defined as the presence of endometrial cells and stroma outside 
the uterine cavity.  It is one of the most common gynecologic diseases, with an incidence 
of approximately 10% to 15% of women of reproductive age (10, 11) and 21% to 44% of 
infertile women (7).  It is observed in up to 25% of all gynecological laparoscopies and 
laparotomies (12). 
 Although the numbers differ among studies, a recent examination of the 
frequency of sites of endometriosis found that the two most common areas were the 
uterosacral ligaments (63%) and the superficial part of the ovary (56%), with less 
incidence involving the ovarian fossae (32.5%), anterior vesical pouch (21.5%), ovarian 
endometriomas (19.5%), pouch of Douglas (18.5%), broad ligament (7.5%), intestines 
(5%), uterus (4.5%), and fallopian tubes/mesosalpinx (4%) (13). 
 It is not possible to know the exact prevalence of endometriosis, as it can only be 
definitively diagnosed via diagnostic laparoscopy.  At this time, prevalence has only been 
assessed based on patient presentation.  This has shown a 7% prevalence in women with 
a first-degree relative with endometriosis, as well as a 15% to 25% prevalence in  infertile 
women (13). One population-based study found a prevalence of 6.2% in the general 
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female population (14), however, other studies have suggested this is low, with anywhere 
from 8% to 15 % of women having the disease.  Its prevalence is considered to be 47% to 
65% in women under age 20 who have chronic pelvic pain and/or dyspareunia (15). 
 
Clinical Presentation of Endometriosis 
 The most common symptoms associated with endometriosis are dysmenorrhea, 
dyspareunia, chronic pelvic pain, and infertility.  There is a poor correlation between 
symptoms and severity of disease; women with extensive endometriosis may be 
asymptomatic and their endometriosis found incidentally upon laparoscopic surgery for 
infertility or another issue.  In the same fashion, women with minimal or mild disease 
may present with severe symptoms (10).   
 Symptoms of endometriosis have been associated with the location of 
endometriotic lesions.  Dysmenorrhea, lower abdominal, pelvic and back pain, 
dyspareunia, infertility, menstrual irregularity, and acute pelvic pain due to rupture or 
torsion of an endometrioma can all be associated with endometriotic implants in the 
female reproductive tract.  Endometriosis in the gastrointestinal tract can be associated 
with cyclical tenesmus, rectal bleeding, diarrhea, and colonic obstruction.  Cyclical 
hematuria and pain, as well as ureteral obstruction have been linked with endometriosis 
within the urinary tract.  Pain and bleeding in surgical scars and in the umbilicus, as well 
as hemoptysis of the lung in a cyclical fashion have all been symptoms of endometriosis 
within those regions (13).  
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Types of Endometriosis 
 Over fifteen laparoscopic appearances of peritoneal endometriosis have been 
described, including classical, vesicular, popular, hemorrhagic, nodular, and healed 
implants, with histologic studies leading to three further subdivisions: free, enclosed, and 
healed implants (13).   According to the most recent correspondence on the American 
Society of Reproductive Medicine (ASRM) classification system, the morphology of 
peritoneal and ovarian lesions should be categorized as red (red, red-pink, and clear 
lesions), white (white, yellow-brown, and peritoneal defects), or black (black and blue 
lesions) (16).   
 Red lesions are more active forms of disease.  Red lesions demonstrate an 
increased level of vascularization, caused by a larger number of larger vessels.  White 
lesions have a greater number of smaller vessels, including an increased number of 
capillaries as compared to red lesions.  Red, flame-like lesions are theorized to be 
representative of an early stage of endometriotic implantation.  Menstrual shedding from 
viable implants could initiate an inflammatory reaction and the scarification process.  The 
implant is subsequently enclosed and the presence of intraluminal debris leads to the 
typical blue or black coloration.  Sometimes these lesions encase bleeding tissue, which 
can contribute a brown pigment as well.  If the lesions are puckered, they may represent a 
combination of glands, stroma, and luminal debris (17).  The black lesions were at one 
time considered the premier visual indication of endometriosis, due to older studies 
characterizing endometriosis as a disease of women in their mid-to-late thirties, which is 
when this stage of lesion is most typically found (18). The inflammatory process 
continues and devascularizes the implant, and white plaques of old collagen remain.  
White lesions typically represent a latent stage of endometriosis that is non-active (17).  
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 Another category of endometriosis frequently referenced in the literature is an 
endometrioma or chocolate cyst.  An endometrioma is an endometriotic cyst of the ovary.  
The term “chocolate cyst” developed due to the dark brown/chocolate-colored contents of 
these ovarian cysts when aspirated during laparoscopic surgery (13) or via ovarioscopy 
(19).  Cystic ovarian endometriosis is often hard to distinguish from a corpus luteum cyst.  
One method of distinguishing them, alongside visualizing the contents of the cyst, is 
recognition of adhesions.  Endometriotic ovarian cysts typically have associated 
adhesions, especially in the ovarian fossa, whereas a corpus luteum cyst typically does 
not (19).  
 
ASRM Classification 
 Several classification schemes have been developed over the years to categorize 
the severity of endometriosis.  As early as 1921, Sampson classified endometriosis by 
modifying a system used to categorize hemorrhagic cysts of the ovary.  A method 
developed by MJ Wicks and CP Larson in 1949, borrowed from a system Broder used to 
stage malignancy, classified lesions as Grade I-IV, based upon histologic examination of 
excised lesions (20).  Linking endometriosis with malignancy, however, led to a 
treatment of hysterectomy with bilateral salpingo-oophorectomy for the majority of 
patients, including adolescents and teenage women (21). 
 Until the 1970’s, no other system was proposed for classifying endometriosis 
(21).  During that time, a few systems were put forward, including Acosta’s, which 
classified endometriosis into mild, moderate, and severe categories based upon site of 
lesions, presence of adhesions, and presence of scarring (13, 21, 22).  Another system, 
developed by Kistner in 1977, incorporated progression of endometriotic disease (13, 21, 
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23).  This was followed by Buttram’s classification, which was considered to be an 
expanded version of Acosta's, and graded patients by peritoneal, ovarian, tubal, and cul-
de-sac involvement (21, 24).  While Acosta’s system had seemed too vague, Buttram’s 
was considered too complicated, therefore another system was proposed by Cohen which 
divided severity into ten states based on laparoscopic findings, including distant organ 
involvement, adenomyosis, and pelvic inflammatory disease (21, 25). 
 The American Fertility Society (AFS, renamed the American Society for 
Reproductive Medicine in 1995) formed a committee to establish a classification system 
for endometriosis in 1978.  A revised version of this classification, published in 1996, is 
the classification system currently utilized by obstetricians and gynecologists.  The 
ASRM classification enables a physician to determine the stage of endometriosis utilizing 
a weighted point system.  Endometriosis, posterior cul-de-sac obliteration, and adhesions 
are evaluated visually and then assigned points based on superficial or deep involvement 
of the peritoneum and/or ovaries (endometriosis), partial or complete obliteration 
(posterior cul-de-sac), and filmy or dense enclosure of the ovaries or fallopian tubes 
(adhesions).  The appearance of superficial implants is also recorded as red, white, or 
black, with the percents of each determined and equaling 100%.  Endometriosis 
visualized in other locations is recorded under “additional endometriosis,” and other 
pathology documented under “associated pathology” with accompanying sketches.  The 
accumulation of all points will determine the stage of endometriosis, with the point 
distributions as follows: Stage I (Minimal), 1-5; Stage II (Mild), 6-15; Stage III 
(Moderate), 16-40; and Stage IV (Severe), >40 (16).  
 Criticism of the ASRM classification system has included arbitrariness in both the 
assignment of points, depending upon the location of an endometriotic lesion, as well as 
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in the lack of distinguishing characteristics between stages.  It is also very important that 
physicians staging endometriosis have experience in utilizing the system and are 
consistent in their diagnoses.  Reproducibility has been questioned and examined, 
looking at both intraobserver and interobserver variability in staging endometriosis.  Prior 
to the most recently revised ASRM classification of endometriosis, a study looking at the 
reproducibility of the 1985 revised AFS endometriosis classification system found a fair 
to good reproducibility (κ = 0.44) that was statistically significant (p < 0.01), when 
comparing assignments to disease stage made by investigators followed by blinded 
reviewers (26). 
 Another, more recent study examined the reproducibility of the revised AFS 
classification scheme when a physician scored the same patient twice, first by 
laparoscopy and then laparotomically during the next cycle.  The inter-method variation 
altered endometriosis staging in 34.5% of patients, with 3.6% of patients’ changed by two 
stages.  The kappa coefficient indicated fair-to-good agreement between the two scoring 
methods (κ = 0.49).  The predominant area of variability in scoring involved the ovaries, 
and this was believed to be due to assessment of some small endometriomas as ovarian 
cysts (27).   
 The correlation between histologic and visual diagnosis has also been 
investigated.  Of 44 patients evaluated, visual AFS scores were an average of 4.0 points 
higher than histologic scores, with the visually-determined stage being higher in 36% 
(16) of patients, including 12 whose diagnoses were downgraded from stage I, II, or III to 
zero (28).   
 A better classification system for endometriosis is needed.  Incorporating factors 
beyond visual assessment of the disease will be beneficial in designing a system that can 
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better delineate between stages of the disease and help in guiding treatment.  Revisions to 
the revised ASRM classification are anticipated as our knowledge of endometriotic 
disease and its relationship to pelvic pain and infertility expands (21).  
 
Tissues within which Endometriosis Has Been Found 
  Endometriosis has been classified as direct/internal/endometriosis interna or 
indirect/external/endometriosis externa (13, 29).  In regard to external endometriosis, this 
category has been further classified into pelvic and extrapelvic.  Pelvic endometriosis 
consists of endometriosis found on the uterus, fallopian tubes, ovaries, and pelvic 
peritoneum (anterior and posterior cul-de-sacs and pelvic side walls).  Extrapelvic 
endometriosis refers to the presence of endometriotic tissue anywhere else (29).  
 Endometriosis has been documented in almost every organ system and tissue in 
the body.  Endometriosis has been found in the central nervous system (CNS), lungs, 
pleura, heart, diaphragm, gallbladder, liver, small bowel, appendix, colon, rectum, 
kidney, bladder, ureter, bone, biceps muscle, and the sciatic nerve (29, 30).  In addition, 
endometriosis has been found in the umbilicus, abdominal wall incisions, including 
Cesarean section scars, and episiotomy scars (13, 29).   
 The gastrointestinal tract is the most common site for extrapelvic endometriosis.  
Women in their thirties are most commonly affected; however, gastrointestinal 
endometriosis is usually asymptomatic and considered to be clinically unimportant.  The 
rectum and the sigmoid colon are the most common sites, representing up to 95% of 
cases.  The appendix is involved 5-20% of the time, and the small bowel is implicated in 
less than 5% of cases, with the terminal ileum being the most common site.  
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Endometriosis of the transverse colon is rare, as is that of the gallbladder, liver, and 
pancreas (29).   
 Urinary tract endometriosis was first published in 1921, and only a few hundred 
cases have been reported since.  One to four percent of women with pelvic endometriosis 
have urinary tract endometriosis too.  Major morbidity includes functional loss of the 
kidney, if endometriosis obstructs a ureter.  The bladder is the most common site of 
urinary tract endometriosis, comprising 80-90% of cases.  Renal endometriosis is rare, 
with less than a dozen cases reported, as is urethral endometriosis.  Typically, unilateral 
disease is found, with the left side more often than the right, although bilateral disease 
does occur (29).   
 Just over one hundred cases of thoracic endometriosis have been reported.  Fifty 
to eighty percent of women with thoracic endometriosis also have pelvic endometriosis.  
Thoracic endometriotic lesions are usually solitary and involve the pleura or the lung 
parenchyma.  The right side is implicated more often than the left (9:1), however bilateral 
diagnoses have been reported.  Signs and symptoms of thoracic endometriosis include 
pneumothorax, followed by hemothorax, hemoptysis, or an asymptomatic lung nodule, 
with concurrent chest pain.  Unlike other forms of pulmonary pathology, the signs and 
symptoms of endometriosis in the thoracic area are generally cyclical, occurring within 
24 to 48 hours of the onset of menses, and the lesions enlarge at this time (29).   
 Extrapelvic endometriosis has also been found in other tissues of the body, most 
commonly in cutaneous tissues, but also in the central and peripheral nervous systems, as 
well as isolated cases in bone and skeletal muscle.  Cutaneous development of 
endometriosis is frequently at sites of previous abdominal operations, with signs and 
symptoms beginning six months to a few years after surgery.  Endometriosis in Cesarean 
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section scars and episiotomy scars has also been found, as well as in the inguinal area, 
labia, perineum, and vagina.  Umbilical endometriosis has developed de novo, as well as 
following laparoscopic tubal ligation.  Endometriotic lesions have also been found in 
abdominal wall trocar tracts, and the incidence of this is expected to grow with increased 
use of laparoscopic surgical techniques.  In addition, endometriosis has been found in an 
amniocentesis needle tract.  Signs and symptoms of cutaneous endometriosis include a 
slowly growing, tender mass that may increase in size and pain during menses.  Cyclical 
bleeding at the site of the lesion may also be present (13, 29). 
 In addition to extrapelvic endometriosis, endometriotic lesions have also been 
found in men.  Although the pathogenesis remains unexplained, all cases have involved 
men with prostate cancer being treated with excessive estrogen therapy.  Endometriosis 
has been found on the right side of the bladder, between the trigone and the domes, on the 
left side of the trigone, and obstructing the right ureter at the right ureterovesical junction, 
producing moderate hydronephros.  Although none of these lesions were found near the 
prostatic utricle, which alongside the appendices testes is considered to be a remnant of 
the mullerian duct in men.  It is believed, however, that some vestigial endometrial 
glands may persist in males (31). 
 
Methods of Diagnosing Endometriosis and Diagnostic Delay 
 The “gold standard” for diagnosing endometriosis is visualization by laparoscopy 
(32).  There is no question that the development of a laboratory test to diagnose 
endometriosis would be invaluable.  Great efforts have been made to discover a non-
invasive method of diagnosis, such as a serum marker.  One example is cancer antigen-
125 (CA-125), which is present in fetal coelomic epithelium and its derivatives such as 
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pleura, pericardium, peritoneum, ovarian surface epithelium, and mullerian ducts after 15 
weeks’ gestation.  It becomes strongly positive in mullerian-derived epithelia of adult, 
such as tubal, endometrial, and endocervical epithelium (33).  Serum interleukin-6 (IL-6) 
and peritoneal fluid tumor necrosis factor-alpha have also been shown, preliminarily, to 
discriminate between women with and without endometriosis (34). 
 A major problem in endometriosis is diagnostic delay.  Studies surveying the 
United States, United Kingdom, and Norway have found that there is considerable delay 
in the diagnosis of endometriosis.  It is estimated that 27% of U.S. women diagnosed 
with endometriosis have had symptoms for over 6 years (13).   
 
Pharmaceutical and Surgical Treatment of Endometriosis 
 Oral contraceptive pills are typically the first-line agent utilized in treating pelvic 
pain suspected of being endometriosis.  Although oral contraceptives have been promoted 
as a possible means of protection from endometriosis, if they are used noncontinuously 
and menstruation is allowed to occur, then blood would still be retrograded into the 
pelvis.  Therefore, continuous administration may be necessary to truly provide 
protection (35).  Oral medroxyprogesterone acetate (Provera) is the most common 
progestational agent used to treat endometriosis, with typical doses up to 50-100 
milligrams per day (36).  GnRH agonists, available in the United States since 1985, 
include leuprolide acetate (Lupron), nafarelin acetate (Synarel), and goserelin acetate 
(Zoladex) (37).  They facilitate the healing process by hormonal inactivation of 
endometriotic tissue.  Another pharmaceutical method of treating endometriosis is 
danazol, which suppresses pituitary secretion of gonadotropins and inhibits ovulation, but 
has a high incidence of side effects including weight gain, hirsutism, liver damage, and 
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irreversible voice deepening (36, 38).  A couple of prospective treatments include 
aromatase inhibitors and pentoxifyllin, an anti-tumor necrosis factor therapy (38, 39). 
 Surgical treatment of endometriosis can be conducted on many levels, including 
minimalistic, conservative, semi-conservative, radical, or definitive.  Laparoscopic 
surgical treatment may include bipolar or thermal coagulation and vaporization, excision 
of lesions with a carbon dioxide laser or unipolar knife, presacral neurectomy, and uterine 
nerve ablation (40). 
 From 1988-1993, 214,059 hysterectomies were performed in the United States on 
women 25-29 years old, including 64,883 performed for the primary diagnosis of 
endometriosis (41).  Hysterectomy with or without bilateral salpingoophorectomy is often 
reserved for those patients with intractable pain who have failed medical and 
conservative surgical therapies.  Typically, patients choose this type of procedure only 
after childbearing has been completed.  However, some women must make such a choice 
at a young age in hope of permanent cure (41). 
 
Theories of Disease Pathogenesis 
 
 Numerous theories have been proposed to explain the pathogenesis of 
endometriosis.  Some hypotheses are based on endometriotic tissue originating from the 
eutopic endometrium, while others are based on tissue originating from somewhere else.  
The most popular theory, implantation following retrograde menstruation, was proposed 
by Sampson in the 1920s (42).  According to this hypothesis, endometriosis is established 
during retrograde menstruation, when menstrual fragments flow out of the fimbriated 
ends of the fallopian tubes and implant on the ovary and other peritoneal sites.  Internal 
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bleeding in ovarian lesions can result in chocolate cysts.  Repeated retrograde 
menstruation can lead to the spread of numerous endometriotic implants throughout the 
pelvic cavity.  Endometriotic lesions are presumed to bleed periodically and stimulate 
inflammatory processes that lead to adhesions between the uterus, ovaries, and pelvic 
viscera.  These lesions regress during menopause and the condition is generally 
considered to be an estrogen-dependent disease.   
 Other theories assuming the origin of endometriotic tissue to be eutopic 
endometrial cells, include the direct-extension theory, the benign metastasis theory, the 
uterotubal theory, and mechanical transplantation.  The Wolffian duct theory, the 
Mullerian duct theory, the coelomic metaplasia theory, the hormonal stimulation theory, 
and the induction phenomenon theory are all based on the endometriosis developing from 
tissues other than eutopic endometrium (43). 
 
 
Retrograde Menstruation 
 
Retrograde menstruation involves the reflux of endometrial tissue through the 
fallopian tubes during menstruation and subsequently implanting on the pelvic organs 
and/or the peritoneum.  Three assumptions are necessary to support this theory.  First, 
retrograde menstruation occurs.  Second, upon being refluxed through the fallopian tubes, 
endometrial cells are viable in the peritoneal cavity.  Lastly, endometrial cells refluxed 
through the fallopian tubes have the ability to adhere to the peritoneum and then invade, 
implant, and proliferate (44).  In a study by Halme et al., 90% of normal and infertile 
women were found to have blood in their peritoneal fluid during the perimenstrual (days 
one to six or 27 to 30) portion of their menstrual cycle (35). 
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However, arguments have been made against Sampson’s theory.  Redwine 
compared the implantation of endometrial cells following retrograde menstruation, with 
other types of autotransplants.  He found that endometriotic tissue is not the same as 
eutopic endometrium, therefore, it lacks characteristics of an autotransplant.  He further 
stated that studies of experimental endometriosis that have not used menstrual 
endometrium may be misleading (45).   In an editorial follow-up to this study, Guo 
critiqued Redwine’s conclusions on several counts.  Guo felt that the differences found 
between eutopic and ectopic endometrium could be due to changes experienced by cells 
that have successfully implanted and undergone subsequent clonal expansion and 
inflammation.  He also criticized Redwine’s dismissal of endometrial cell damage within 
the fallopian tube, stating that due to the enormous turnover of cells due to monthly 
shedding, it is certainly possible for genomic alterations of cells to occur that might 
enable cells to implant and lead to endometriosis.  Guo referred to the loss of 
heterozygosity and other genomic alterations that have been found in the cells of 
endometriotic implants (46). 
 
Coelomic Metaplasia 
The notion that “endometrium begets endometriosis” has been used to support the 
retrograde menstruation and transplantation theory of endometriotic pathogenesis.  
However, a case involving the discovery of ovarian and tubal endometriosis in a 26-year-
old woman without the presence of eutopic endometrium has been reported (47).  A 
similar situation was seen in a young girl in whom endometriosis was found developing 
within the left cornu of a bicornuate uterus, but associated pelvic pain had been 
experienced in a cyclical nature eight months prior to menarche (48). 
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The coelomic metaplasia theory was introduced at the turn of the century by 
Iwanoff and Meyer (13, 44, 49).  It proposed that endometriosis develops from 
metaplasia of cells that line the pelvic peritoneum (13, 49).  The development of 
endometriosis in men is typically thought of as proof of the coelomic metaplasia theory.  
However, the men within which endometriosis was found were undergoing estrogen 
therapy, and the possibility of estrogen stimulation of müllerian rests cannot be excluded.  
Pleural endometriosis could result from local metaplasia of pleural mesothelium, but it 
might result from transdiaphragmatic passage of endometrial fragments (44).  If this 
theory is correct, metaplasia should occur in other regions where coelomic membranes 
are present, and an increased frequency would be expected with aging (13, 44).  
However, endometriotic disease is typically present in women of reproductive age, with a 
dramatic decrease in prevalence as women become postmenopausal (13).  Therefore, 
proof of the coelomic metaplasia theory is inconclusive (44).   
Endometriosis found in the extremities has also been cited in support of the 
coelomic metaplasia theory of endometriosis.  Misintegration of coelomic membrane-
related cells into the limb buds has been proposed, due to the fact that mesenchymal limb 
buds develop next to coelomic epithelium during early embryogenesis.  These cells could 
then be stimulated by ovarian steroids and develop into endometriosis (49). 
 
Induction Theory 
 The induction theory is an extension of the coelomic metaplasia theory.  It was 
introduced by Levander and Normann in 1955 (50).  This theory proposes that 
endogenous biochemical or immunologic factors of menstrual effluent can induce 
undifferentiated cells to differentiate into endometrial tissue (44, 51).     
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Embryonic Rest Theory 
 
Von Recklinghausen and Russell introduced the embryonic rest theory in the 
1890s.  The embryonic rest theory proposed that cell rests of müllerian origin could be 
activated to differentiate into endometrium in the presence of a specific stimulus.  The 
transformation of embryonic rests is considered to be a possible explanation for the rare 
cases of endometriosis reported in males (44). 
 
 
Lymphatic and Vascular Metastasis Theories 
The theory that endometriosis could result from lymphatic and hematogenous 
dissemination of endometrial cells was proposed by Halban and Sampson in the 1920s.  It 
had been found that endometrial cells could metastasize via lymphatic and hematogenous 
routes (44).  In an original communication by Sampson, he wrote: 
“Could bits of endometrial tissue escape into the venous 
circulation from the mucosa lining the uterine cavity by any other means 
than as a result of a menstrual reaction? . . . We could also understand that 
a similar endometrial lesion might rupture into an adjoining lymph vessel 
or capillary during its reaction to menstruation . . . I can see only one 
correct interpretation of the etiology of the embolic endometrial lesions in 
the veins about these endometrial cavities and that is they arose from the 
implantation of endometrial tissue, disseminated into the veins from the 
menstrual rupture of the walls of the endometrial cavities into these 
vessels”  (42). 
 
 Metastasis of endometrial cells through the lymphatic system to distant areas, 
such as pleura, umbilicus, retroperitoneal space, lower extremity, vagina, and cervix is 
anatomically possible because of communication of lymphatics among these structures.  
Lymphatic or vascular metastasis could explain rare cases of endometriosis that have 
been reported in bone, muscle, brain, nerve, lung parenchyma, vertebral space, and 
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extremities (44).  Lymphatic spread has also been thought to explain the presence of 
endometriosis in lymph nodes (33). 
 
Iatrogenic Dissemination 
 Endometriosis has developed due to iatrogenic transplantation of endometrial 
cells during gynecologic surgeries and obstetrical procedures.  It has been found in 
abdominal wall scars after Cesarean sections, myomectomies, and hysterectomies, as 
well as within episiotomy scars (13).   
 
 
Steps in Pathogenesis 
 
 
 The steps involved in the pathogenesis of peritoneal endometriotic implants 
include: (1) attachment of endometrial cells to peritoneal surface; (2) invasion of 
endometrial cells into mesothelium; (3) angiogenesis around nascent endometriotic 
implants; (4) endometrial cell proliferation; and (5) recruitment of inflammatory cells 
subservient to the implant (44, 52). 
 
 
Relationship between Endometriosis and other Disease 
 
 
Autoimmune disease   
 The presence of endometriotic tissue has long been thought to involved 
disruptions in the immune system or surveillance.  One study, conducted by the 
Endometriosis Association looked at the rates of comorbidities of autoimmune, 
endocrine, and chronic fatigue or pain states in women with surgically diagnosed 
endometriosis.  Of the 3680 respondents included in the analyses, approximately 20% 
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had at least one co-existing disease.  The percentage of women with endometriosis with 
certain disorders versus the estimated prevalence of these disorders in the general U.S. 
female population were as follows:  Systemic lupus erythematosus (0.8 versus 0.04%), 
multiple sclerosis (0.5 versus 0.07%), rheumatoid arthritis (1.8 versus 1.2%), Sjogren’s 
syndrome (0.6 versus 0.03%), hypothyroidism (9.6 versus 1.5%), fibromyalgia (5.9 
versus 3.4%), and chronic fatigue syndrome (4.6 versus 0.03%).  All percentages were 
greater in women with endometriosis at a high level of significance (p < 0.0001), except 
for rheumatoid arthritis (p = 0.001) (53). 
 
Cancer   
 Sampson hypothesized that endometriosis sometimes undergoes malignant 
change.  Although usually benign, endometriosis exhibits some characteristics 
reminiscent of malignancy, including local invasion and metastases.  Endometriosis and 
ovarian cancer share many risk factors, including early menarche, regular periods, shorter 
cycle lengths, and lower parity.  There have been a number of studies investigating the 
association between endometriosis and ovarian cancer (54-58).   
 One of the most common sites of endometriosis is the ovary.  The first molecular 
genetic evidence that at least a subset of endometriotic lesions may be premalignant came 
from an analysis for loss of heterozygosity (LOH) at candidate tumor-suppressor gene 
loci in a series of 40 endometriosis cases.  Fifteen microsatellite markers were used to 
detect LOH for chromosome regions 6q, 9p, 11q, 17p, 17q, and 22q.  These regions were 
selected because they were thought to harbor tumor-suppressor genes involved in the 
development of ovarian and other epithelial cancers.  Eleven of 40 cases (27.5%) 
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demonstrated LOH of 9p, 11q, and 22q.  In the endometrioid ovarian carcinomas, LOH 
was seen on 6q, 9p, 11q, 17p, 17q, and 22q (12). 
  A follow-up to this study analyzed genetic alterations present in endometriosis 
synchronous with ovarian cancer, to determine whether cancer had arisen de novo or by 
clonal expansion from endometriosis.  Fourteen cases of ovarian endometriosis 
synchronous with ovarian carcinoma were analyzed.  LOH analysis was performed using 
25 microsatellite markers for chromosome regions 2q, 4q, 5p, 5q, 6q, 7p, 9p, 11q, 17p, 
17q, 22q, and Xq.  Five of seven cases with carcinoma adjacent to endometriosis 
displayed common LOH events.  All four cases with carcinoma arising within an 
endometriotic cyst displayed at least two LOH events in common.  None of the three 
cases where endometriosis and cancer were from contralateral ovaries displayed any 
common LOH.  LOH was only detected for 5q, 9p, 11q, and 22q among solitary 
endometriosis cases.  LOH was also detected at these loci in the endometriosis cases with 
associated carcinoma.  The chromosome regions showing the highest LOH frequency 
among endometriosis cases (5q, 9p, 11q, 22q) were among the most frequent LOH 
regions in low-grade and early-stage endometrioid ovarian cancer.  This data was 
considered support for the view that endometriosis could undergo malignant 
transformation and implied that tumor-suppressor gene alterations are likely to be 
involved in the proliferation and maintenance of endometriotic implants (59). 
 
 
Endometriosis and the Peritoneal Environment 
 
 
 Mechanisms must exist that promote endometrial cell adhesion to the peritoneum 
and their subsequent survival and proliferation.  Shed endometrial cells are removed by 
immune cells in the peritoneal cavity (e.g. macrophages).  The fate of endometrial cells 
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that elude this process may be modulated by adhesion molecules expressed on their cell 
surface.  Adhesion could also be favored if the peritoneal surface is damaged by trauma, 
low-grade inflammation, infection, or excessive retrograde menstruation.  However, 
small implants are now considered a variant of normal physiological processes.  For these 
to progress to endometriosis, they must undergo cellular modification, growth, and 
vascularization, all of which are promoted by hormones, growth factors, and cytokines 
(4). 
 Macrophages constitute 85% of the cells in the peritoneal fluid.  Their number 
and level of activation varies over the course of the menstrual cycle, with a maximum in 
the post-menstrual period for removal from the peritoneal cavity of endometrial debris, 
spermatozoa, and follicular cells.  In endometriosis patients, peritoneal macrophages are 
more numerous and have a higher level of activation (60). 
 The peritoneal fluid of endometriosis patients contains chemotactic cytokines, 
originating from T-cells, macrophages, mesothelial cells, and ectopic endometrium.  The 
endometrium of endometriosis patients liberates only small amounts of cytokines that 
regulate the activation of macrophages, in contrast to the endometrium of unaffected 
women.  The cytotoxicity of peritoneal macrophages in endometriosis patients with 
respect to the endometrium is reduced which could be more significant than that of the 
circulating macrophages.  The alteration of the cytotoxicity could be specific to the 
endometrium be it eutopic or ectopic, since the macrophages of endometriosis patients 
normally destroy the usual target cells of macrophages (60). 
 Macrophages are primarily responsible for the phagocytosis of cellular debris, 
including sperm, in the pelvis.  In a study by Muscato et al. (61), peritoneal macrophages 
phagocytized sperm in vitro and were more active in women with endometriosis than 
25 
those in women without the disease.  Therefore, peritoneal fluid diffusing into the tubal 
and endometrial environment may affect sperm and their interaction with the oocyte (8).   
 Freshly isolated peritoneal macrophages from infertile women with 
endometriosis, compared to those from normal fertile women, have higher nitric oxide 
synthase (NOS) activity and produce more nitric oxide (NO) in vitro (7).  A strong 
correlation has been found between the number of peritoneal macrophages in 
endometriosis patients and the total amount of peritoneal fluid NO.  In addition to 
increased peritoneal fluid volume and macrophage number, women with endometriosis 
have significantly more oviductal macrophages than women without endometriosis.  The 
oviduct lumen is contiguous with the peritoneal cavity, and peritoneal macrophages in 
endometriosis emigrate into the oviducts, resulting in elevated numbers of oviductal 
macrophages (7).   
The presence of NO-producing peritoneal macrophages in the oviducts of women 
with endometriosis may be a reason for reduced fertility in the disease.  At low 
concentrations, NO enhances sperm motility and capacitation.  High concentrations of 
NO inhibit sperm motility, respiration, and viability.  NO may also display toxic effects 
on the oocyte and embryo.  Low levels are important in ovarian function and 
implantation and cause relaxation of oviduct muscles.  Development of both murine and 
bovine embryos in vitro is inhibited by high levels of NO.  In addition to its effects on 
reproduction, peritoneal NO may serve as a mediator of inflammation and be a major 
determinant of the sterile peritoneal inflammation seen in women with endometriosis (7).  
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Genetic Studies involving Endometriosis 
 
 Since the 1940s, published reports have recorded multiple affected relatives with 
endometriosis, often suggesting genetic tendencies.  Epidemiological findings have 
shown familial tendency with increased risk (6.9%) and severity of endometriosis in first 
degree relatives of probands (62).  Studies of twins have also suggested that 
endometriosis may have a genetic basis, including a recent study on 3,096 twin sister 
pairs, 215 of whom reported endometriosis, a prevalence rate of 0.07.  In addition, 
concordance in monozygotic twins exceeded that in dizygotic twins by a factor of 2 (63).  
However, until genetic markers are determined, it is difficult to counsel individuals that 
have a first-degree relative with endometriosis.   
 Two forms of genetic mutations are germ line and somatic.  Germ line mutations 
are inherited mutations affecting all cells, while somatic mutations involve genetic 
damage due to extrinsic or intrinsic factors, which may be exacerbated by inherited 
mutations.  Somatic mutations affect only one cell type.  Molecular genetic defects in 
endometriosis do not affect all cells, therefore, endometriosis is believed to be the result 
of somatic cell damage (64).   
 
Polymorphism Studies 
 Several polymorphism studies have been done within the last decade involving 
endometriosis.  In 2001, an analysis of the human arylhydrocarbon receptor repressor 
(AHRR) gene polymorphism was performed.  Although a novel polymorphism was 
found, involving a substitution of alanine by proline at codon 185 in exon 5 of the AHRR 
gene, no significant difference in the frequency of genotypes or alleles was observed 
between women with and women without endometriosis.  In addition, differences in the 
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frequencies of genotypes for the arylhydrocarbon receptor (AHR), as well as differences 
in allelic frequencies of known single nucleotide polymorphisms in AHR, aryl 
hydrocarbon receptor nuclear translocator (ARNT), and the cytochrome P450IA1 
(CYP1A1) promoter were examined in women with and without endometriosis, with no 
significant differences found.  The researchers felt that a subsequent study with a larger 
group of subjects would be necessary to determine whether polymorphisms within the 
AHR gene or the AHRR gene affect susceptibility to endometriosis (65). 
 Another group studied the p53 codon 72 polymorphism in Chinese women.  They 
examined the distributions of p53 polymorphisms in women with and without 
endometriosis finding that the p53 polymorphisms differed significantly between groups 
(p < 0.001).  In women with endometriosis, Arg/Arg homozygotes were represented in 
10.2% of the population, with Pro/Pro being 22.9%, and Arg/Pro 66.9%.  This differed 
from women without endometriosis, with 30.7%, 19.3%, and 50%, respectively.  The Arg 
polymorphism was more common in normal women versus more Pro homozygotes and 
heterozygotes among the women with endometriosis.  The researchers believed that p53 
polymorphisms might be a useful marker in predicting endometriosis development, since, 
based on their study population, the odds that a woman with Arg/Pro or Pro/Pro will 
experience endometriosis was 3.9 times greater than that of a woman with the Arg/Arg 
genotype (66).  
 Recently, a second group examined the prevalence of p53 codon 72 
polymorphisms in a Japanese population.  The frequencies of the Arg/Arg, Arg/Pro, and 
Pro/Pro genotypes in endometriosis versus controls were 35.2% vs. 39.4%, 48.6% vs. 
41.7%, and 16.2% vs. 18.9% indicating no significant difference in the frequency of p53 
codon 72 polymorphisms.  Upon examining a subgroup of women with stage IV disease 
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only, the ratios for Arg/Arg, Arg/Pro, Pro/Pro, and Arg/Pro or Pro/Pro in endometriosis 
versus controls was, 30.4% vs. 39.4%, 52.3% vs. 41.7%, 13.6% vs. 18.9%, and 65.9% vs. 
60.6%, respectively, also showing no significant difference (67). 
 Wieser et al. (68) investigated the frequency of a 306-base pair insertion of the 
PV/HS-1 Alu subfamily in intron G of the progesterone receptor (PR) gene 
polymorphism PROGINS in women with and without endometriosis.  The distribution of 
genotype frequencies was found to differ significantly in women with versus those 
without endometriosis.  Women with endometriosis were found to have an increased 
frequency of the mutant allele (T2).  The receptor changes caused by the PROGINS 
mutation may affect ligand and hormone binding and lead to insufficient regulation of 
estrogen receptor-driven proliferation.  The authors stated that these results supported the 
theory of estrogen over-activation in endometriosis and suggested that PROGINS is 
associated with endometriosis in white women (68).  
 A group examined a common NOS polymorphism (a G→T substitution at 
nucleotide position 894, resulting in a change from Glu to Asp) and its potential 
association with endometriosis.  The frequencies of the TG and TT genotypes were found 
to be significantly higher in women with endometriosis than in normal women, 87.2% 
versus 23%, respectively (p < 0.001).  In addition, the frequency of the T allele was 
higher in endometriosis compared with the controls (63.8% versus 22.5%, p < 0.001).  
The authors found a 10-fold increased risk of developing endometriosis in patients 
possessing the mutant T allele (69). 
 The androgen receptor (AR) gene has a polymorphic cytosine, adenine, and 
guanine (CAG) microsatellite in exon 1 that codes for variable length glutamine repeats 
in the amino-terminal domain of the AR protein.  In 2001, Hsieh et al. examined the 
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distribution of CAG repeats in 110 Chinese women with endometriosis versus 99 Chinese 
women without endometriosis.  They found that women possessing one allele of 
genotype M (21 CAG repeats) had a statistically significant greater risk of developing 
endometriosis compared to women not possessing that genotype (p = 0.007).  The 
primary genotype found in women without endometriosis was genotype L (20 repeats), 
although CAG repeats ranged from 9 repeats (genotype A) to 31 repeats (genotype W).  
The researchers believed that an AR gene polymorphism likely contributes to the 
pathogenesis of endometriosis, considering the AR protein is present in the endometrial 
tissue and pelvic organs, has been detected in endometriosis, adenomyosis, and 
endometrial carcinoma, and plays a role in modulating the cyclic change of the 
endometrium.  The 21-CAG repeat polymorphism may be a variation of the AR gene that 
is involved in the formation of endometriosis (70). 
 A more recent study examined AR CAG polymorphisms in white Italian women.  
AR CAG length was analyzed in 105 women with endometriosis and 92 women without 
endometriosis (71).  The number of repeats ranged from eight to 27 in the women with 
endometriosis and 11 to 27 in the control group, and therefore did not differ significantly 
(p = 0.53).  Upon analyzing the endometriosis group’s alleles based on stage of 
endometriosis, superficial and deep peritoneal implants, number of endometriomas, and 
adhesion scores, there were still no significant differences found based upon variables of 
severe disease.  The difference in results between this study and that of Hsieh et al. may 
be due to differences in the AR gene locus between Asian and white populations.  The 
researchers felt that AR CAG repeats might differently influence the development of 
endometriosis in different ethnic groups.  Therefore, they believed more studies need to 
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be done involving different ethnic groups and utilizing specific endometriosis tissues 
versus blood (71).      
 The peroxisome proliferator-activated receptor (PPAR)-γ2 Pro-12-Ala 
polymorphism may be involved in the pathogenesis of endometriosis.  DNA samples 
from 51 Caucasian women with endometriosis and 55 Caucasian women without 
endometriosis were analyzed for the Pro-12-Ala polymorphism in PPAR-γ2.   The 
frequency of the Pro-12-Ala polymorphism in women with endometriosis was 0.41, 
which was significantly different from the controls (0.20, p < 0.02).  However, 
differences between endometriotic stages were not statistically significant (stage I, 0.42; 
stage II, 0.43; stage III, 0.35; stage IV, 0.42; p > 0.05).  PPAR-γ2 is involved in 
transcriptional down-regulation of aromatase, an enzyme believed to be important in the 
pathophysiology of endometriosis.  If the Pro-12-Ala polymorphism results in reduced 
down-regulation of aromatase, then higher levels of aromatase could stimulate implant 
growth by autocrine production of estrogen.  Therefore, more studies are necessary to 
examine the roles of PPAR-γ2 polymorphisms in endometriosis, and the effects PPAR-γ2 
agonists might have on the prevention and treatment of endometriosis.  
Thiazolidinediones (TZDs) are ligands of PPAR-γ2, and have been shown to inhibit 
monocyte migration.  Therefore, treatment of endometriosis with TZDs could reduce cell 
proliferation and might also reduce the amount of inflammatory cells within the 
peritoneal cavity, which could assist in deterring the development and progression of 
endometriosis (72).  
 Although elevated levels of tumor necrosis factor alpha (TNF-α) have been found 
in the peritoneal fluid of women with endometriosis, three separate studies on TNF-α 
polymorphisms at positions 308 and 238 have not shown a statistical significance 
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between women with and without endometriosis.  These studies were conducted on 
Taiwanese, Korean, and Caucasian women (73-75).   IL-6, previously found to be 
increased in women with endometriosis (76, 77), was also examined for possible 
association of its G/C polymorphism at position 174 and the presence of endometriosis.  
In studies of both Korean and Caucasian women, no significant differences were found in 
between the IL-6 genotypes (G/G, G/C, or C/C) and the presence of endometriosis (73, 
78).  There was, however, an association between the 174G allele and endometriosis 
among Caucasian women with chocolate cysts (p = 0.037).  Serum IL-6 levels were 
significantly higher in women with endometriosis (p < 0.001), but when broken down by 
genotype of the IL-6 polymorphism, no significant differences were found (78).  
 Increased levels of interleukin-1 (IL-1) have been found within the peritoneal 
fluid and endometrium of women with endometriosis (79, 80).  In addition, increased 
Interleukin-1β (IL-1β) mRNA expression has been found in peritoneal macrophages of 
women with endometriosis (81).  An association has been shown between the IL-1β exon 
5 polymorphism and chronic inflammatory and malignant diseases, as well as increased 
monocyte production of IL-1β (82, 83).  Wieser et al. (84) investigated whether the 
incidence of the IL-1β exon 5 polymorphism was higher in women with endometriosis 
than women without endometriosis.  They also examined whether the presence of this 
polymorphism is associated with altered IL-1β levels.  Following pyrosequencing of 
DNA from 92 women with endometriosis and 69 controls, no significant difference was 
found between the groups regarding E1/E2 heterozygotes and E2/E2 homozygotes.  In 
addition, no significant differences were found regarding the level of serum IL-1β and 
patient genotype (84).   
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Linkage Studies 
 
 There have been only a few attempts at linkage studies in families with  
endometriosis.  One study examined 52 sister-pairs with Stage III-IV endometriosis 
utilizing three markers from the region of chromosome 1 (1p13) to which glutathione S-
transferase M1 (GSTM1), a gene whose null mutation has been associated with 
endometriosis, had been mapped.  The three markers were: D1S2635-10cM-D1S2844-
5cM-D1S2762.  No significant differences were found from expected values of identical-
by-descent sharing.  However, the researchers believed the ability to detect linkage may 
have been restricted due to recruitment of subjects from varied patient populations.  This 
study also looked at the association of a null mutation of GSTM1 with endometriosis and 
did not find a significant difference in the frequency of the mutation in women with 
endometriosis versus those without (85). 
 A recent study was the first to identify a major susceptibility locus for 
endometriosis by examining affected members from 1176 families.  It found a region of 
chromosome 10q26 that exhibited significant linkage (p = 0.047), and another region that 
was considered to be suggestive of linkage on chromosome 20p13 with a maximum loss 
of odds (LOD) score of 2.09 (86).   
 
Loss of Heterozygosity 
 
 Until 1997, few cytogenetic studies had been performed examining the incidence 
of somatic chromosomal changes in endometriotic tissues.  The studies that had been 
done indicated no consistent chromosome alteration in patients with endometriosis, most 
likely due to mixed tissue specimens and techniques that did not enable direct detection 
of low levels of chromosomal aneuploidy.  Shin et al. employed a multi-color 
fluorescence in-situ hybridization (FISH) approach to examine single cells and reported 
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non-random chromosome alterations, including trisomy 11 and monosomy 16 and 17 in 
late-stage disease (62).  Their results suggested that chromosome-specific numerical 
abnormalities may be involved in the development and/or progression of endometriosis, 
possibly reflecting clonal expansion of chromosomally abnormal cells.  Several 
oncogenes and tumor-suppressor genes had been mapped to chromosomes 11, 16, and 17, 
which also suggested that chromosomal loss or gain plays a role in the development and 
progression of endometriosis.  They compared these findings to those of colorectal 
tumorigenesis, in which a series of somatic genetic changes involved the activation of 
oncogenes and loss of tumor-suppressor genes.  They believed a similar process could be 
acting in endometriosis, in which the progression from mild to severe forms could be due 
to a series of somatic genetic changes that involve the activation of oncogenes and 
inactivation of tumor-suppressor genes (62).  
 Bischoff and Simpson (87) proposed that the pathogenesis of endometriosis could 
involve a multi-step process similar to that of neoplasia.  Similar to cancer development, 
both mutations could be somatic or one could be a germ-line mutation and the second 
somatic.  However, in contrast to the neoplasia model, not all of the genes in 
endometriosis pathogenesis would have to be oncogenes or tumor suppressor genes.  
Bischoff and Simpson believe that the first “hit” might involve a gene conferring an 
increased predisposition to adhesion and implantation of refluxed endometrial tissue 
(retrograde menstruation), including genes involved in the cytoskeleton, cell adhesion, or 
macrophage scavenging.  The second gene, or “hit”, could be a gene involved in 
supporting endometrial growth, such as genes involved in the ineffective metabolism of 
chemicals and/or toxins, causing build-up within the peritoneal cavity and oxidative 
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stress.  They also hypothesize that additional hits could involve oncogenes and/or tumor 
suppressor genes, leading to uncontrolled cellular proliferation (88, 89).   
 LOH refers to a loss of DNA by deletion of an allele or an entire chromosome.  
Comparative genomic hybridization (CGH) is a method enabling location and mapping 
of genomic regions for chromosomal gains and/or losses.  Regions showing an increased 
copy number may harbor dominant oncogenes, whereas regions with a decreased copy 
number may contain tumor suppressor genes.  In a study of endometriotic lesions 
utilizing CGH, chromosomal imbalances occurred in 15 of 18 lesions examined.  The 
DNA copy number abnormalities varied from 1 to 8 per lesion and were not related to the 
histological type or to the site of the endometriotic lesion.  The most common regions of 
loss were located on 1p, involving at least 1p32-36 (50%), 5p (33%), 6q (27%), 7p14-
p22ter (22%), and 22q12.3-qter (50%) segments.  Less common regions of loss were 9q 
(22%), 16q (22%), and 17q (one case).   Loss of heterozygosity involving chromosome 1 
was common in all types and stages of endometriosis, including peritoneal implants, 
endometriomas, and umbilical nodules.  Chromosomal gains were less common and 
localized to chromosomes 6q and 17q in two cases (90).   
 Kosugi et al. (91) also studied endometriosis utilizing FISH and observed a 
significant increase in the frequency of chromosome 17 aneuploidy in late-stage 
endometriosis as compared to normal endometrium.  This increase in aneuploidy and 
heterogeneity among aneuploid cells demonstrated for the first time a possible role for 
somatic alterations in the chromosome 17 in the pathogenesis of endometriosis, although 
genetic alterations involving chromosome 17 had already been implicated in ovarian and 
breast cancer (91).  Chromosome 17p13.1 contains the gene for tumor protein p53 
(TP53), a transcription factor involved in cell death and cell-cycle regulation at G1.  
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Human epidermal growth factor receptor 2 (HER-2/neu) is located at 17q11.2-q2 and is 
an oncogene, transmembrane tyrosine kinase receptor, and member of the epidermal 
growth factor receptor (EGFR) family.  17q21 is the location of breast cancer 1, early 
onset (BRCA1), a tumor suppressor gene (87). 
 
Specific Candidate Genes 
 Over 45 candidate genes have been associated with pathogenic hypotheses of 
endometriosis (http://www.well.ox.ac.uk/~krinaz/genepi_endo.htm).  These include 
genes involved in retrograde menstruation and cervical stenosis (galactose-1-phosphate 
uridyl transferase), cell adhesion (E-cadherin; intercellular adhesion molecule-1), 
hormonal factors (catechol-O-methyltransferase; cytochrome P450, family 17; 
cytochrome P450, family 19; hydroxysteroid (17-beta) dehydrogenase 2; nuclear receptor 
subfamily 5, group A, member 1), hormone receptor variability (estrogen receptor 1; 
estrogen receptor 2; progesterone receptor), immunological factors (major 
histocompatibility complex, class I, A; major histocompatibility complex, class I, B; 
major histocompatibility complex, class I, C; major histocompatibility complex, class II, 
DR beta 1; major histocompatibility complex, class II, DP beta 1; major 
histocompatibility complex, class II, DQ beta 1; interleukin  1, alpha; interleukin 1, beta; 
interleukin 1 receptor antagonist; interleukin 4; interleukin 6; interleukin 10; luteinizing 
hormone, beta subunit; tumor necrosis factor-α), proteolytic enzymes (matrix 
metallopeptidases 1, 3, and 7), growth factors and tumor suppressor genes (interleukin 1 
receptor, type 1; p21; p53; vascular endothelial growth factor), altered endometrial 
development (homeobox A10; homeobox A11), and detoxification (aryl hydrocarbon 
receptor; aryl hydrocarbon receptor repressor; aryl hydrocarbon receptor nuclear 
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translocator; cytochrome P450, family 1, subfamily A, polypeptides 1 and 2; cytochrome 
P450 family 1, subfamily B, polypeptide 1; glutathione S-transferase M1; glutathione S-
transferase theta 1; N-acetyltransferases 1 and 2) (92).  
 A factor that could increase exposure to retrograde menstruation, and thus the risk 
of endometriosis, is cervical stenosis.  Cervical stenosis could be caused by subtle 
Müllerian agenesis.  Müllerian agenesis has been associated with impaired galactose 
metabolism, which can be caused by mutations in the galactose-1-phosphate uridyl 
transferase (GALT).  The N314D and Q188R polymorphisms of GALT reduce its enzyme 
activity.  Current evidence suggests a possible role for the N314D polymorphism in 
infertility, but not necessarily in endometriosis.  One study found a significantly higher 
proportion of 33 infertile women with endometriosis (30%) carried at least one N314D 
allele compared to 111 healthy population controls (14%) (93).  However, more recently, 
no difference was found in the N314D allele frequency between 85 affected women with 
a family history of endometriosis and 213 female and male population controls.  In 
addition, no evidence of linkage to chromosome 9p was observed, where the GALT gene 
is located (94).  Based on these results and other existing reports, it is not likely that the 
gene encoding the GALT protein, or a gene in its vicinity, is associated with 
endometriosis.  
 In 1993, a study reported that monkeys exposed daily to dioxin showed 
development of moderate to severe endometriosis in a dose-dependent manner (95).  This 
prompted several studies on dioxin and endometriosis.  It is conceivable that dioxin may 
cause endometriosis by transactivating the promoters of the cytochrome gene, giving rise 
to increased levels of cytochrome p-450 enzymes in endometrial tissues that reach pelvic 
peritoneal surfaces by retrograde menstruation.  The enzymes may activate chemically 
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diverse procarcinogens in these tissues and give rise to development and growth of 
endometriotic implants (96).  
 The expression of CYP1A1, CYP1A2, CYP1B1, AHR, and ARNT was studied in 
human eutopic endometrial and endometriotic tissues.  The transcript level of expression 
of AHR, ARNT, CYP1A2, and CYP1B1 were the same in both endometriotic and eutopic 
endometrial tissues.  CYP1A1 transcript levels, however, were significantly higher in 
endometriotic tissues versus eutopic endometrium.  CYP1A1 genes catalyze the metabolic 
transformation of estrogen to catechol estrogens, which are short-lived estrogen 
metabolites that are speculated to play an important role in the growth and development 
of estrogen-responsive disorders such as breast cancer and endometriosis.  CYP1A1 
overexpression in endometriosis may represent a common pathway for a direct dioxin 
effect and a dioxin-independent transactivation of the CYP1A1 gene through aberrant 
expression of transcription factors in the tissue.  Regardless of the role of dioxin, the end 
result of CYP1A1 overexpression would be the development and growth of endometriotic 
tissue (97).      
 In the study of candidate genes that may play a role in the endometriosis 
pathogenesis, two that are of particular interest are the homeobox genes, HOXA10 and 
HOXA11.  HOXA10 and HOXA11 mediate embryonic development, including the 
development of the reproductive tract (98).  They play an analogous role in endometrial 
development during the adult menstrual cycle, and their expression may possibly regulate 
growth and development of the human endometrium.  HOXA10 and HOXA11 gene 
expression varies in response to sex steroids during the menstrual cycle, with dramatic 
up-regulation in the mid-secretory phase, the time of implantation.  They are essential for 
implantation in the mouse, and have been shown to likely play a similar role in human 
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implantation.  In a study of eutopic endometrium from women with and without 
endometriosis, the expected up-regulation of these two genes’ expression was observed in 
the mid-luteal phase.  However, in patients with endometriosis, an equivalent up-
regulation of gene expression was not observed for either gene at the time of 
implantation.  This failure to increase HOX gene mRNA levels did not depend on the 
stage of the disease and occurred despite in-phase endometrial histology.  This failure of 
the normal increase in HOXA10 and HOXA11 mRNA levels to occur at the beginning of 
the window of implantation may be one mechanism responsible for endometriosis-related 
infertility (98).  
 In August, 2001, the OXEGENE and Australian (Genes Behind Endometriosis) 
studies, which both began in 1995, were merged into the International Endogene Study.  
The International Endogene Study represents a collaboration between the University of 
Oxford and the Australian Cooperative Research Centre for Discovery of Genes for 
Common Human Diseases (Gene CRC).  As of April 2002, the combined data set 
consisted of 2,932 families.  This is the largest clinical resource for linkage and 
association studies in endometriosis ever assembled.  This merger increases the power to 
detect genes predisposing women to endometriosis and it demonstrates the value of large-
scale international collaboration.  By the end of 2002, genotyping was completed on the 
affected sibling-pair (ASP) families and linkage associations were better characterized, 
utilizing a genome-wide scanning of informative polymorphic microsatellite markers to 
identify regions of significant excess sharing in affected siblings for given genetic 
markers that are identical by descent (IBD) from their parents.  This information will lead 
to candidate gene testing in those regions associated with endometriosis (99). 
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Recently, Zondervan, Cardon, and Kennedy, announced the development of a 
web site which incorporates evidence of genetic variants associated with endometriosis 
and new etiological hypotheses, as well as links to up-to-date genomic information 
relevant to the candidate genes from a range of bioinformatics databases.  The web site, 
http://www.well.ox.ac.uk/~krinaz/genepi_endo.htm, contains a regularly updated review 
of opinions on etiological hypotheses and supporting biological, clinical, and 
epidemiological evidence, tables summarizing candidate genes investigated in association 
studies, hyperlinks to information about each gene’s location, structure, function (if 
known), and maps of neighboring polymorphic markers held in Internet-based 
bioinformatics databases, including Online Mendelian Inheritance in Man (OMIM), 
Genecards, National Center for Biotechnology Information (NCBI) Locuslink, Ensembl, 
the University of California Santa Cruz (UCSC) Human Genome Browser or Golden 
Path, and the Single Nucleotide Polymorphism database (dbSNP).  It also contains 
literature references with hyperlinks to abstracts published in PubMed 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi) for each candidate gene.  The team is 
currently conducting bimonthly searches of PubMed to find new association studies that 
present findings for or against association between endometriosis and specific genetic 
variants.  They believe that this website will be of great benefit and will be a useful 
information tool for endometriosis researchers (92). 
 As a complex and multifactorial disorder, endometriosis is ideally suited as a 
target for genome-wide scanning.  Techniques such as subtractive cDNA hybridization 
have identified glycodelin-A as a specific product of human endometrium believed to 
play an important role in embryonic receptivity (100).  Microarray studies have shown 
that mRNA expression of glycodelin-A was upregulated in normal mid-secretory 
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endometrium, but reduced in mid-secretory eutopic endometrium of women with 
endometriosis.  Other techniques, including differential display polymerase chain 
reaction (PCR) and comparative genomic hybridization have assisted in identifying up-
regulation of proteins and chromosome regions that are altered in endometriosis.  The 
field of bioinformatics is evolving rapidly, and genomic and proteomic technologies are 
poised to revolutionize the diagnosis and treatment of endometriosis and other diseases 
(100). 
 
Microarray Studies involving Endometriosis 
 
 
Eutopic versus Ectopic Microarray Studies 
 
Genomic studies of endometriosis utilizing microarrays were first presented and 
published only a few years ago.  Eyster et al. (5) were the first to publish a paper on 
utilizing DNA microarray analysis and endometriosis.  This pilot study consisted of 
recruiting three women scheduled for surgery for endometriosis.  The women were not on 
hormonal therapy and were in the follicular phase of their menstrual cycle when the 
surgery was performed.  Eutopic endometrial and ectopic endometriomal samples were 
obtained.  Total ribonucleic acid (RNA) extracted from these tissues was hybridized to 
Research Genetics Named Human Genes GeneFilter GF211 microarrays, which contain 
4,133 human genes.  1,028 of these genes were expressed in the eutopic and/or ectopic 
endometrium.  Eight genes displayed differential gene expression; this expression was 
greater in ectopic endometrium in all eight instances (5).   
The eight genes showing greater expression in ectopic endometrium were β-actin, 
α-2 actin, vimentin, 40S ribosomal protein S23, Ig-λ light chain, Ig germline H chain G-
E-A region γ-2 constant region, complement component 1 S subcomponent, and major  
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histocompatibility complex class 1,C.  Following comparisons of the 1,028 genes 
expressed in endometrium with sets of genes expressed in other tissues, only 75 genes 
were unique to the endometrium.  Therefore, of the eight genes differentially expressed 
between eutopic and ectopic endometrium, six were unique to the endometrium 
(vimentin, 40S ribosomal protein S23, Ig-λ light chain, Ig germline H chain G-E-A 
region γ-2 constant region, complement component 1 S subcomponent, and major  
histocompatibility complex class 1,C), while β-actin and α-2 actin have been found active 
in other tissues as well.  In fact, β-actin is often used as a housekeeping gene for the 
normalization of expression of other genes (5). 
In addressing the differential gene expression of the other six genes, the authors 
first looked at the invasive properties of endometriotic tissues.  Vimentin is an 
intermediate filament involved in cytoskeletal integrity, therefore, it was believed that the 
invasive nature of endometrial implants might explain the up-regulation of vimentin, as 
well as β-actin and α-2 actin.  The authors also cited reports of the effects of estrogen on 
the synthesis and expression of vimentin (via the increased demand for lipid droplets in 
steroidogenic cells and the necessary movement of these droplets into mitochondria via 
rearrangements of cytoskeletal elements), β-actin, and 40S ribosomal protein 23.  In all 
three cases, they speculated that increased synthesis and/or presence of estrogen could 
result in increased expression of these genes in endometriotic implants (5). 
The increased expression of Ig-λ light chain, Ig germline H chain G-E-A region γ-
2 constant region, complement component 1 S subcomponent, and major  
histocompatibility complex class 1,C was considered to strengthen the importance of 
immune system dysfunction in endometriosis.  The authors stated that B cells were 
known to be present in endometrial implants, although a difference between eutopic and 
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ectopic endometrium was not known.  In a normal immune response, they would have 
expected an increase in the expression of the Ig-λ light chain as well as the κ light-chain 
gene, but this gene was not present on the GeneFilter microarray they utilized (5). 
The differential gene expression they were most interested in was that of the Ig 
germline H chain G-E-A region.  Normally, this gene undergoes rearrangements, 
selective transcription, and RNA processing that results in the synthesis of Ig heavy 
chains.  According to the authors, the expression of this gene in its entirety suggested 
aberrant gene expression, because no cell type should express this gene in its unmodified 
germline state (5).  Therefore, they considered this gene to be appealing for further study  
and a potential diagnostic tool for endometriosis.  Their study also showed that 
microarray analysis could be utilized to study differential expression in genes in eutopic 
and ectopic endometrium (5). 
At the 58th Annual ASRM meeting, a pilot study was presented that compared 
eutopic endometrial gene expression with that of chocolate cyst ectopic endometrium.  
Eutopic endometrial tissue was obtained from three women with endometriosis, as well 
as ectopic endometrial tissues from chocolate cysts.  A human cDNA microarray system 
of 9,600 genes, including known regulatory genes and expressed sequence tags were 
utilized to study differential gene expression.  163 genes were found to be up-regulated 
three-fold or higher in ectopic endometrium, while only 14 genes were up-regulated in 
eutopic endometrium.  Six genes were studied further by immunohistochemistry.  These 
included B-cell leukemia/lymphoma 2 (Bcl-2), cyclin B1, vascular cell adhesion 
molecule 1 (VCAM-1), bone morphogenetic protein 4 (BMP-4), transforming growth 
factor beta (TGF-β) receptor, glutathione S-transferase A2 (GSTA2), and cell 
differentiation antigen 36 (CD36).  Immunostaining results validated the microarray 
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studies, as all six genes were over-expressed in ectopic endometrium at the protein level 
(101). 
A more comprehensive investigation of the genes involved in the pathogenesis of 
endometriosis was conducted utilizing cDNA microarrays consisting of 23,040 genes to 
study differential gene expression of ovarian endometrial cysts.  Endometrial cysts were 
obtained from 23 women undergoing cystectomy.  Nine participants were in the 
proliferative phase of the menstrual cycle, and 14 were in secretory phase at the time of 
surgery (102).  Eutopic endometrial tissues were obtained as controls from seven of the 
proliferative phase participants and seven secretory phase participants.  Epithelial cells 
were isolated from all samples, followed by RNA extraction (102).  
Three rounds of RNA amplification were performed on the cyst epithelial cells, 
and two rounds performed on the control samples.  Two universal controls were 
prepared, one from the eutopic amplified RNA (aRNA) mixture from the seven patients 
in proliferative phase, and the other from the seven secretory phase patients’ aRNA.  One 
set of expression comparisons was made between cysts in the nine proliferative phase 
patients versus the universal control of eutopic endometrium from the seven women in 
that phase.  The other set of comparisons was made between the 14 cysts collected from 
women in the secretory phase versus the universal control prepared from the seven 
women in that phase (102). 
Fifteen genes, including two expressed sequence tags (ESTs), were up-regulated 
in 70% of the 23 cases.  Forty-two genes, including 15 ESTs, were up-regulated only in 
the proliferative phase, and 40 genes, including 10 ESTs, were up-regulated only in the 
secretory phase.  Some genes were up-regulated exclusively in one phase or the other: 
S100 calcium-binding protein A13 (S100A13), myosin regulatory light chain 2, and 
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smooth muscle isoform (MYRL2) were up-regulated only in the proliferative phase; testis 
specific-like protein, Y-encoded (TSPYL) and four and a half LIM domains 2 (FHL2) 
were up-regulated only in the secretory phase (102). 
The study also demonstrated down-regulation of numerous genes in the 
endometriotic cysts.  Three hundred thirty-seven genes, including 164 ESTs, were 
commonly under-expressed in greater than 70% of the cysts collected from women both 
in proliferative and secretory phase.  One hundred forty-four genes, including 41 ESTs, 
were under-expressed only in the proliferative phase, and 835 genes, including 438 ESTs, 
were down-regulated only in the secretory phase (102).  Semi-quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) was utilized to confirm the differences 
in expression indicated by the microarray studies (102).   
Several genes involved in the immune system were found to up-regulated 
throughout the menstrual cycle, including HLA-DPA1, HLA-DQA1, HLA-DQB1, HLA-
DRA, HLA-DRB1, and CD14.  Genes encoding complements factors C3, BF, C1S, C1R, 
C2, CEBPD, and HLA-F were up-regulated primarily during the secretory phase.  Up-
regulation of genes involved in the immune system was hypothesized to be involved in 
poor reproductive outcomes, while increased expression of HLA antigens could involve 
recognition and presentation by macrophages, leading to an autoimmune reaction via 
endometrial autoantibodies.  The increased expression of complement components were 
inferred to result from severe inflammation, due to the presence of endometriotic lesions, 
which could potentially damage fallopian tubes and ovaries, leading to infertility.  
Transforming growth factor, beta 1 was also found to be up-regulated throughout the 
menstrual cycle.  Its role in inhibiting natural killer cell activity, while inducing 
angiogenesis and proliferation of endometrial stromal cells, was suggested to potentially 
45 
play a part in the progression of endometriosis and infertility.  Other genes with increased 
expression included ribosomal proteins S23, L11, and S11, whose synthesis is know to 
increase in response to estrogens (102). 
Genes involved in embryo protection, tumor suppression, and apoptosis were 
found to be down-regulated throughout both the proliferative and secretory phases of the 
menstrual cycle.  Oviductal glycoprotein 1 (OVPG1), which is involved in protecting the 
early embryo and fallopian tube from potentially noxious extracellular environments, was 
found to be down-regulated throughout the entire menstrual cycle (102).  Decreased 
expression of this gene was speculated, therefore, to lead to infertility in women with 
endometriosis.  Down-regulation of TP53 and tumor protein p53 binding protein 2 
(TP53BP2) were believed to support the notion that endometriosis, although a benign 
condition itself, exhibits tumor-like features, including cellular proliferation, invasion, 
and neoangiogenesis.  In addition, the expression of growth arrest and DNA-damage-
inducible 34 (GADD34), 45 alpha (GADD45A), and beta (GADD45B) proteins, as well as 
tumor protein p53 inducible protein 11 (PIG11), was found to be down-regulated 
throughout the menstrual cycle.  The researchers felt that decreased expression of these 
genes in the endometrial epithelial cells might affect apoptotic signaling and enhance the 
tumor-like characteristics of endometriosis (102). 
Gene expression has also been compared between different types of endometriosis 
utilizing microarray technology.  In a study by Mahadevappa et al. (103), gene expression 
was compared between normal endometrium, peritoneal endometriosis, and ovarian 
endometriosis.  Samples included eighteen of normal endometrium, twelve peritoneal 
lesions, and fifteen ovarian endometriomas.  cDNA was hybridized to Human U133A 
oligonucleotide arrays (Affymetrix, Inc.) containing approximately 22,000 genes.  
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Candidate genes were identified by both parametric (Students t-test) and non-parametric 
methods (Mann-Whitney test), segregated by hierarchical clustering, and a select group       
confirmed by quantitative reverse transcription-polymerase chain reaction (QRT-PCR).  
Candidate genes identified and confirmed included steroidogenic acute regulatory protein 
(STAR), myosin, heavy polypeptide 11 (MYH11), dienelactone hydrolase (DLH), and 
wingless-type mouse mammary tumor virus (MMTV) integration site family member 1 
(WNT1) inducible signaling pathway protein 2 (WISP2) (103). 
 
Transducer of ErbB (Tob)-1 
IL-1β, a product of peritoneal macrophages, performs several important roles in 
the establishment and maintenance of endometriotic lesions (104).  It has been shown to 
stimulate angiogenesis and monocyte chemotaxis in endometriotic cells, as well as induce 
mitogenesis in other types of cells.  Lebovic et al. (105) explored the relationship 
between IL-1β and the survival of endometriotic tissue.  They wanted to find a 
mechanism through which the exaggerated immune response seen with endometriosis 
might be linked to the enhanced survival of endometriotic lesions through IL-1β 
induction of cell-cycle regulatory proteins.  Therefore, they studied the effect exposure to 
IL-1β had on gene expression of normal endometrial stromal cells versus endometriotic 
stromal cells (105). 
Four eutopic endometrial samples were collected from women undergoing 
laparoscopy or laparotomy, with pathologic diagnoses of uterine leiomyomata, but no 
clinical evidence of endometriosis, and ovarian endometrioma biopsies were collected 
from four other women.  Normal endometrial stromal and endometriotic stromal cells 
were separated from glandular epithelial cells and cultured with IL-1β.  Atlas Human 
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cDNA Expression arrays (Clontech), with 597 genes, were utilized to screen for affected 
mRNA expression due to IL-1β exposure (105).   
Only one gene, transducer of ErbB (Tob)-1, showed down-regulated expression 
due to exposure to IL-1β.  Although Tob-1 expression was reduced by 48% in 
endometriotic stromal cells following IL-1β treatment, in normal endometrial stromal 
cells, the effect was significantly less (16% inhibition).  The inhibitory effect of IL-1β on 
Tob-1 was studied further by Northern blot hybridization.  Following 12-hour incubations 
with IL-1β, the treated endometriotic stromal cells showed a 25 ± 5% decrease in Tob-1 
mRNA induction (p < 0.05) versus untreated endometriotic stromal cells.  In the normal 
endometrial stromal cells, however, a < 3% in Tob-1 mRNA decrease was observed in 
the treated versus untreated cells (105).  
Tob-1 is a tumor suppressor gene that inhibits cell growth by sequestering cells in 
G0/G1 phases of the cell cycle (105).  The gene for Tob-1 is located on 17q21, and 
functional loss of this chromosome has been implicated in endometriotic lesions (91).  
However, Tob-1 has not been sufficiently studied in other cell systems; therefore the 
impact of a 25% reduction in mRNA expression is not known.  Nonetheless, the 
researchers acknowledged that the suppression of Tob-1 in endometriotic stromal cells by 
IL-1β provided a mechanism for the enhanced growth potential of endometriotic lesions 
(105). 
 
Eutopic Endometrial Microarray Studies 
A few studies have examined eutopic endometrium in women with and without 
endometriosis.  The first was presented at the VIII World on Endometriosis.  Chen et al. 
obtained endometrial biopsy samples from four women and mRNA extracted from the 
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tissues and hybridized to human cDNA microarrays with 9,600 genes, including known 
regulatory genes and expressed sequence tags.  Seventeen genes had higher expression in 
endometrium from the normal women during the proliferative phase, and 197 genes 
showed greater expression in the eutopic endometrium of women with endometriosis (6).  
The genes differentially expressed included cell growth-related factors (e.g., epidermal 
growth factor, insulin-like growth factor-II), cell adhesion molecules (e.g., thymus cell 
surface antigen 1, integrin beta-4 binding protein), signal transduction molecules (e.g., 
ras-related oncoprotein), apoptosis-related factors (e.g., death-domain related genes), 
hormones/cytokines (e.g., epidermal growth factor, TGF-β, neuropeptide Y receptor, 
natural killer cells-stimulated proliferative factor), cytoskeleton/extracellular matrix 
proteins (e.g. keratin 18), and some ESTs (6). 
A second study comparing eutopic endometrium in women with versus women 
without endometriosis was presented as a poster at the 59th Annual meeting of the 
ASRM.  Endometrial biopsies were obtained from three women with endometriosis and 
three age and cycle-matched controls without endometriosis.  The samples were collected 
during the luteal phase of the menstrual cycle (days 25-27).  Total RNA from each 
sample was hybridized to a human Genechip containing 33,000 transcripts (Affymetrix, 
Inc.).  Three genes, cystatin B (stefin B), heat shock 70kD protein 1B, and enolase (1, 
alpha), were identified whose expression was significantly higher in the endometrium of 
the women with endometriosis.  The expression of insulin-like growth factor binding 
protein 5, tyrosine 3-monooxygenase, tryptophan 5-monooxygenase activation protein, 
and epsilon polypeptide (14-3-3 protein) was significantly down-regulated in women 
with endometriosis versus normal women (106). 
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One of the most comprehensive studies of endometrial gene expression in women 
with versus those without endometriosis was conducted by Kao et al (10).  Initial results 
were presented at the VIII World Congress on Endometriosis (107) and at the National 
Institutes of Health workshop “Endometriosis: Emerging Research and Intervention 
Strategies” (108).  Eutopic endometrial samples were collected from eight women with 
and twelve women without surgically-confirmed endometriosis.  Collection of samples 
was timed to the luteinizing hormone (LH) surge, therefore tissue biopsies were 
performed during the window of implantation, eight to ten days following the LH surge.  
RNA was hybridized to Affymetrix Genechip Hu95A oligonucleotide microarrays 
composed of 12,686 genes.  Genes of different expression fold changes were randomly 
selected for validation by RT-PCR and/or Northern or dot-blot analyses (10). 
 During the window of implantation, 91 genes, including 28 ESTs, were up-
regulated in the endometrium of women with endometriosis versus those without, and 
115 genes, including 29 ESTs, were down-regulated in women with endometriosis versus 
without.  Therefore, 63 genes were up-regulated by a minimum of two-fold and 86 genes 
were down-regulated by two-fold or greater in the eutopic endometrium of women with 
endometriosis as compared to expression in normal women.  Genes with functions 
involving or categorized as apoptosis, protein or RNA processing, transporter proteins, 
zinc metalloenzymes, DNA repair, immune function, secretory proteins, signal 
transduction, cell surface proteins, and transcription factors, as well as other unspecified 
pathways, were up-regulated according to the study’s algorithm to the maximum of 100-
fold.  The genes demonstrating the greatest down-regulation (reaching a maximum of 
100-fold) were involved in calcium binding, RNA polymerase, serine protease/inhibition, 
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signal transduction, transcription factors, immune function, cell surface proteins, cytokine 
receptor genes, ion transporters, and secretory proteins (10). 
 Kao et al. then compared the results of this study with that of a previous set of 
microarray experiments they had performed comparing gene expression in normal human 
endometrium during the implantation window with expression in the late proliferative 
phase (109).  Three groups of target genes were identified, based on expression within the 
window of implantation and presence of endometriotic disease.  Group 1 consisted of 
eight genes normally up-regulated in the window of implantation that were significantly 
down-regulated in women with endometriosis (10).  These included interleukin-15 (IL-
15), proline-rich protein (PRP/C4BP), immediate early response protein B61 (ephrin-
A1), Dickkopf-1 (DKK1), glycodelin, N-acetylglucosamine-6-O-sulfotransferase 
(GlcNAc6ST), putative lymphocyte G0/G1 switch gene (G0S2), and purine nucleoside 
phosphorylase.  Group 2 consists of semaphorin E, neuronal olfactomedin-related 
endoplasmic reticulum localized protein mRNA, and Sam68-like phosphotyrosine protein 
α (SALP), which are genes normally down-regulated during the window of implantation, 
but were up-regulated in women with endometriosis.  The final group (Group 3) was 
composed of one gene, neuronal pentraxin II, which is normally down-regulated during 
the window of implantation and displayed even greater down-regulation in women with 
endometriosis (10). 
 The genes within these three groups, as well as a few others, were hypothesized to 
play roles in implantation failure and infertility, as well as in the pathogenesis of the 
disease.  This was due to the differences in gene expression during the window of 
implantation in women with versus without endometriosis.  The genes considered as 
candidates for implantation failure and infertility in endometriosis included GlcNAc6ST, 
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olfactomedin, C4BP, IL-15, DKK1, purine nucleoside phosphorylase, neuronal pentraxin 
II, glycodelin, S100 calcium binding protein A3 (S100E), and bile salt export pump 
(BSEP).  The genes proposed to contribute to the pathogenesis of endometriosis included 
integrin α, aromatase, progesterone receptor (PR), ephrin-A1, G0S2, kallikrein, 
semaphorin E, and SALP (10). 
 
Tissue Microarrays 
 Most recently, the first experiment utilizing tissue microarray technology in 
studying endometriosis was performed to assess the differential gene expression of 
estrogen receptor (ER)-α, PR, matrix metalloproteinases (MMPs)-1, 7, and 11, dosage-
sensitive sex adrenal hypoplasia congenital critical region on the X chromosome gene 1 
(DAX-1), and caveolin-1 (CAV-1).  Tissue samples were collected from fifty-one women 
with endometriosis and nine controls.  Of the women with endometriosis, 10% had mild 
endometriosis, 23% moderate, and 67% had severe endometriosis.  Samples collected 
included eutopic endometrium (25%), ovarian endometriosis (48%), and peritoneal 
endometriosis (27%).  Core biopsies of two millimeters were assembled onto tissue 
microarrays, and immunohistochemistry was used to assess the expression of the 
aforementioned genes.  The extent of antibody expression (negative, weakly positive, or 
strongly positive) was correlated to the presence, severity, and site of endometriosis 
(110).  
The expression of ER-α was significantly greater in the endometriotic tissues 
versus the controls (p = 0.009), and eutopic endometrium from women with 
endometriosis showed significantly stronger ER-α than controls (p < 0.0001).  
Endometriotic tissues also demonstrated significantly down-regulated expression of PR 
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as compared to controls (p = 0.003).  Odds for disease were significantly lower with 
strong expression of PR, compared with those with negative and mild expression        
(OR 0.06).  In addition, MMP-1 showed a trend of being over-expressed, especially in the 
peritoneal implants (p = 0.05).  The expressions of MMP-7, MMP-11, DAX-1, and CAV-1 
did not display any significant differences between endometriotic and control tissues.  
The researchers believed that increased expression of ER-α and decreased expression of 
PR in endometriotic tissues indicated the presence of altered receptivity of endometriotic 
implants (110). 
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CHAPTER III 
 
 
MATERIALS AND METHODS 
 
 
Research Subjects 
 
 
The population of interest was women of reproductive age, both with and without 
endometriosis.  The study sample was women of reproductive age, at least eighteen years 
of age, who were scheduled for laparoscopic surgery.  Normal subjects were recruited 
from women undergoing laparoscopic surgery for tubal ligation, while endometriosis 
subjects were recruited from women undergoing laparoscopic surgery for evaluation of 
pelvic pain and/or infertility believed to be associated with endometriosis.  Each potential 
study participant was read an informed consent letter approved by the Oklahoma State 
University Center for Health Sciences College of Osteopathic Medicine Institutional 
Review Board (Appendix II).  At this time, the potential participants’ questions were 
answered and all procedures explained.   
Once enrolled, each study participant was assigned a number.  The list identifying 
patient name and number was kept in a classified folder to which only the primary 
researcher or physicians associated with the study had access.  All participants were 
asked to fill out a questionnaire on their medical history, family history of disease, 
infertility, surgical history, and prescribed and herbal medications use, as well as rate 
their pain, if applicable, on a gynecological pain scale.  At the conclusion of the study, 
the list identifying patient name and number were destroyed.   
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Sample Collection 
 
 
 An obstetrician/gynecologist performed the laparoscopic surgeries at Tulsa 
Regional Medical Center.  For the normal participants enrolled in the study, three 
samples were taken: (1) an endometrial biopsy, (2) peritoneal fluid, and (3) normal pelvic 
peritoneum.  For the endometriosis participants, four samples were collected: (1) 
peritoneal fluid, (2) normal pelvic peritoneum, (3) endometriotic lesion, and (4) an 
endometrial biopsy.  All samples were collected utilizing sterile technique while the 
participant was under general anesthesia. 
 
Normal Participants 
 
 
 Endometrial Biopsy.  The endometrial biopsy was obtained prior to 
commencement of the laparoscopic procedure.  The endometrial biopsy was collected 
through insertion of an Endocurette® Endometrial Suction Curette (Utah Medical 
Products, Inc., Catalog # CUR-100) through the cervix into the uterus.  The suction 
plunger was pulled out and the curette pushed into the uterus and pulled out several times 
while rotating the instrument, in order to collect eutopic endometrial cells.  The curette 
was then placed into a 15ml centrifuge tube filled with 10 ml RNAlater™ (Ambion, 
Catalog #7020) and placed on ice.  Per RNAlater™ recommendations, the sample was 
stored at 4ºC overnight, and then transferred to -20ºC and stored until RNA extraction. 
 
Normal Pelvic Peritoneum.  A biopsy of normal pelvic peritoneum was obtained 
utilizing a grasping laparoscopic forcep instrument.  The sample was put into 5 ml of 
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RNAlater™ and placed on ice.  The sample was stored at 4ºC overnight, and then 
transferred to -20ºC and stored until RNA extraction. 
 
Endometriosis Participants 
For endometriosis participants, no samples were collected unless endometriosis 
was visually confirmed.  If endometriosis was present, the operating physician visually 
staged the endometriotic lesions, based upon the revised ASRM classification of 
endometriosis (16).  The endometrial biopsy, peritoneal fluid, and normal pelvic 
peritoneal biopsy were obtained in the same manner as in the normal participants. 
 
Endometriosis.  A biopsy of endometriotic tissue was collected utilizing a 
grasping laparoscopic forcep instrument.  The biopsy was collected from the uterine cul-
de-sac and placed into 5 ml RNAlater™.  The sample was stored at 4ºC overnight, and 
then transferred to -20ºC for storage. 
 
Total RNA Extraction 
 
 
Endometrial Biopsies 
 RNA was extracted from endometrial samples utilizing the RNeasy Mini Kit 
(Qiagen, catalog # 74104).  Endometrial tissue was removed from each 15 ml centrifuge 
tube using sterile forceps and weighed.  The tissue was then placed in 600 μl Buffer RLT 
with β-Mercaptoethanol (β-ME) in a 1.5-ml microtube.  The Buffer RLT/ β-ME mixture 
was freshly made prior to beginning the RNA extraction protocol; 10 μl β-ME was added 
to 1 ml Buffer RLT.  The tissue was then homogenized using a rotor-stator homogenizer 
until the sample was uniformly homogenous (20-40 seconds).  The lysate was then 
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further homogenized by passing ten times through a 20-gauge needle fitted to a sterile 
syringe.   
 The lysate was centrifuged at maximum speed (13,000 rpm) for three minutes in a 
microcentrifuge.  The supernatant was transferred to a new microtube by pipetting, and 
600 μl of 70% ethanol was added to the lysate and mixed immediately by pipetting.  One-
half of the sample (600 μl) was applied to an RNeasy mini column placed in a 2 ml 
collection tube.  The tube was closed gently and microcentrifuged for 15 seconds at 
10,000 rpm.  The flow-through was discarded, and the remaining 600 μl was applied to 
the column.  The tube was closed gently and microfuged at 10,000 rpm for 15 seconds, 
after which the flow-through was discarded.  Buffer RW1 (350 μl) was pipetted onto the 
RNeasy mini column, followed by a 15-second microcentrifugation at 10,000 rpm to 
wash.  Afterwards, the flow-through was discarded.   
 The DNase I incubation mix was prepared by added 10 μl DNase I stock solution 
to 70 μl Buffer RDD.  The DNase I stock solution and Buffer RDD were mixed gently by 
inverting the tube.  The DNase I incubation mix was pipetted directly onto the RNeasy 
silica-gel membrane and then incubated at room temperature for 15 minutes.  Following 
the incubation, 350 μl Buffer RW1 was pipetted onto the RNeasy mini column, followed 
by a 15-second microcentrifugation at 10,000 rpm.  The RNeasy mini column was then 
transferred to a new 2 ml collection tube.   
 500 μl Buffer RPE was pipetted onto the RNeasy column.  The tube was closed 
gently and microcentrifuged for 15 seconds at 10,000 rpm to wash the column.  The 
flow-through was discarded, and another 500 μl Buffer RPE was pipetted onto the 
RNeasy column.  The tube was closed gently and microcentrifuged for two minutes at 
10,000 rpm to dry the RNeasy silica-gel membrane.  The RNeasy column was placed in a 
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new 1.5 ml microtube and microcentrifuged at full speed for one minute to eliminate any 
chance of possible Buffer RPE carryover. 
 To elute, the RNeasy column was transferred to a new 1.5 ml microtube.  30 μl 
RNase-free water was pipetted directly onto the RNeasy silica-gel membrane.  The tube 
was closed gently and incubated at room temperature for ten minutes.  Following the 
incubation, the tube was microcentrifuged for one minute at 10,000 rpm to elute.  The 
eluate was reapplied to the column for a second elution.  The tube was incubated for 
another ten minutes at room temperature and then microcentrifuged for one minute at 
10,000 rpm to elute.  Two microliters of the eluate were placed in a separate 0.5 ml 
microtube for subsequent RNA concentration evaluation.  Both the 1.5 ml and 0.5 ml 
with total RNA were stored at -80ºC. 
 
Normal Pelvic Peritoneum 
 RNA was extracted from normal pelvic peritoneum utilizing the RNeasy Micro 
Kit (Qiagen, catalog # 74004).  Normal pelvic peritoneum was removed from each 15 ml 
centrifuge tube using sterile forceps and weighed.  The tissue was then placed in 350 μl 
Buffer RLT with β-ME in a 1.5-ml microtube.  (The Buffer RLT/ β-ME mixture was 
made prior to beginning the RNA extraction protocol.  10 μl β-ME was added to 1 ml 
Buffer RLT.)  The tissue was then homogenized using a rotor-stator homogenizer until 
the sample was uniformly homogenous (20-40 seconds).  The lysate was then further 
homogenized by passing ten times through a 20-gauge needle fitted to a sterile syringe.   
 The lysate was then spun at maximum speed (13,000 rpm) for three minutes in a 
microcentrifuge.  The supernatant was transferred to a new microtube by pipetting.  350 
μl of 70% ethanol was added to the lysate and mixed immediately by pipetting.  The 
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sample was applied to an RNeasy MinElute Spin Column placed in a 2 ml collection 
tube.  The tube was closed gently and microcentrifuged for 15 seconds at 10,000 rpm.  
The flow-through was discarded.  350 μl Buffer RW1 was pipetted into the RNeasy 
MinElute Spin Column, followed by a 15-second microcentrifugation at 10,000 rpm to 
wash the column.  The flow-through was discarded.   
 The DNase I incubation mix was prepared by added 10 μl DNase I stock solution 
to 70 μl Buffer RDD.  The DNase I stock solution and Buffer RDD were mixed gently by 
inverting the tube.  The DNase I incubation mix was pipetted directly onto the RNeasy 
MinElute silica-gel membrane and then incubated at room temperature for 15 minutes.  
Following the incubation, 350 μl Buffer RW1 was pipetted onto the RNeasy MinElute 
Spin Column, followed by a 15-second microcentrifugation at 10,000 rpm.  The RNeasy 
MinElute Spin Column was then transferred to a new 2 ml collection tube.   
 500 μl Buffer RPE was pipetted onto the RNeasy MinElute Spin Column.  The 
tube was closed gently and microcentrifuged for 15 seconds at 10,000 rpm to wash the 
column.  The flow-through was discarded.  500 μl 80% ethanol was pipetted onto the 
RNeasy MinElute Spin Column.  The tube was closed gently and microcentrifuged for 
two minutes at 10,000 rpm to dry the RNeasy silica-gel membrane.  The RNeasy column 
was placed in a new 1.5 ml microtube.  The cap of the spin column was opened and 
microcentrifuged at full speed for one minute. 
 To elute, the RNeasy MinElute Spin Column was transferred to a new 1.5 ml 
microtube.  14 μl RNase-free water was pipetted directly onto the RNeasy MinElute 
silica-gel membrane.  The tube was closed gently and incubated at room temperature for 
ten minutes.  Following the incubation, the tube was microcentrifuged for one minute at 
10,000 rpm to elute.  The eluate was reapplied to the column for a second elution.  The 
59 
tube was incubated for another ten minutes at room temperature and then 
microcentrifuged for one minute at 10,000 rpm to elute.  Two microliters of the eluate 
were placed in a separate 0.5 ml microtube for subsequent RNA concentration evaluation.  
Both the 1.5 ml and 0.5 ml microtubes with total RNA were stored at -80ºC. 
 
RNA Concentration 
  
  
Spectroscopy   
 RNA concentration was determined utilizing a NanoDrop® ND-1000 
Spectrophotometer.  With the sampling arm open, a 1.5 μl sample of total RNA was 
pipetted onto the lower measurement pedestal.  The sampling arm was closed and a 
spectral measurement initiated using the operating software on the PC.  The sample 
column was automatically drawn between the upper and lower measurement pedestals 
and the spectral measurement made.  When the measurement was completed, the 
sampling arm was opened the sample was wiped from both the upper and lower pedestals 
using a Kim-Wipe.  The pedestals were then cleaned with de-ionized water after each last 
measurement. 
 
RNA Amplification 
 
 
First Strand cDNA Synthesis with dT Primer  
 For each RNA sample, an RNA/primer mix was prepared in a microtube on ice.  
This was composed of 1-9 µl total RNA, not exceeding 2 µg, 2 µl SenseAmp dT24 RT 
primer (50 ng/µl), and nuclease free water to a volume of 11 µl.  This was heated to 80ºC 
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for 10 minutes, and then placed on ice immediately for 2 minutes.  After a brief 
microfuge, the RNA/primer mix was returned to ice.   
 A Master Mix (MM1) was prepared for each reaction in a separate tube on ice.  
MM1 was comprised of 4 µl 5X First Strand Buffer, 2 µl 0.1M dithiotreitol (DTT), 1 µl 
Superase-In, 1 µl dNTP Mix, and 1 µl Superscript II, for a total volume of 9 µl.  MM1 
and the RNA/primer mix were combined, mixed gently, microfuged, and then incubated 
at 42ºC for 2 hours.  Following the incubation, the cDNA reaction was microfuged 
briefly.   80 µl 1X TE Buffer was added for a final volume of 100 µl.  
 
Purification of cDNA   
 The cDNA was purified using the MinElute PCR Purification Kit (Qiagen, 
catalog # 28006) as follows.  500 µl Buffer PB was added to the 100 µl cDNA sample 
and mixed.  The cDNA mixture was applied to the MinElute column and centrifuged for 
1 minute at 10-14,000 x g (~13,000 rpm) in a conventional tabletop microcentrifuge.  The 
flow-through was discarded and the MinElute column placed into the same collection 
tube.  750 µl Buffer PE was added to the MinElute column and centrifuged for 1 minute.  
The flow-through was discarded and the MinElute column placed into the same 
collection tube.  500 µl 80% ethanol was added to the MinElute column and centrifuged 
for 2 minutes. The flow-through was discarded and the MinElute column placed into the 
same collection tube.  The column cap was opened and placed in the microfuge, with the 
cap opposite the direction of rotation of the rotor to avoid breaking the cap off, and 
centrifuged for 5 minutes.  The MinElute column was placed into a clean, labeled 1.5 ml 
microfuge tube.  To elute cDNA, 10 µl Buffer EB was added to the center of the column 
membrane, and the tube incubated at room temperature for 2 minutes, followed by a two-
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minute centrifugation.  The column was discarded.  If the eluted cDNA was less than 10 
µl, the volume was brought to 10 µl with nuclease free water.  
 
Tailing of First Strand cDNA   
 The purified cDNA was heated to 80ºC for 10 minutes.  It was then placed on ice 
immediately for 2 minutes.  The cDNA was briefly microfuged and then returned to ice.  
For each reaction, a Master Mix (MM2) was prepared in a separate tube on ice.  MM2 
was composed of 2 µl 10X Reaction Buffer, 2 µl Nuclease Free Water, 4 µl 10mM dTTP, 
and 2 µl TdT Enzyme.  MM2 was combined with the cDNA for a total volume of 20 µl, 
mixed gently, microfuged, and incubate in a 37ºC heat block for 3 minutes, paying 
attention, so as to not exceed 3 minutes.  The reaction was stopped by heating to 80ºC for 
10 minutes, followed by a brief microfuge, and then cooling to room temperature for 1-2 
minutes. 
  
T7 Promoter Synthesis   
 2 µl T7 Template Oligo was added to 6 ul of nuclease free water, briefly vortexed, 
and microfuged.  2 µl of this dilution was added to the tailed cDNA, for a final volume of 
22 µl, which was then vortexed briefly and microfuged.  It was then incubated at 37ºC for 
10 minutes to anneal the strands.  To each reaction, 1 µl 10X Reaction Buffer, 1 µl dNTP 
mix, and 1 µl Klenow Enzyme was added.  This mixture was mixed gently and 
microfuged, followed by a 30-minute incubation at room temperature.  The reaction was 
stopped by heating to 65ºC for ten minutes.  The tube was then placed on ice.   
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In Vitro Transcription   
 12.5 µl of cDNA was incubated at 37ºC for ten minutes to re-anneal the strands.  
The T7 Nucleotide Mix and 10X T7 Reaction Buffer were thawed at room temperature.  
The 10X T7 Reaction Buffer was thoroughly vortexed prior to using.  To each cDNA 
sample, 8 µl T7 Nucleotide Mix, 2.5 µl 10X T7 Reaction Buffer, and 2 µl T7 Enzyme 
Mix was added at room temperature.  This reaction was gently mixed and microfuged 
prior to incubating at 37ºC in a thermocycler with a heated lid for 16 hours. 
 
Purification of senseRNA   
 The senseRNA was purified using the RNeasy MinElute Kit (Qiagen catalog 
number 74204) following Qiagen’s protocol for RNA Cleanup.  75 µl of RNase-free 
water was added to the senseRNA for a final volume of 100 µl.  This was accomplished 
by first transferring the 25 µl senseRNA mix into a new 1.5 ml microtube.  Then 75 µl 
RNase-free water was placed into the PCR reaction tube utilized for the overnight 
incubation, pipetted up and down a few times to wash the sides of the tube, and the entire 
solution pipetted up and then placed into the 1.5 ml microtube and mixed thoroughly with 
the senseRNA.   
 350 µl Buffer RLT was placed into the tube and mixed thoroughly by pipetting.  
Then 250 µl 100% ethanol was added and mixed by pipetting.  The entire 700 µl was 
applied to an RNeasy MinElute Spin Column in a 2 ml collection tube and was 
centrifuged at 10,000 rpm for 15 seconds.  The flow-through was discarded, and the 
column transferred into a new 2 ml collection tube.  500 µl Buffer RPE was placed onto 
the spin column, the lid closed gently, and the column centrifuged at 10,000 rpm for 15 
seconds for washing.  The flow-through was discarded, and 500 µl 80% ethanol was 
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added to the column.  The lid was closed gently, and the tube centrifuged for 2 minutes at 
10,000 rpm to dry the silica-gel membrane.  Afterwards, the flow-through and collection 
tube were discarded.   
 The spin column was transferred into a new 2 ml collection tube, the cap opened, 
and then centrifuged at full speed (13,000 rpm) for 5 minutes.  The flow-through and 
collection tube were discarded.  The spin column was transferred into a 1.5 ml collection 
tube, and 14 µl RNase-free water was pipetted directly onto the membrane for elution.  
The tube was left at room temperature for ten minutes, and then it was centrifuged for 1 
minute at 13,000 rpm to elute the sample (approximately 12 µl). 
 
Poly (A) Tailing of senseRNA 
 The volume of senseRNA was brought to 15.5 µl with nuclease free water.  The 
ATP mix was diluted in 1mM Tris pH 8.0 for each tailing reaction, according to the 
following formula:  
µg of senseRNA 50 = Dilution of ATP Mix 
A 1:5 dilution of the PAP Enzyme in 1X PAP Buffer was made by first preparing a 1X 
PAP Buffer, by adding 2 µl of 5X PAP Buffer to 8 µl nuclease free water.  This dilution 
was vortexed briefly and microfuged.  1 µl of the PAP Enzyme was added to 4 µl of 1X 
PAP Buffer, tapped gently to mix, microfuged briefly, and then placed on ice until ready 
to use.   
 For each reaction, 5.0 µl 5X PAP Buffer, 2.5 µl MnCl2, 1.0 µl ATP Mix, and 1.0 
µl diluted PAP Enzyme were added to the 15.5 µl of sense RNA, for a total volume of 25 
µl.  The reaction was mixed gently, microfuged, and incubated at 37ºC for 15 minutes.  
The reaction was stopped by adding 3 µl of 0.5M EDTA, tapped to mix, and briefly 
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microfuged.  The tailed senseRNA was purified using the RNeasy MinElute Kit 
following Qiagen’s protocol for RNA Cleanup as previously described under 
“Purification of senseRNA.”  The senseRNA was stored at -80ºC. 
  
Microarray Studies 
 
Microarray Acquisition and Prehybridization  
 The microarrays utilized were purchased from the University of Texas 
Southwestern Medical Center Microarray Core Facility, Dallas, TX, USA.  The 
microarrays were human synthetic polynucleotide (70-mer) microarrays spotted with the 
Human Oligo Set, Version 2, from Operon, representing 21,329 human genes.    
 
Microarray Labeling and Hybridization 
 The microarrays were labeled utilizing the Genisphere 3DNA Array 900 
Expression Array Detection Kit (Hatfield, PA, USA). 
 
 cDNA Synthesis from Total RNA.  In a microtube, 2 µg total RNA (1-5 µl), 1 µ l 
RT primer (1 pmole/µl Alexa Fluor 546 or Alexa Fluor 647), and nuclease free water to a 
final volume of 6 µl were combined to prepare the RNA-RT primer mix.  The RNA-RT 
primer mix was mixed and microfuged briefly to collect the contents in the bottom of the 
tube.  The RNA-RT primer mix was heated to 80°C for five minutes and then 
immediately transferred to ice for 2-3 minutes.   
In a separate microtube, a reaction master mix (RMM) was prepared on ice.  The   
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RMM was formulated to a final volume dependent on the number of cDNA syntheses 
that were to be conducted.  Each cDNA synthesis required 4.5 µl of the RMM, which was 
composed of 2 µl 5X SuperScript II First Strand Buffer, 1 µl 0.1M DTT, 0.5 µl Superase-
in RNAse Inhibitor, 0.5 µl deoxynucleotide Triphosphate Mix (dNTP) mix (10mM each 
dATP, dCTP, dGTP, dTTP), and 0.5 µl Superscript II enzyme, 200 units (Gibco, catalog 
#18064-014 – 10,000 Units @ 200U/µl).  The RMM was gently mixed and microfuged 
briefly to collect the contents in the bottom of the tube.  4.5 µl of the RMM was added to 
the 6 µl of each RNA-RT primer mix, for a final volume of 10.5 µl.  This was gently 
mixed (not vortexed) and incubated at 42ºC for four hours.  
   The cDNA synthesis reaction was stopped by adding 1 µl of 0.5M NaOH/50mM 
EDTA.  This was followed by a 10-minute incubation at 65°C to denature the DNA/RNA 
hybrids and degrade the RNA.  The reaction was neutralized with 1.2 µl of 1M Tris-HCl, 
pH 7.5.   
 
 cDNA Hybridization.  A 2X Formamide-Based Hybridization Buffer was thawed 
at room temperature and resuspended by heating to 65-70°C for at least ten minutes or 
until completely resuspended.  The components were vortexed to ensure they were 
resuspended evenly.  The buffer was then microfuged for one minute. 
For each array, a cDNA Hybridization Mix (cDHM) was prepared.  This was 
composed of the 12.7 µl Pooled RNA cDNA reaction, the 12.7 µl Experimental RNA 
cDNA reaction, 2 µl LNA dT Blocker, 40 µl 2X Hybridization buffer, and 12.6 µl 
nuclease-free water, for a total of 80 µl cDHM.  The cDHM was gently vortexed and 
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briefly microfuged, followed by a 10-minute incubation at 75-80°C, and then at the 
hybridization temperature (47°C) until loading the array. 
 The microarrays were prewarmed to the hybridization temperature of 47°C prior 
to being placed in a Telechem hybridization chamber.  A 24 x 60 mm LifterSlip (Erie 
Scientific, Portmouth, NH, USA) was applied to each array.  The cDHM was gently 
vortexed and briefly microfuged prior to being applied beneath the LifterSlip to a pre-
warmed array.  Any precipitate was left at the bottom of the microtube.  12 µl of 3X SSC 
was added at each end of the Telechem chamber.   The arrays were incubated for 16 
hours in a dark humidified chamber at 47°C.   
 
 Post cDNA Hybridization Wash.  After hybridization, the slides were washed 
briefly several times to remove unbound cDNA molecules.  The cover slips were 
removed by washing the arrays in 2X SSC, 0.2% SDS for 2-5 minutes at room 
temperature (or until cover slip floats off).  This wash continued for a total time of 10-15 
minutes.  Next, the arrays were washed at room temperature in 2X SSC.  The final wash 
was in 0.2 X SSC for 10-15 minutes at room temperature.  Each array was then 
immediately transferred to a microarray high-speed centrifuge for rapid removal of the 
wash buffer (approximately 30 seconds).   
 
 3DNA Hybridization.  The 3DNA Array 900 Capture Reagent for each Alexa 
Fluor was prepared by first thawing at room temperature 20 minutes in the dark.  Then, 
the capture reagents are vortexed at the maximum setting for 3 seconds, followed by brief 
microfugation and incubation at 50-55°C for 10 minutes.  Following the incubation, they 
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are vortexed at the maximum setting for 3-5 seconds, followed by another brief 
microfugation to collect the contents at the bottom.  At the same time, the 2X 
Formamide-Based Buffer has been thawed and resuspended by heating to 70°C for at 
least 10 minutes or until completely resuspended.  This was followed by vortexing and 
microfugation for one minute. 
 A 3DNA Hybridization Mix (3HM) was prepared for each array in separate 
microtubes.  To 40 µl of 2X Formamide-Based Hybridization Buffer, 35 µl nuclease-free 
water, 2.5 µl Alexa Fluor 546 3DNA Capture Reagent, and 2.5 µl Alexa Fluor 647 
3DNA Capture Reagent was added, to render a final 3HM volume of 80 µl.  The 3HM 
was gently vortexed and briefly microfuged, followed by incubation for ten minutes at 
75-80°C, and then at the hybridization temperature (45°C) until loading the array.  The 
microarrays were prewarmed to the hybridization temperature of 45°C prior to being 
placed in a Telechem hybridization chamber.  A 24 x 60mm LifterSlip was applied to 
each array.  The 3HM was gently vortexed and briefly microfuged prior to being applied 
beneath the LifterSlip to a pre-warmed array.  Any precipitate was left at the bottom of 
the microtube.  12 µl of 3X SSC was added to each end of the Telechem chamber.   The 
arrays were incubated for three hours in a dark humidified chamber at 45°C.   
 
 Post 3DNA Hybridization Wash.  After hybridization, the slides were washed 
briefly several times to remove unbound cDNA molecules.  The coverslips were removed 
by washing the arrays in 2X SSC, 0.2% SDS for 2-5 minutes at room temperature (or 
until cover slip floats off).  This wash continued for a total time of 10-15 minutes.  Next, 
the arrays were washed at room temperature in 2X SSC.  The final wash was in 0.2 X 
SSC for 10-15 minutes at room temperature.  Each array was then immediately 
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transferred to a microarray high-speed centrifuge for rapid removal of the wash buffer.  
The slides were immediately transferred to a light-protective slide box, taking care not to 
touch the array surface.  
 
Microarray Scanning 
 The microarrays were scanned and hybridization signals measured with the 
ScanArray Express (PerkinElmer, Boston, MA, USA). 
 
Microarray Image Analysis and Spot Quanitification 
 Scanned images were analyzed utilizing GenePix Pro 4.0.  Individual images 
were uploaded into GenePix Pro, as well as the GenePix Array List (GAL) file specific 
for the arrays utilized in the experiments.  Each image was visually analyzed block-by-
block, and features flagged that were considered inappropriate for inclusion in statistical 
analysis, due to either increased background intensity, increased fluorescence secondary 
to damage or a foreign particle on the array, or overlap of the feature with an adjacent 
feature(s).  
 
Data Pre-Processing and Normalization Using Genepix Pro Auto-Processor 
 Pre-processing of data was accomplished using GenePix Autoprocessor (GPAP)  
(http://darwin.biochem.okstate.edu/gpap/) (Ayoubi et al., unpublished results).   This 
analysis included: 1) removal of data where the fluorescence signal intensity in both 
channels was less than the background plus two standard deviations; 2) removal of data 
points where the signal was less than 200 Relative Fluorescence Units in both the 
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channels; 3) removal of bad quality spots flagged during processing of the image using 
GenePix Pro; 4) log 2 transformation of the background subtracted Alexa 647/Alexa 546 
median ratios.  Following pre-processing, the expression results were normalized using 
print tip LOWESS normalization and a t-statistic, p-value, and B-statistic were calculated 
for each gene based on the Empirical Bayes approach using the R-project statistical 
environment (http://www.r-project.org/) with the Bioconductor 
(http://www.bioconductor.org/) and Limma packages through the GPAP web site 
(http://darwin.biochem.okstate.edu/gpap3/) (Ayoubi et al., unpublished results).   
 
Selection of Significant Genes 
 Results from GPAP were imported into a Microsoft Excel file and genes of 
interest selected based upon the following parameters.  Log2 ratios were converted to 
absolute values, and those genes with an absolute log2 ratio of less than one (fold-change 
less than two), were removed.  The list was then resorted according to the number of 
spots/replicates utilized in the GPAP processing.  For the eutopic endometrium studies, 
only genes with at least 8 out of 12 spots utilized for statistical analysis, or the equivalent 
(i.e. ≥ 16/24), were retained.  For the normal pelvic peritoneum studies, only genes with 
at least 6 out of 8 spots used in GPAP were retained.  The list was then resorted based 
upon p-value, and only genes with a p-value <0.01 were retained.  The remaining genes 
were those considered to demonstrate significant differential gene expression between 
women with and without endometriosis and subject to further analysis.   
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Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
cDNA Synthesis 
 cDNA was synthesized for each total RNA utilized in the microarray experiments, 
utilizing the ThermoScriptTM RT-PCR System for First-Strand cDNA Synthesis 
(Invitrogen, catalog # 11146-024).  Therefore, individual cDNAs were made for each of 
the experimental RNA samples, as well as for the pooled eutopic endometrium and 
pooled normal pelvic peritoneum samples.  The ThermoScriptTM RT-PCR System for 
First-Strand cDNA Synthesis includes ThermoScriptTM RT (15 units/μl), oligo(dT)20 (50 
μM), random hexamers (50 ng/μl), 5X cDNA synthesis buffer, 0.1 M DTT, 10 mM dNTP 
mix, RNaseOUTTM RNase inhibitor (40 units/μl), E. coli RNase H (2 units/μl), and 
diethylpyrocarbonate (DEPC)-treated water. 
 In a 0.2 ml tube, 0.5 μl oligo(dT)20 primer, 0.5 μl random hexamers, 2.0 μl dNTP, 
total RNA (100 ng to 2 μg) were combined, with DEPC-treated water added to a final 
volume of 12 μl.  They were mixed well by pipetting, microfuged briefly, and then the 
RNA and primers were denatured by incubating at 65°C for 5 minutes.  Afterwards, they 
were microfuged briefly and placed on ice.  A master mix was prepared on ice with 4 µ l 
5x cDNA Synthesis Buffer (vortexed for five seconds just prior to use), 1 µl 0.1 M DTT, 
1 µl RNaseOUTTM, 1 µl DEPC-treated water, and 1 µl ThermoScriptTM RT for each 
reaction plus enough of each component for one additional reaction to compensate for 
pipetting errors.  8 µl of master reaction mix was pipetted into each reaction tube on ice.  
The tubes were incubated at 25°C for 10 minutes, followed by 50 minutes at 55°C.  The 
reaction was terminated by incubating at 85°C for 5 minutes.  1 µl of RNase H was added 
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to each reaction, followed by an incubation at 37°C for 20 minutes.  The cDNA synthesis 
reactions were stored at -20°C until use in RT-PCR reactions. 
 
Primer Design  
 Primers were designed utilizing Invitrogen’s OligoPerfectTM Designer 
(http://www.invitrogen.com/content.cfm?pageid=9716).  Forward and reverse primer 
sequences were entered into NCBI’s BLAST Queue for “short, nearly exact matches” 
(nucleotide-nucleotide BLAST) and limited to the Homo sapiens database for 
confirmation of the forward and reverse primer pair being specific the gene of interest.  
Primers were ordered from the Midland Certified Reagent Company (Midland, Texas) or 
Invitrogen (Tables I and II).   
 
Quantitative Reverse Transcription-Polymerase Chain Reaction 
 PCR reaction mixes were composed of 15.8 μl sterile water, 2.5 μl 10X PCR 
Buffer (Invitrogen), 1 μl Magnesium Chloride (Invitrogen), 0.5 μl dNTP mix (Invitrogen, 
catalog #18427-013), 0.1 μl 30% BSA (Sigma-Aldrich), 2.5 μl Sybr Green (Molecular 
Probes, Inc, Eugene, Oregon) (working stock made fresh daily by adding 0.25 μl Sybr 
Green to 500 μl sterile water for final concentration in each reaction of 1:20,000), 0.1 μl 
Platinum® Taq DNA polymerase (Invitrogen, catalog # 10966-026), 0.5 μl template 
cDNA, and 1 μl (20 pM) each of forward and reverse gene primers, for a total reaction 
volume of 25 μl. 
 A Cepheid Smart Cycler (Sunnyvale, California) was utilized for the PCR 
reactions.  Each reaction began with a 95ºC hot start for 180 seconds.  Samples were 
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subjected to 40 amplification cycles, which included a denaturing step at 95ºC for 15 
seconds, a primer dependent annealing step at 58-64ºC for 45 seconds, and an extension 
step at 72ºC for 45 seconds.  Optical data was collected during the annealing step.  A 
melting curve was performed at the end of every run to ensure a single product was 
amplified. 
 
Analysis  
 Optical Data from each RT-PCR experiment were transferred into a Microsoft 
Excel worksheet.  The raw optics data were first converted into a logarithmic format, then 
gene to control (glyceraldeheyde-3-phosphate dehydrogenase, GAPDH) ratios calculated 
for each run and multiplied by one thousand to determine product abundance.  An 
average for each sample was calculated based upon the number of PCR experiment 
replicates (typically three).  The average of each experimental subject’s abundance was 
divided by that of the pooled normals to determine fold-change.  The average fold-change 
was calculated by adding all experimental subjects fold-change values and dividing by 
six (eutopic endometrium experiments) or three (normal pelvic peritoneum experiments).  
Replicates were excluded only when the optics data for the control gene (GAPDH) or 
gene of interest indicated an error within the RT-PCR reaction. 
 
 
 
 
 
 
 
 
 
 Table I. Primers Utilized in Validation Studies of Eutopic Endometrium Microarray Results. 
 
Primer Name Sequence Size of PCR band 
   
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), forward 
5’-TGATGACATCAAGAAGGTGGTGAAG-3’ 240 base pairs 
GAPDH, reverse 5’-TCCTTGGAGGCCATGTGGGCCAT-3’  
   
Homo sapiens BCOO9393, forward 5’-CCCTCATCGTGTCAAGTCAA-3’ 237 base pairs 
Homo sapiens BCOO9393, reverse 5’-AGGCATCAAAGTTGGCAAAG-3’  
   
Growth arrest and DNA-damage-inducible, 
beta (GADD45B), forward 
5'-CAG AAG ATG CAG ACG GTG AC-3' 214 base pairs 
GADD45B, reverse 5'-TGT CAC AGC AGA AGG ACT GG-3'  
   
Mammoglobin (MGB1), forward 5’-CTC CCA GCA CTG CTA CGC AGG CTC-3’ 201 base pairs 
MGB1, reverse 5’-CAC CTC AAC ATT GCT CAG AGT TTC ATC CG-3’  
   
Thrombospondin 3 (THBS3), forward 5’-ACT GCC TTT TGA CAC CCA AC-3’ 179 base pairs 
THBS3, reverse 5’-ATT GTC ACA GGC ATC ACC AA-3’  
   
G2 & S phase expressed 1 (GTSE1), forward 5’-GGG ATG TTC TCC CTG ACA AA-3’  232 base pairs 
GTSE1, reverse 5’-GAT TTA GCT TTG CCC ACT GC-3’  
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 Table II.  Primers Utilized in Validation Studies of Normal Pelvic Peritoneum Microarray Results. 
 
Primer Name Sequence Size of PCR band 
   
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), forward 
5’-TGATGACATCAAGAAGGTGGTGAAG-3’ 240 base pairs 
GAPDH, reverse 5’-TCCTTGGAGGCCATGTGGGCCAT-3’  
   
Suppressor of cytokine signaling 2 (SOCS2) forward 5’-AAC AGC AGT AAA TAA ACA CTT TGA A-3’ 249 base pairs 
SOCS2, reverse 5’-GCA ACT CAA TCC CCG TTA AT-3’  
   
Minichromosome maintenance deficient 5, cell division 
cycle 46 (MCM5), forward 
5’-CTA CAC TGG ACT CAT GGA CTC G-3’  213 base pairs 
MCM5 reverse 5’-ATT AAC GGA TGC CAA AAG CA-3’  
   
A20-binding inhibitor of NF-kappaB activation 2 
(TNIP2), forward 
5’-AAG TGT GCT TTA ACT TCC GGC-3’ 209 base pairs 
TNIP2, reverse 5’-GGG AGT CAC TTG TAT GGT CCC-3’  
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CHAPTER IV 
 
 
RESULTS 
 
 
Participant Characteristics 
 
 
 Seven women with endometriosis and seven women without disease were utilized 
in the microarray studies.  The average age of the women with endometriosis was 26.43 
(SD ± 5.83), and the average age of the normal participants was 26.57 (SD ± 5.62).  
Three women had Stage I endometriosis, two women had Stage II, and two women had 
Stage III.  All endometriosis participants had a history of pelvic pain, with 6 of 7 
complaining of dysmenorrhea, 5 of 7 having dyspareunia, and three complaining of pain 
with bowel movements.  None of the normal participants endorsed a history of pelvic 
pain.  In regards to infertility, one woman with endometriosis and one without admitted 
to this, however, the women without endometriosis had been pregnant previously, and 
stated that her infertility involved her last attempt at conceiving taking 23 months.  Three 
of seven women with endometriosis had a family member with endometriosis, in contrast 
to only one normal participant. 
 Three women without endometriosis were utilized for the normal pool of eutopic 
endometriosis (average age 25.67, SD ± 6.43).  Six women with endometriosis were 
utilized for the endometriosis experiments (mean age 26.00, SD ± 6.26).  Normal pelvic 
peritoneum from four normal participants (mean age 27.25, SD ± 5.85) and from three 
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women with endometriosis (mean age 24.00, SD ± 5.57) was utilized in the second series 
of microarray experiments.   
 
 
Differential Gene Expression Studies of Eutopic Endometrium in Women with and 
without Endometriosis 
 
 
 756 genes were found to be significantly up- or down-regulated in the eutopic 
endometrium of women with endometriosis versus those without (Table III).  352 genes 
were up-regulated greater than 2-fold with a p-value <0.01, and 404 were down-regulated 
greater than two-fold.  The most up-regulated gene was Kelch-like 1 (NM_020866) with 
a fold change of +36.429 (log2 ratio 5.187, SD 1.336).  Nine replicates were utilized in 
the analysis, with a p-value of 6.83 x 10-6.  The gene most down-regulated, with a  fold-
change of -113.300 (log2 ratio -6.824, SD 0.935) was Homo sapiens HIV-1 Rev binding 
protein-like (BC009393).  Ten replicates were utilized in its analysis, rendering a p-value 
of 4.35 x 10-10. 
 
 Table III. Log Ratio Changes of Gene Expression in Eutopic Endometrium of Women with Endometriosis versus Without. 
 
Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
NM_020866 Kelch-like 1 (Drosophila) KLHL1 36.429 5.187 1.336 0.284 9.936 6.83E-06 8.173 9 
NM_015887 Putative peroxisome microbody protein 
175.1 
LOC51051 23.703 4.567 1.486 0.416 7.526 1.19E-04 4.294 11 
AL050175 Homo sapiens mRNA  23.296 4.542 1.503 0.331 11.410 3.18E-06 9.269 11 
AK021930 Homo sapiens cDNA FLJ11868 fis  21.963 4.457 0.680 0.157 15.310 1.30E-07 13.918 9 
NM_032293 GTPase activating Rap/RanGAP 
domain-like 
GARNL3 20.692 4.371 0.520 0.124 21.900 4.62E-09 18.736 11 
NM_006732 FBJ murine osteosarcoma viral 
oncogene homolog B 
FOSB 20.210 4.337 1.278 0.283 11.220 2.16E-06 9.800 8 
AB014542 Trinucleotide repeat containing 15 TNRC15 15.835 3.985 1.399 0.351 11.100 2.36E-06 9.574 12 
AK025643 Homo sapiens cDNA: FLJ21990 fis  15.671 3.970 1.308 0.302 8.866 1.97E-05 6.662 11 
NM_005738 ADP-ribosylation factor-like 4A ARL4 14.035 3.811 1.321 0.347 11.230 2.16E-06 9.722 12 
NM_005252 V-fos FBJ murine osteosarcoma viral 
oncogene homolog 
FOS 13.823 3.789 0.812 0.185 8.624 2.54E-05 6.405 8 
AK022048 Homo sapiens cDNA FLJ11986 fis  13.813 3.788 1.638 0.644 5.353 1.68E-03 0.831 8 
NM_020433 Junctophilin 2  JPH2 13.260 3.729 1.528 0.405 9.631 9.39E-06 7.801 9 
NM_017947 Molybdenum cofactor sulfurase HMCS 12.355 3.627 1.352 0.373 10.450 4.14E-06 8.773 12 
NM_001249 Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTPD5 12.227 3.612 0.535 0.149 23.390 6.26E-09 18.212 10 
NM_017936 Homo sapiens KIAA2010 KIAA2010 11.984 3.583 1.040 0.290 13.310 4.76E-07 12.006 12 
S66666 P53  11.852 3.567 0.709 0.214 11.480 1.74E-06 10.081 8 
NM_005420 Sulfotransferase family 1E, estrogen-
preferring, member 1 
STE 11.672 3.545 1.777 0.501 7.804 6.24E-05 5.082 12 
AB051514 KIAA1727 protein  11.400 3.511 1.347 0.382 10.180 5.40E-06 8.460 11 
AB037715 KIAA1294 protein  11.377 3.508 0.694 0.209 14.580 1.95E-07 13.240 11 
NM_003215 Tec protein tyrosine kinase TEC 11.035 3.464 0.939 0.271 14.200 2.51E-07 12.882 12 
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 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
AF116656 Homo sapiens PRO1167 mRNA  10.793 3.432 2.244 0.723 6.117 8.23E-04 1.880 9 
AK055405 Homo sapiens cDNA FLJ30843 fis  10.440 3.384 1.628 0.475 8.040 6.90E-05 5.151 8 
AK055061 Homo sapiens cDNA FLJ30499 fis  10.225 3.354 0.551 0.154 15.800 9.85E-08 14.336 9 
AK057198 Homo sapiens cDNA FLJ32636 fis  10.218 3.353 1.928 0.563 6.834 1.94E-04 3.617 9 
AI871129 ESTs  9.911 3.309 0.644 0.192 17.760 2.90E-08 15.909 10 
NM_006174 Neuropeptide Y receptor Y5 NPY5R 9.680 3.275 2.005 0.671 6.800 2.67E-04 3.202 11 
NM_013315 Transmembrane phosphatase with tensin 
homology 
TPTE 9.640 3.269 1.213 0.368 9.281 1.30E-05 7.360 8 
AF330042 Homo sapiens Alu repeat mRNA 
sequence 
 9.626 3.267 1.529 0.467 8.452 3.03E-05 6.123 10 
NM_007281 Scrapie responsive protein 1 SCRG1 9.468 3.243 0.727 0.237 13.270 4.87E-07 11.982 10 
NM_000635 Regulatory factor X, 2 (influences HLA 
class II expression) 
RFX2 9.383 3.230 1.321 0.405 9.520 1.03E-05 7.623 10 
AK055220 Homo sapiens cDNA FLJ30658 fis  9.370 3.228 1.944 0.587 6.493 2.94E-04 3.038 9 
NM_001145 Angiogenin, ribonuclease, Rnase A 
family, 5 
RNASE4 9.088 3.184 1.403 0.396 6.807 2.01E-04 3.467 11 
AK022029 Homo sapiens cDNA FLJ11967 fis  8.821 3.141 1.069 0.340 11.360 1.90E-06 9.882 12 
NM_018321 Brix domain containing 2 BRIX 8.815 3.140 0.984 0.361 7.092 1.42E-04 4.044 8 
NM_003764 Syntaxin 11 STX11 8.815 3.140 1.505 0.469 8.099 4.53E-05 5.666 8 
AB033104 Serine/threonine kinase 36 (fused 
homolog, Drosophila) 
STK36 8.562 3.098 0.599 0.206 13.340 4.75E-07 12.050 10 
NM_017765 PQ loop repeat containing 2 PQLC2 8.550 3.096 0.708 0.217 13.550 3.99E-07 12.244 11 
BC014396 Copine IV CPNE4 8.386 3.068 1.219 0.439 7.756 6.60E-05 5.008 11 
AK054975 Homo sapiens cDNA FLJ30413 fis  8.374 3.066 0.738 0.237 14.640 1.93E-07 13.319 9 
AK054969 Homo sapiens cDNA FLJ30407 fis  8.276 3.049 0.953 0.312 13.610 3.83E-07 12.323 20 
AK024118 Homo sapiens cDNA FLJ14056 fis  8.208 3.037 0.680 0.220 14.910 1.69E-07 13.566 9 
NM_014797 Zinc finger and BTB domain containing 
24 
ZBTB24 7.994 2.999 1.532 0.601 7.607 1.08E-04 4.448 19 
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 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
BC012136 ISL2 transcription factor, 
LIM/homeodomain (islet-2) 
ISL2 7.890 2.980 1.273 0.426 9.250 1.33E-05 7.256 10 
AK026419 Homo sapiens cDNA: FLJ22766 fis  7.835 2.970 0.826 0.305 9.758 8.20E-06 7.940 9 
AB051488 KIAA1701 protein  7.717 2.948 1.536 0.516 7.425 9.53E-05 4.514 11 
NM_024753 Tetratricopeptide repeat domain 21B TTC21B 7.600 2.926 1.371 0.512 9.865 1.19E-05 7.507 11 
AL049650 Transglutaminase 3-like TGM3L 7.444 2.896 0.976 0.331 11.040 2.45E-06 9.575 9 
NM_030820 Collagen, type XXI, alpha 1 COL21A1 7.200 2.848 1.083 0.401 9.247 1.33E-05 7.224 21 
NM_007215 Polymerase (DNA directed), gamma 2, 
accessory subunit 
POLG2 7.106 2.829 1.043 0.410 10.660 3.48E-06 9.084 21 
AB020691 KIAA0884 protein, GTPase activating 
Rap/RanGAP domain-like 1 
GARNL1 6.979 2.803 0.860 0.303 12.010 1.17E-06 10.660 10 
BC013114 Homo sapiens aarF domain containing 
kinase 4 
 6.960 2.799 1.058 0.375 9.918 1.14E-05 7.599 9 
AL137707 Homo sapiens mRNA  6.921 2.791 0.453 0.150 12.660 7.25E-07 11.343 10 
AF339803 Homo sapiens clone IMAGE:246773  6.797 2.765 1.144 0.401 8.629 2.53E-05 6.412 9 
NM_014810 Centrosome-associated protein 350kDa CAP350 6.779 2.761 1.004 0.361 10.510 3.89E-06 8.873 11 
NM_013416 Neutrophil cytosolic factor 4, 40kDa NCF4 6.671 2.738 1.236 0.449 8.316 5.19E-05 5.472 10 
AK054623 Homo sapiens cDNA FLJ30061 fis  6.561 2.714 1.386 0.505 7.581 7.91E-05 4.831 9 
NM_004617 Transmembrane 4 superfamily member 
4 
TM4SF4 6.525 2.706 0.737 0.268 13.000 5.95E-07 11.717 10 
AL137361 Homo sapiens genomic DNA DKFZP43
4C0826 
6.467 2.693 1.251 0.456 8.123 4.42E-05 5.633 10 
NM_002666 Perilipin PLIN 6.431 2.685 0.643 0.261 10.650 3.48E-06 9.051 10 
NM_024845 Hypothetical protein FLJ14154 FLJ14154 6.360 2.669 1.025 0.384 10.050 6.08E-06 8.273 12 
NM_016426 G-2 and S-phase expressed 1 GTSE1 6.347 2.666 1.067 0.396 9.620 9.47E-06 7.757 10 
Z00008 Immunoglobulin kappa variable 1D-8 IGKV1D-8 6.333 2.663 0.532 0.198 17.320 3.96E-08 15.574 10 
NM_032447 Fibrillin 3 FBN3 6.281 2.651 0.743 0.277 12.410 8.58E-07 11.076 11 
AL136945 Zinc finger protein 265 ZNF265 6.238 2.641 1.166 0.492 7.056 1.48E-04 3.882 11 
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 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
NM_012204 General transcription factor IIIC, 
polypeptide 4, 90kDa 
GTF3C4 6.097 2.608 1.077 0.407 9.066 1.61E-05 7.001 10 
AK024867 Homo sapiens cDNA: FLJ21214 fis  6.050 2.597 1.262 0.473 7.756 6.60E-05 5.105 9 
NM_003407 Zinc finger protein 36, C3H type, 
homology (mouse) 
ZFP36 5.938 2.570 0.916 0.323 8.236 3.90E-05 5.771 10 
AL359599 Homo sapiens genomic DNA  5.938 2.570 0.421 0.163 19.530 2.80E-08 16.011 10 
NM_014370 Serine/threonine kinase 23 STK23 5.934 2.569 1.107 0.495 6.517 2.85E-04 3.005 10 
AK023446 Homo sapiens cDNA FLJ13384 fis, 
aminoadipate-semialdehyde synthase 
AASS 5.889 2.558 1.055 0.412 9.374 1.19E-05 7.369 12 
NM_005701 RNA, U transporter 1 RNUT1 5.776 2.530 0.707 0.279 13.560 3.99E-07 12.250 12 
NM_004414 Down syndrome critical region gene 1 DSCR1 5.756 2.525 0.801 0.283 7.581 7.91E-05 4.831 8 
AK055705 Homo sapiens cDNA FLJ31143 fis  5.748 2.523 1.101 0.438 9.070 1.61E-05 7.070 8 
AK055210 Homo sapiens cDNA FLJ30648 fis  5.744 2.522 1.097 0.430 8.873 1.96E-05 6.729 10 
AB058717 KIAA1814 protein  5.708 2.513 1.120 0.443 8.770 2.17E-05 6.584 10 
AK001044 Homo sapiens cDNA FLJ10182 fis  5.653 2.499 0.588 0.253 11.710 1.43E-06 10.300 10 
NM_002045 Growth associated protein 43 GAP43 5.560 2.475 1.320 0.529 7.033 1.51E-04 3.988 8 
NM_030751 Transcription factor 8 (represses 
interleukin 2 expression) 
TCF8 5.560 2.475 1.411 0.560 6.772 2.08E-04 3.475 10 
AF131846 Homo sapiens clone 25028 mRNA 
sequence 
 5.449 2.446 1.141 0.465 8.345 3.44E-05 5.934 11 
NM_014757 Mastermind-like 1 (Drosophila) MAML1 5.393 2.431 0.954 0.392 9.814 7.76E-06 7.961 12 
NM_015996 CGI-40 protein, SID1 transmembrane 
family, member 2 
SIDT2 5.367 2.424 1.028 0.475 7.263 1.15E-04 4.254 10 
AB033114 AT2 receptor-interacting protein 1 MTSG1 5.359 2.422 1.241 0.509 7.583 7.90E-05 4.767 11 
AK025766 Homo sapiens cDNA: FLJ22113 fis  5.337 2.416 0.981 0.448 7.705 6.93E-05 4.927 11 
NM_006853 Kallikrein 11 KLK11 5.234 2.388 0.936 0.357 7.673 7.19E-05 4.877 11 
AK057060 Homo sapiens cDNA FLJ32498 fis  5.205 2.380 1.510 0.626 6.239 4.14E-04 2.594 9 
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 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
NM_005415 Solute carrier family 20 (phosphate 
transporter), member 1 
SLC20A1 5.177 2.372 1.303 0.545 6.938 2.28E-04 3.498 8 
NM_002618 Peroxisome biogenesis factor 13 PEX13 5.095 2.349 0.907 0.371 9.138 1.48E-05 7.163 8 
NM_002888 Retinoic acid receptor responder 
(tazarotene induced) 1 
RARRES1 5.091 2.348 0.981 0.400 8.554 2.73E-05 6.338 8 
NM_006763 BTG family, member 2 BTG2 5.056 2.338 0.809 0.339 10.810 3.08E-06 9.315 8 
NM_000583 Group-specific component (vitamin D 
binding protein) 
GC 5.000 2.322 0.944 0.405 9.484 1.07E-05 7.546 11 
NM_005032 Plastin 3 (T isoform) PLS3 4.993 2.320 0.751 0.359 8.444 3.06E-05 6.051 11 
NM_022145 Leucine zipper protein FKSG14 FKSG14 4.959 2.310 1.049 0.402 6.218 4.27E-04 2.448 11 
AF063020 PC4 and SFRS1 interacting protein 2 PSIP2 4.884 2.288 1.156 0.503 7.683 7.12E-05 4.924 11 
AK055656 Homo sapiens cDNA FLJ31094 fis LOC21968
8 
4.843 2.276 0.448 0.211 12.400 8.58E-07 11.104 8 
U79280 Human clone 23575 mRNA PIPPIN 4.837 2.274 1.521 0.656 5.941 6.19E-04 2.107 8 
NM_022496 ARP6 actin-related protein 6 homolog  ACTR6 4.830 2.272 0.741 0.357 8.967 1.80E-05 6.804 11 
U72518 Human destrin-2 pseudogene mRNA  4.813 2.267 1.021 0.448 8.669 2.42E-05 6.438 10 
NM_015450 Protection of telomeres 1 POT1 4.787 2.259 1.051 0.474 9.374 1.19E-05 7.370 21 
AK056642 Homo sapiens cDNA FLJ32080 fis  4.783 2.258 1.583 0.696 5.640 9.40E-04 1.476 10 
NM_014432 Interleukin 20 receptor, alpha IL20RA 4.754 2.249 0.902 0.401 5.082 2.03E-03 0.356 10 
AL080077 Homo sapiens mRNA  4.734 2.243 0.910 0.401 9.043 1.65E-05 6.940 11 
AL049357 Homo sapiens mRNA  4.714 2.237 1.058 0.473 8.224 3.95E-05 5.785 10 
AK027772 Homo sapiens cDNA FLJ14866 fis C13orf10 4.611 2.205 1.122 0.501 7.362 1.03E-04 4.447 10 
NM_006551 Lipophilin B (uteroglobin family 
member) 
SCGB1D2 4.557 2.188 1.693 0.774 5.053 2.12E-03 0.301 12 
NM_003362 Uracil-DNA glycosylase UNG 4.554 2.187 0.608 0.274 12.900 6.07E-07 11.616 10 
NM_004599 Sterol regulatory element binding 
transcription factor 2 
SREBF2 4.510 2.173 1.449 0.663 5.868 6.88E-04 1.857 11 
NM_001371 Dynein DNAH8 4.503 2.171 0.772 0.407 6.989 1.59E-04 3.772 11 
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NM_002634 Prohibitin PHB 4.485 2.165 0.439 0.226 8.939 1.84E-05 6.793 10 
NM_002411 Mammaglobin 1 SCGB2A2 4.469 2.160 1.618 0.740 5.246 1.61E-03 0.740 10 
AJ420568 DKFZP586D0623 protein  4.438 2.150 1.060 0.493 7.848 5.96E-05 5.150 12 
BC007594 Nucleolar protein 3 (apoptosis 
repressor), Homo sapiens, Similar to 
RIKEN cDNA 4931428F04 gene 
 4.405 2.139 0.911 0.484 7.052 1.48E-04 3.908 10 
AK021665 Homo sapiens cDNA FLJ11603 fis  4.392 2.135 1.002 0.463 8.065 4.70E-05 5.546 10 
NM_003083 Small nuclear RNA activating complex SNAPC2 4.368 2.127 0.726 0.348 9.271 1.31E-05 7.286 10 
NM_052815 Immediate early response 3 IER3 4.323 2.112 1.325 0.625 6.243 4.12E-04 2.527 11 
AK055015 Homo sapiens cDNA FLJ30453 fis  4.317 2.110 1.148 0.528 6.685 2.32E-04 3.327 10 
NM_013288 DNA binding protein for surfactant 
protein B 
HUMBIN
DC 
4.314 2.109 1.442 0.750 5.872 8.58E-04 1.659 11 
NM_014465 Sulfotransferase family SULT1B1 4.284 2.099 1.294 0.606 6.484 2.99E-04 3.063 8 
NM_025040 Hypothetical protein FLJ21941 FLJ21941 4.216 2.076 1.020 0.398 4.979 2.35E-03 0.273 8 
AK056177 Homo sapiens cDNA FLJ31615 fis  4.211 2.074 1.244 0.604 6.463 3.07E-04 2.911 11 
NM_000917 Procollagen-proline P4HA1 4.202 2.071 1.238 0.598 6.501 2.91E-04 2.944 12 
NM_053278 Homo sapiens G protein-coupled 
receptor 102 
GPR102 4.187 2.066 1.104 0.533 7.280 1.12E-04 4.281 11 
NM_005442 Eomesodermin homolog (Xenopus 
laevis) 
EOMES 4.184 2.065 0.821 0.362 7.609 7.71E-05 4.776 11 
NM_003435 Zinc finger protein 134 (clone pHZ-15) ZNF134 4.144 2.051 0.511 0.269 10.810 3.08E-06 9.222 11 
AL353937 KIAA1280 protein KIAA1280 4.135 2.048 1.291 0.624 6.397 3.35E-04 2.912 8 
NM_005201 Chemokine (C-C motif) receptor 8 CCR8 4.124 2.044 0.951 0.463 8.300 3.62E-05 5.866 11 
NM_005245 FAT tumor suppressor homolog 1 
(Drosophila) 
FAT 4.112 2.040 0.790 0.430 9.777 8.04E-06 7.912 23 
AK021484 Homo sapiens cDNA FLJ11422 fis  4.101 2.036 0.713 0.328 11.730 1.42E-06 10.311 23 
NM_005077 Transducin-like enhancer of split 1 
(E(sp1) homolog, Drosophila) 
TLE1 4.070 2.025 0.594 0.330 8.006 5.03E-05 5.455 9 
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NM_000247 MHC class I polypeptide-related 
sequence 
MICA 4.045 2.016 1.348 0.663 5.818 7.39E-04 1.765 11 
NM_022829 Solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 3 
SLC13A3 4.028 2.010 0.901 0.446 8.541 2.76E-05 6.222 11 
AL049218 Homo sapiens mRNA FLJ11712 4.022 2.008 1.754 0.871 4.599 4.10E-03 -0.463 9 
AK022346 Homo sapiens cDNA FLJ12284 fis  3.953 1.983 0.625 0.353 8.334 3.48E-05 5.949 9 
NM_033226 ATP-binding cassette, sub-family C, 
member 12 
ABCC12 3.926 1.973 0.915 0.464 8.291 3.65E-05 5.824 12 
BC012458 Homo sapiens  3.907 1.966 0.523 0.262 12.390 8.60E-07 11.073 10 
NM_001220 Calcium/calmodulin-dependent protein 
kinase (CaM kinase) II beta 
CAMK2B 3.848 1.944 1.858 0.926 4.222 7.12E-03 -1.161 8 
NM_002061 Glutamate-cysteine ligase GCLM 3.834 1.939 0.686 0.398 7.442 9.30E-05 4.543 10 
NM_002229 Jun B proto-oncogene JUNB 3.821 1.934 0.952 0.492 7.827 6.09E-05 5.118 12 
NM_003408 Zinc finger protein 37 homolog (mouse) ZFP37 3.803 1.927 1.327 0.563 4.289 6.45E-03 -1.117 9 
NM_003059 Solute carrier family 22 (organic cation 
transporter), member 4 
SLC22A4 3.789 1.922 0.998 0.517 7.450 9.23E-05 4.555 11 
NM_012446 Single-stranded DNA binding protein 2 SSBP2 3.789 1.922 1.985 1.363 4.013 9.62E-03 -1.707 20 
AF172398 Junctional adhesion molecule 1 F11R 3.782 1.919 0.536 0.279 13.200 5.12E-07 11.887 12 
NM_006182 Discoidin domain receptor family DDR2 3.771 1.915 1.171 0.607 6.405 3.32E-04 2.846 10 
NM_022832 Hypothetical protein FLJ12552 USP46 3.769 1.914 0.997 0.517 7.368 1.02E-04 4.424 11 
AL157425 Homo sapiens cDNA FLJ12764 fis  3.755 1.909 0.808 0.414 8.766 2.17E-05 6.609 9 
BC015239 Homo sapiens  3.714 1.893 1.021 0.528 7.150 1.33E-04 4.140 9 
AK055946 Homo sapiens cDNA FLJ31384 fis  3.665 1.874 0.653 0.432 5.371 1.37E-03 0.976 9 
AY039760 Homo sapiens V-ATPase G3 subunit 
(ATP6V1G3) mRNA 
ATP6V1G
3 
3.648 1.867 1.173 0.622 6.222 4.24E-04 2.525 10 
NM_015474 SAM domain and HD domain SAMHD1 3.645 1.866 1.318 0.704 5.551 1.06E-03 1.275 11 
AK055644 Homo sapiens cDNA FLJ14429 fis  3.640 1.864 0.928 0.486 6.950 3.10E-04 3.163 8 
NM_003657 Breast carcinoma amplified sequence 1 BCAS1 3.618 1.855 0.633 0.333 10.660 3.48E-06 9.133 8 
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Y11918 H.sapiens IMAGE cDNA clone 26881  3.605 1.850 0.899 0.480 7.704 6.93E-05 4.957 11 
AB014530 KIAA0630 protein HIPK1 3.600 1.848 0.629 0.368 9.096 1.56E-05 6.987 11 
NM_001338 Coxsackie virus and adenovirus receptor CXADR 3.598 1.847 0.764 0.500 5.472 1.19E-03 1.128 10 
AL137411 Homo sapiens mRNA  3.595 1.846 1.870 0.993 3.997 9.82E-03 -1.608 8 
NM_005177 ATPase ATP6V0A
1 
3.593 1.845 0.595 0.348 9.523 1.03E-05 7.572 11 
AK025527 Homo sapiens cDNA: FLJ21874 fis INSR 3.588 1.843 0.399 0.216 15.970 9.25E-08 14.479 11 
NM_002034 Fucosyltransferase 5 (alpha (1,3) 
fucosyltransferase) 
FUT5 3.570 1.836 1.407 0.732 4.969 2.37E-03 0.300 8 
AK055794 Homo sapiens cDNA FLJ31232 fis  3.533 1.821 1.012 0.555 6.993 1.59E-04 3.811 11 
AB025432 Delta sleep inducing peptide, 
Glucocorticoid-induced leucine zipper 
protein 
GILZ 3.523 1.817 0.738 0.400 9.265 1.32E-05 7.306 9 
NM_024594 Hypothetical protein FLJ12899 PANK3 3.519 1.815 0.964 0.529 7.041 2.04E-04 3.583 10 
AK055962 ARG99 protein ARG99 3.516 1.814 0.819 0.460 7.769 6.51E-05 5.090 17 
AK057147 Homo sapiens cDNA FLJ32585 fis  3.509 1.811 0.481 0.266 12.470 8.13E-07 11.166 10 
AK000801 Homo sapiens cDNA FLJ20794 fis  3.502 1.808 0.858 0.563 5.816 7.41E-04 1.799 9 
AK055332 Homo sapiens cDNA FLJ30770 fis  3.494 1.805 0.779 0.426 8.521 2.79E-05 6.193 11 
NM_025174 Hypothetical protein FLJ23040 FLJ20203 3.487 1.802 1.412 1.471 5.795 7.65E-04 1.843 16 
AK023846 Hypothetical protein MGC3067 MGC3067 3.487 1.802 1.096 0.594 6.316 3.71E-04 2.730 9 
AK026924 Homo sapiens cDNA: FLJ23271 fis  3.482 1.800 0.637 0.354 10.610 3.59E-06 8.981 12 
NM_018282 Paraspeckle protein 1 PSP1 3.470 1.795 0.918 0.622 4.948 2.46E-03 0.135 10 
NM_016468 Hypothetical protein C14orf112 3.453 1.788 0.716 0.445 7.805 6.24E-05 5.219 17 
AK056506 Homo sapiens cDNA FLJ31944 fis  3.444 1.784 0.813 0.452 8.304 3.62E-05 5.904 10 
NM_007112 Thrombospondin 3 THBS3 3.422 1.775 1.100 0.571 6.030 5.48E-04 2.114 23 
NM_006739 MCM5 minichromosome maintenance 
deficient 5, cell division cycle 45 (S. 
cerevisiae) 
MCM5 3.420 1.774 0.444 0.283 9.047 1.64E-05 7.005 8 
U18004 HSU18004 Homo sapiens cDNA  3.413 1.771 0.929 0.520 7.413 9.66E-05 4.565 9 
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NM_024744 Amyotrophic lateral sclerosis 2 
(juvenile) chromosome region, candidate 
8 
ALS2CR8 3.408 1.769 1.096 0.624 6.321 3.69E-04 2.739 9 
AK024177 Homo sapiens cDNA FLJ14115 fis  3.406 1.768 1.538 0.865 4.546 4.43E-03 -0.610 10 
AK055990 Homo sapiens cDNA FLJ31428 fis DNAH9 3.392 1.762 0.929 0.527 7.304 1.10E-04 4.288 12 
AK025151 Homo sapiens cDNA: FLJ21498 fis  3.373 1.754 1.234 0.708 5.597 1.00E-03 1.397 10 
NM_033292 Caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) 
CASP1 3.368 1.752 1.257 0.787 5.621 1.20E-03 1.306 9 
AL050353 Opa-interacting protein 2 OIP2 3.366 1.751 0.914 0.518 7.322 1.08E-04 4.349 11 
AF057036 Collagen-like tail subunit (single strand 
of homotrimer) of asymmetric 
acetylcholinesterase 
COLQ 3.340 1.740 0.711 0.409 9.271 1.31E-05 7.229 12 
NM_004417 Dual specificity phosphatase 1 DUSP1 3.338 1.739 1.470 0.838 4.621 3.97E-03 -0.501 11 
AB001523 Transmembrane protein 1 TMEM1 3.336 1.738 0.866 0.493 7.667 7.25E-05 4.931 10 
AK056032 Homo sapiens cDNA FLJ31470 fis  3.329 1.735 0.861 0.486 7.561 8.08E-05 4.800 9 
NM_003275 Tropomodulin TMOD1 3.304 1.724 0.794 0.467 8.480 2.94E-05 6.104 23 
AB067501 Hypothetical protein FLJ14564  3.304 1.724 1.579 0.908 4.275 6.59E-03 -1.185 11 
NM_002462 Myxovirus (influenza virus) resistance 1 MX1 3.299 1.722 1.488 0.855 4.600 4.09E-03 -0.462 9 
NM_001523 Hyaluronan synthase 1 HAS1 3.278 1.713 0.872 0.604 5.532 1.09E-03 1.276 9 
BC012204 Homo sapiens  3.260 1.705 0.967 0.558 6.705 2.26E-04 3.361 10 
NM_014330 Protein phosphatase 1 PPP1R15A 3.258 1.704 0.449 0.257 12.000 1.17E-06 10.673 9 
NM_002451 Methylthioadenosine phosphorylase MTAP 3.254 1.702 0.907 0.533 7.307 1.09E-04 4.395 9 
NM_016310 Polymerase (RNA) III (DNA directed) 
polypeptide K, 12.3 kDa 
POLR3K 3.245 1.698 1.015 0.591 6.475 3.03E-04 2.968 10 
AK025620 Non-kinase Cdc42 effector protein 
SPEC2 
SPEC2 3.236 1.694 0.562 0.408 5.787 7.72E-04 1.709 10 
NM_016932 Sine oculis homeobox homolog 2 
(Drosophila) 
SIX2 3.233 1.693 0.715 0.419 8.904 1.89E-05 6.773 10 
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NM_005667 Zinc finger protein 103 homolog 
(mouse) 
RNF103 3.231 1.692 0.929 0.549 7.009 1.56E-04 3.805 12 
NM_000016 Acyl-Coenzyme A dehydrogenase ACADM 3.227 1.690 1.144 0.656 5.800 7.59E-04 1.852 8 
NM_001782 CD72 antigen CD72 3.224 1.689 0.871 0.495 7.057 1.48E-04 4.027 8 
NM_005664 Makorin MKRN3 3.220 1.687 1.056 0.525 4.379 5.62E-03 -1.013 11 
AL162040 Homo sapiens mRNA  3.207 1.681 0.658 0.386 9.364 1.19E-05 7.473 8 
NM_015675 Growth arrest and DNA-damage-
inducible, beta 
GADD45B 3.171 1.665 0.600 0.360 10.360 4.47E-06 8.665 12 
NM_021200 PH domain containing protein in retina 1 PLEKHB1 3.145 1.653 1.110 0.672 5.767 7.94E-04 1.638 12 
NM_001500 GDP-mannose 4 GMDS 3.141 1.651 0.739 0.381 5.858 6.96E-04 1.875 9 
NM_003388 Cytoplasmic linker 2 CYLN2 3.130 1.646 0.967 0.586 6.641 2.46E-04 3.253 10 
NM_015984 Ubiquitin C-terminal hydrolase UCH37 UCHL5 3.123 1.643 1.182 1.049 5.985 5.84E-04 2.144 18 
BC011883 Homo sapiens  3.108 1.636 0.857 0.525 7.349 1.04E-04 4.393 11 
AK022337 Homo sapiens cDNA FLJ12275 fis  3.095 1.630 0.452 0.249 7.969 5.17E-05 5.367 10 
AL137507 Homo sapiens mRNA  3.093 1.629 1.147 0.688 5.484 1.17E-03 1.229 9 
AL390172 Homo sapiens cDNA: FLJ21270 fis BCAT1 3.082 1.624 0.992 0.611 6.314 3.73E-04 2.618 12 
NM_018083 Zinc finger protein 358 ZNF358 3.072 1.619 0.894 0.550 6.748 2.84E-04 3.118 10 
AB032963 ATPase ATP8B2 3.057 1.612 0.370 0.276 6.888 1.82E-04 3.670 9 
AF155827 Helicase HELLS 3.050 1.609 1.202 0.726 5.274 1.56E-03 0.880 8 
NM_022916 Vacuolar protein sorting 33A (yeast) VPS33A 3.046 1.607 1.361 0.808 4.594 4.13E-03 -0.429 8 
AL133574 Homo sapiens mRNA  3.044 1.606 0.564 0.447 4.921 2.55E-03 0.082 10 
AL049341 Kruppel-like zinc finger protein  3.042 1.605 0.674 0.361 6.162 4.59E-04 2.421 9 
BC008442 Transmembrane 4 superfamily member 
1 
TM4SF1 3.040 1.604 1.461 0.904 4.295 6.40E-03 -1.145 11 
AK057215 Homo sapiens cDNA FLJ32653 fis  3.017 1.593 0.547 0.341 10.520 3.87E-06 8.891 11 
NM_006568 Cell growth regulatory with ring finger  CGRRF1 3.008 1.589 1.008 0.634 6.085 5.08E-04 2.212 12 
AB002331 Death associated transcription factor 1 DATF1 3.000 1.585 0.713 0.438 7.822 6.12E-05 5.173 10 
AK025307 Carnitine palmitoyltransferase I CPT1 2.996 1.583 0.942 0.595 6.470 3.04E-04 2.890 12 
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NM_018416 FOXJ2 forkhead factor FHX 2.990 1.580 1.145 0.696 5.326 1.45E-03 0.977 8 
NM_006435 Interferon induced transmembrane 
protein 
IFITM2 2.986 1.578 0.943 0.603 6.210 5.55E-04 2.235 10 
AL117595 Homo sapiens mRNA  2.981 1.576 0.527 0.417 9.420 2.83E-05 6.414 9 
AF064839 Hypothetical protein  2.981 1.576 1.120 0.731 4.978 3.33E-03 -0.028 8 
NM_032227 Hypothetical protein FLJ22679 FLJ22679 2.973 1.572 0.973 0.617 6.260 4.01E-04 2.557 11 
NM_018030 Oxysterol binding protein-like 1A OSBPL1A 2.973 1.572 0.588 0.423 6.788 2.05E-04 3.502 9 
NM_003440 Zinc finger protein 140 (clone pHZ-39) ZNF140 2.965 1.568 0.719 0.601 4.385 5.58E-03 -0.966 10 
AK055427 Homo sapiens cDNA FLJ30865 fis  2.961 1.566 0.977 0.617 6.076 5.14E-04 2.306 9 
NM_000454 Superoxide dismutase 1 SOD1 2.944 1.558 0.324 0.226 10.870 2.89E-06 9.300 11 
AK023371 Homo sapiens cDNA FLJ11872 fis  2.932 1.552 0.672 0.510 6.080 5.12E-04 2.238 10 
NM_024928 Hypothetical protein FLJ22559 FLJ22559 2.928 1.550 0.956 0.761 4.413 5.38E-03 -0.946 11 
NM_006085 3'(2'), 5'-bisphosphate nucleotidase 1 BPNT1 2.910 1.541 1.308 0.827 4.699 3.54E-03 -0.223 8 
AK055515 Homo sapiens cDNA: FLJ21260 fis  2.906 1.539 0.862 0.670 4.971 2.37E-03 0.142 11 
NM_012417 Retinal degeneration B beta PITPNC1 2.898 1.535 0.774 0.572 6.100 4.99E-04 2.240 11 
BC000073 Hypothetical protein MGC3260 KIAA1271 2.876 1.524 0.964 0.631 5.925 8.05E-04 1.752 10 
NM_016101 Hypothetical protein CGI-37 2.858 1.515 0.968 0.634 5.838 8.96E-04 1.602 10 
AK022134 Homo sapiens cDNA FLJ12072 fis CAT 2.834 1.503 0.552 0.314 6.739 2.17E-04 3.457 8 
NM_006457 PDZ and LIM domain 5, transcript 
variant 1 
PDLIM5 2.830 1.501 0.452 0.301 11.960 1.20E-06 10.563 12 
BC009838 Homo sapiens ELOVL5 2.826 1.499 0.842 0.562 6.817 1.98E-04 3.484 12 
BC016858 Homo sapiens  2.823 1.497 0.396 0.262 12.940 6.07E-07 11.656 10 
NM_020988 Guanine nucleotide binding protein (G 
protein), alpha activating activity 
polypeptide O 
GNAO1 2.793 1.482 1.095 0.730 5.264 1.58E-03 0.776 10 
NM_004841 RAS protein activator like 2 RASAL2 2.793 1.482 0.570 0.374 8.853 1.98E-05 6.733 9 
AL133064 Homo sapiens mRNA  2.766 1.468 0.578 0.448 6.346 3.58E-04 2.782 8 
Y11339 GalNAc alpha-2 ST6GalNA
cI 
2.745 1.457 0.941 0.697 6.112 6.31E-04 2.198 8 
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AB046845 E3 ubiquitin ligase SMURF1 SMURF1 2.738 1.453 0.417 0.286 12.200 1.00E-06 10.870 10 
AL512749 Homo sapiens mRNA SLC7A2 2.723 1.445 1.160 0.780 4.823 2.96E-03 -0.028 9 
AK022049 Homo sapiens cDNA FLJ11987 fis  2.717 1.442 0.845 0.490 4.923 2.54E-03 0.125 9 
NM_024588 Hypothetical protein FLJ23584 FLJ23584 2.715 1.441 0.479 0.334 10.780 3.13E-06 9.214 11 
NM_017923 Hypothetical protein FLJ20668 FLJ20668 2.713 1.440 0.520 0.357 9.632 1.44E-05 7.246 9 
NM_032188 Histone acetyltransferase MYST1 MYST1 2.698 1.432 1.035 0.718 5.394 1.33E-03 1.020 10 
NM_018142 Hypothetical protein FLJ10569 FLJ10569 2.691 1.428 0.748 0.513 6.905 2.39E-04 3.446 8 
AK022272 Homo sapiens cDNA FLJ12210 fis  2.683 1.424 0.663 0.521 6.634 2.48E-04 3.173 11 
NM_012175 F-box only protein 3 FBXO3 2.663 1.413 0.873 0.751 4.642 3.86E-03 -0.422 9 
NM_023948 Hypothetical protein AF053356_CDS3 AF053356
_CDS3 
2.661 1.412 1.217 0.869 4.544 4.44E-03 -0.614 10 
AK001133 Homo sapiens cDNA FLJ10271 fis  2.659 1.411 0.606 0.419 7.842 5.99E-05 5.238 9 
NM_003819 Poly(A) binding protein PABPC4 2.657 1.410 0.931 0.682 6.106 4.95E-04 2.284 22 
NM_004964 Histone deacetylase 1 HDAC1 2.656 1.409 0.473 0.363 8.536 2.76E-05 6.215 10 
NM_024308 Hypothetical protein MGC4172 MGC4172 2.637 1.399 0.728 0.516 7.317 1.08E-04 4.375 10 
NM_004997 Myosin binding protein H MYBPH 2.634 1.397 0.561 0.458 6.804 2.01E-04 3.495 10 
NM_005506 CD36 antigen (collagen type I receptor, 
thrombospondin receptor)-like 2 
CD36L2 2.617 1.388 0.866 0.623 6.136 4.75E-04 2.374 10 
NM_032332 Hypothetical protein MGC4238 MGC4238 2.608 1.383 0.742 0.542 6.795 2.03E-04 3.592 8 
NM_006730 Deoxyribonuclease I-like 1 DNASE1L
1 
2.603 1.380 1.058 0.757 5.076 2.04E-03 0.418 10 
AL080186 DKFZP564B0769 protein DKFZp564
B0769 
2.595 1.376 0.946 0.682 5.761 7.99E-04 1.782 8 
AB011123 KIAA0551 protein KIAA0551 2.590 1.373 0.682 0.474 8.270 3.75E-05 5.822 19 
AL049254 Homo sapiens mRNA  2.588 1.372 0.965 0.703 5.476 1.18E-03 1.101 12 
NM_003375 Voltage-dependent anion channel 2 VDAC2 2.586 1.371 0.694 0.627 4.973 2.37E-03 0.182 10 
NM_004334 Bone marrow stromal cell antigen 1 BST1 2.583 1.369 0.391 0.301 12.000 1.17E-06 10.610 23 
NM_014674 KIAA0212 gene product EDEM1 2.583 1.369 0.995 0.735 5.420 1.28E-03 1.110 9 
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NM_032785 Hypothetical protein FLJ14442  2.511 1.328 0.665 0.489 7.114 1.39E-04 4.044 10 
NM_018195 Hypothetical protein FLJ10726 FLJ10726 2.488 1.315 0.575 0.437 8.530 2.77E-05 6.206 11 
NM_015972 RNA polymerase I 16 kDa subunit MGC9850 2.481 1.311 0.344 0.257 10.620 3.56E-06 9.042 10 
NM_021073 Bone morphogenetic protein 5 BMP5 2.466 1.302 0.625 0.471 7.448 9.24E-05 4.586 10 
AL117638 Homo sapiens mRNA  2.459 1.298 0.625 0.476 7.622 7.62E-05 4.827 11 
NM_031475 Espin ESPN 2.457 1.297 0.902 0.695 5.526 1.10E-03 1.193 12 
NM_005300 G protein-coupled receptor 34 GPR34 2.449 1.292 0.768 0.621 6.423 3.24E-04 2.878 20 
NM_020529 Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, alpha 
NFKBIA 2.449 1.292 0.774 0.589 6.382 3.40E-04 2.845 9 
AK021840 Homo sapiens cDNA FLJ11778 fis  2.447 1.291 0.627 0.486 7.720 6.82E-05 4.951 12 
AK000271 Homo sapiens cDNA FLJ20264 fis  2.444 1.289 0.494 0.451 5.667 9.03E-04 1.527 9 
NM_006037 Histone deacetylase 4 HDAC4 2.440 1.287 0.799 0.621 6.152 4.65E-04 2.333 12 
NM_016084 RAS RASD1 2.439 1.286 0.495 0.423 7.514 8.57E-05 4.657 10 
NM_031431 Tethering factor SEC34 SEC34 2.437 1.285 0.959 0.734 5.151 1.85E-03 0.560 10 
NM_032130 Hypothetical protein DKFZp434J0113 DKFZP43
4J0113 
2.435 1.284 0.462 0.296 5.390 1.33E-03 1.052 8 
NM_025080 Hypothetical protein FLJ22316 ASRGL1 2.427 1.279 0.735 0.576 6.641 2.46E-04 3.218 11 
NM_002633 Phosphoglucomutase 1 PGM1 2.427 1.279 0.527 0.467 6.605 2.56E-04 3.157 10 
BC009649 Serologically defined colon cancer 
antigen 16 
SDCCAG1
6 
2.427 1.279 0.357 0.320 7.831 6.07E-05 5.187 9 
NM_017892 Formin binding protein 3 FNBP3 2.405 1.266 0.871 0.686 5.604 9.92E-04 1.373 11 
NM_005195 CCAAT/enhancer binding protein 
(C/EBP) 
KIAA0146 2.402 1.264 1.137 0.899 4.343 5.96E-03 -1.050 11 
AB067506 KIAA1919 protein NaGLT1 2.402 1.264 1.039 0.825 4.734 3.35E-03 -0.281 11 
AJ237663 Homo sapiens ORF1  2.398 1.262 0.790 0.624 6.165 4.58E-04 2.426 10 
NM_013975 Ligase III LIG3 2.393 1.259 0.586 0.520 9.111 2.36E-05 6.646 8 
NM_006873 Stoned B/TFIIA-alpha/beta-like factor SBLF 2.385 1.254 1.032 0.811 4.822 2.96E-03 0.015 8 
NM_002971 Special AT-rich sequence binding SATB1 2.378 1.250 0.599 0.546 6.085 5.08E-04 2.247 10 
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BC008613 Homo sapiens  2.367 1.243 0.474 0.427 6.845 1.92E-04 3.563 10 
NM_007007 Cleavage and polyadenylation specific 
factor 6, 68kDa 
CPSF6 2.354 1.235 0.587 0.538 6.284 3.88E-04 2.600 10 
NM_004869 Suppressor of K  transport defect 1 VPS4B 2.341 1.227 0.612 0.499 7.502 8.71E-05 4.606 12 
NM_003930 Src family associated phosphoprotein 2 SCAP2 2.338 1.225 0.998 0.818 4.798 3.07E-03 -0.118 10 
NM_015507 EGF-like-domain EGFL6 2.321 1.215 0.382 0.370 6.854 1.89E-04 3.651 8 
AL049390 Homo sapiens mRNA  2.310 1.208 0.787 0.641 5.845 7.09E-04 1.891 9 
NM_004582 Rab geranylgeranyltransferase RABGGT
B 
2.297 1.200 0.890 0.734 5.070 2.45E-03 0.318 8 
BC012851 Uroplakin 1B UPK1B 2.291 1.196 1.008 0.834 4.677 3.66E-03 -0.266 8 
NM_017620 Hypothetical protein FLJ20011  2.288 1.194 0.573 0.470 7.443 9.30E-05 4.577 10 
NM_002937 Ribonuclease RNASE4 2.277 1.187 1.011 0.815 4.560 4.33E-03 -0.494 8 
NM_025034 Hypothetical protein FLJ21290 USH1C 2.274 1.185 0.409 0.418 5.952 6.11E-04 2.045 9 
AB046784 KIAA1564 protein HELSNF1 2.261 1.177 0.873 0.722 5.186 1.75E-03 0.712 8 
NM_006534 Nuclear receptor coactivator 3 NCOA3 2.253 1.172 0.990 0.838 4.618 3.99E-03 -0.468 10 
NM_032865 Hypothetical protein FLJ14950 CTEN 2.249 1.169 0.649 0.712 4.333 6.05E-03 -1.070 10 
NM_012208 Histidyl-tRNA synthetase-like HARSL 2.235 1.160 0.409 0.319 7.595 7.83E-05 4.786 10 
NM_031229 Chromosome 20 open reading frame 18 C20orf18 2.228 1.156 0.511 0.400 6.727 2.20E-04 3.332 11 
NM_014211 Gamma-aminobutyric acid (GABA) A 
receptor, pi 
GABRP 2.228 1.156 0.926 0.801 4.799 3.06E-03 -0.189 12 
NM_015344 Leptin receptor overlapping transcript-
like 1 
LEPROTL
1 
2.225 1.154 1.078 0.914 4.143 7.96E-03 -1.407 10 
NM_018428 Hepatocellular carcinoma-associated 
antigen 66 
HCA66 2.210 1.144 0.666 0.544 6.611 2.53E-04 3.134 23 
BC015994 Homo sapiens  2.192 1.132 0.643 0.568 6.616 2.52E-04 3.142 12 
AB037771 KIAA1350 protein  2.192 1.132 0.676 0.597 6.320 3.70E-04 2.629 12 
NM_005875 Translation factor sui1 homolog GC20 2.187 1.129 0.552 0.489 7.564 8.07E-05 4.706 12 
90
 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
NM_000962 Prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase) 
PTGS1 2.184 1.127 0.986 0.865 4.393 5.53E-03 -0.950 11 
J05582 Mucin 1, human pancreatic mucin 
mRNA 
MUC1 2.164 1.114 0.770 0.691 5.512 1.12E-03 1.169 12 
AK057446 Homo sapiens cDNA FLJ32884 fis  2.161 1.112 0.563 0.509 7.347 1.04E-04 4.498 8 
NM_002826 Quiescin Q6 QSCN6 2.157 1.109 0.413 0.372 9.517 1.03E-05 7.565 12 
AK002107 Homo sapiens cDNA FLJ11245 fis RAB3B 2.154 1.107 0.823 0.753 5.138 1.88E-03 0.536 10 
NM_032827 Hypothetical protein FLJ14708 HATH6 2.142 1.099 0.896 0.796 4.652 3.81E-03 -0.403 10 
NM_019000 Hypothetical protein FLJ20152 2.139 1.097 0.979 0.860 4.289 6.45E-03 -1.074 9 
NM_005746 Pre-B-cell colony-enhancing factor PBEF 2.132 1.092 0.552 0.504 7.324 1.08E-04 4.353 11 
BC004501 Homo sapiens MGC3386
7 
2.130 1.091 0.557 0.511 7.301 1.10E-04 4.349 10 
AK055768 Homo sapiens cDNA FLJ31206 fis  2.130 1.091 1.031 0.938 4.137 8.02E-03 -1.419 10 
NM_031959 Keratin associated protein 3.2 KRTAP3-2 2.127 1.089 0.787 0.710 5.195 1.73E-03 0.730 8 
AB046843 KIAA1623 protein KIAA1623 2.111 1.078 0.533 0.405 5.139 1.87E-03 0.580 8 
AK024303 Homo sapiens cDNA FLJ14241 fis  2.107 1.075 0.879 0.818 4.692 3.58E-03 -0.398 12 
NM_000107 Damage-specific DNA binding protein 
2, 48kDa 
DDB2 2.104 1.073 0.940 0.888 4.427 5.27E-03 -0.844 10 
AF339829 Homo sapiens clone IMAGE:609847  2.104 1.073 0.234 0.201 10.100 5.77E-06 8.362 10 
NM_003768 Phosphoprotein enriched in astrocytes 
15 
PEA15 2.102 1.072 0.663 0.799 4.098 8.50E-03 -1.537 10 
NM_004262 Airway trypsin-like protease HAT 2.092 1.065 0.902 0.858 4.518 4.60E-03 -0.622 9 
NM_023078 Hypothetical protein FLJ13852 FLJ13852 2.091 1.064 0.604 0.599 5.485 1.17E-03 1.151 21 
NM_016824 Adducin 3 (gamma) ADD3 2.088 1.062 0.641 0.598 6.164 4.58E-04 2.388 11 
NM_000961 Prostaglandin I2 (prostacyclin) synthase PTGIS 2.088 1.062 0.595 0.560 6.655 2.42E-04 3.209 12 
BC012758 Homo sapiens LOC14960
3 
2.081 1.057 0.875 0.828 4.507 5.37E-03 -0.816 10 
NM_004456 Enhancer of zeste homolog 2 EZH2 2.073 1.052 0.896 0.808 4.450 5.10E-03 -0.711 8 
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NM_003501 Acyl-Coenzyme A oxidase 3 ACOX3 2.071 1.050 0.743 0.888 4.044 9.20E-03 -1.645 10 
AF209930 Chordin CHRD 2.071 1.050 0.862 0.894 4.227 7.08E-03 -1.241 19 
NM_003131 Serum response factor (c-fos serum 
response element-binding transcription 
factor) 
SRF 2.069 1.049 0.597 0.552 6.496 2.93E-04 3.083 8 
AK054789 Homo sapiens cDNA FLJ30227 fis  2.069 1.049 0.774 0.732 5.208 1.70E-03 0.668 10 
AF130056 Homo sapiens clone FLB5227 PRO1367 
mRNA 
RNF12 2.068 1.048 0.878 0.806 4.394 5.52E-03 -0.908 10 
NM_016410 Hypothetical protein HSPC177 HSPC177 2.056 1.040 0.399 0.384 9.175 1.44E-05 7.097 12 
NM_002970 Spermidine/spermine N1-
acetyltransferase 
SAT 2.053 1.038 0.539 0.614 5.217 1.68E-03 0.613 22 
NM_016264 GIOT-2 for gonadotropin inducible 
transcription repressor-2 
ZNF44 2.051 1.036 0.706 0.683 5.608 9.87E-04 1.418 10 
NM_052886 Mal MAL2 2.042 1.030 0.882 0.827 4.538 4.48E-03 -0.538 8 
AB067502 KIAA1915 protein KIAA1915 2.036 1.026 0.697 0.684 5.563 1.05E-03 1.297 11 
NM_021622 Pleckstrin homology domain containing, 
family A (phosphoinositide binding 
specific) member 1 
PLEKHA1 2.034 1.024 0.554 0.541 6.841 1.92E-04 3.524 12 
X06389 Synaptophysin SYP 2.032 1.023 0.508 0.486 7.188 1.27E-04 4.203 9 
BC013305 Homo sapiens  2.024 1.017 0.744 0.727 5.209 1.70E-03 0.634 11 
NM_000343 Solute carrier family 5 (sodium/glucose 
cotransporter), member 1 
SLC5A1 2.021 1.015 0.844 0.969 4.478 5.56E-03 -0.782 9 
NM_001356 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked 
DDX3X 2.020 1.014 0.449 0.504 6.321 3.69E-04 2.700 9 
NM_024836 Hypothetical protein FLJ22301 FLJ22301 2.020 1.014 0.608 0.585 5.862 6.93E-04 1.883 10 
NM_002231 Kangai 1 (suppression of tumorigenicity 
6, prostate) 
KAI1 2.020 1.014 0.933 0.923 4.211 7.22E-03 -1.312 11 
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NM_003250 Thyroid hormone receptor THRA 2.014 1.010 0.743 0.736 5.169 1.80E-03 0.522 12 
NM_053043 Hypothetical protein MGC20460  -2.003 -1.002 0.910 2.407 -4.143 7.96E-03 -1.446 16 
BC013164 Homo sapiens cDNA: FLJ22646 fis  -2.006 -1.004 0.953 0.943 -4.114 8.30E-03 -1.466 10 
AK024986 Homo sapiens cDNA: FLJ21333 fis PTEN -2.010 -1.007 0.399 0.386 -7.372 1.02E-04 4.463 10 
AK024302 Homo sapiens cDNA FLJ14240 fis OCIA -2.022 -1.016 0.721 0.709 -5.376 1.36E-03 0.948 11 
NM_005778 RNA binding motif protein 5 RBM5 -2.027 -1.019 0.967 0.941 -4.066 8.89E-03 -1.600 11 
NM_015980 HMP19 protein HMP19 -2.029 -1.021 0.905 0.883 -4.463 4.99E-03 -0.684 8 
NM_023080 Hypothetical protein FLJ20989 FLJ20989 -2.035 -1.025 0.762 1.309 -5.961 6.05E-04 2.025 20 
NM_052946 Hypothetical protein MGC20702 NOSTRIN -2.035 -1.025 0.691 0.664 -5.586 1.01E-03 1.461 8 
BC012362 RAP2B, member of RAS oncogene 
family 
RAP2B -2.039 -1.028 0.682 0.652 -5.648 9.31E-04 1.492 10 
NM_000346 SRY (sex determining region Y)-box 9 
(campomelic dysplasia, autosomal sex-
reversal) 
SOX9 -2.041 -1.029 0.943 0.931 -4.258 6.76E-03 -1.136 9 
AK023948 Homo sapiens cDNA FLJ13886 fis  -2.046 -1.033 0.742 0.744 -4.812 3.00E-03 -0.003 8 
NM_014635 KIAA0336 gene product GCC185 -2.051 -1.036 0.890 0.872 -4.445 5.14E-03 -0.767 9 
NM_016038 CGI-97 protein SBDS -2.078 -1.055 0.802 0.757 -5.048 2.13E-03 0.327 11 
NM_004904 cAMP response element-binding protein 
CRE-Bpa 
CREB5 -2.085 -1.060 0.728 0.669 -5.373 1.36E-03 0.980 10 
NM_014292 Chromobox homolog 6 CBX6 -2.092 -1.065 0.761 0.708 -5.313 1.47E-03 0.831 11 
NM_012071 BUP protein BUP -2.097 -1.068 0.623 0.583 -6.431 3.21E-04 2.822 12 
NM_022343 17kD fetal brain protein C9orf19 -2.097 -1.068 0.562 0.517 -6.855 1.89E-04 3.614 10 
BC010117 Hypothetical protein MGC13038 BCAN -2.105 -1.074 0.887 0.818 -4.638 3.88E-03 -0.469 11 
NM_001455 Forkhead box O3A FOXO3A -2.114 -1.080 0.754 0.827 -4.486 4.84E-03 -0.803 11 
NM_006991 Zinc finger protein 197 ZNF197 -2.117 -1.082 0.999 0.980 -4.794 3.60E-03 -0.236 17 
NM_021111 Reversion-inducing-cysteine-rich 
protein 
RECK -2.121 -1.085 0.545 0.626 -8.086 4.58E-05 5.576 18 
NM_007043 HIV-1 rev binding protein 2 HRB2 -2.124 -1.087 0.794 0.719 -5.186 1.75E-03 0.627 10 
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NM_001565 Small inducible cytokine subfamily B 
(Cys-X-Cys), member 10 
CXCL10 -2.144 -1.100 0.363 0.375 -6.962 1.65E-04 3.758 10 
BI832330 ESTs  -2.145 -1.101 0.500 0.454 -8.051 4.77E-05 5.461 12 
AL110248 Homo sapiens mRNA  -2.145 -1.101 0.694 0.634 -6.003 5.68E-04 2.100 11 
NM_001374 Deoxyribonuclease I-like 2 DNASE1L
2 
-2.160 -1.111 0.354 0.333 -7.080 1.44E-04 4.064 8 
NM_021178 Enhancer of invasion 10, Cyclin B1 
interacting protein 1, transcript variant 1 
CCNB1IP1 -2.161 -1.112 0.619 0.562 -6.630 2.49E-04 3.199 11 
BC012882 Homo sapiens LOC15035
6 
-2.164 -1.114 0.447 0.486 -5.406 1.30E-03 1.004 10 
NM_001730 Kruppel-like factor 5 (intestinal) KLF5 -2.186 -1.128 0.696 0.779 -4.005 9.73E-03 -1.640 8 
AL136878 Paraneoplastic cancer-testis-brain 
antigen 
PNMA3 -2.195 -1.134 0.564 0.490 -7.092 1.42E-04 3.974 11 
NM_006670 Trophoblast glycoprotein TPBG -2.196 -1.135 0.786 0.676 -5.417 1.29E-03 1.062 10 
NM_002933 Ribonuclease RNASE1 -2.198 -1.136 0.843 0.743 -5.192 1.74E-03 0.638 10 
NM_003135 Signal recognition particle 19kD SRP19 -2.198 -1.136 0.590 0.523 -7.120 1.38E-04 4.091 9 
NM_022553 SAC2 suppressor of actin mutations 2-
like 
VPS52 -2.202 -1.139 0.855 0.962 -4.057 9.03E-03 -1.578 17 
AK023317 Homo sapiens cDNA FLJ13255 fis HSPA9B -2.205 -1.141 0.466 0.357 -6.396 3.35E-04 2.869 8 
AL109705 Homo sapiens mRNA full length insert 
cDNA clone 
 -2.205 -1.141 0.260 0.229 -13.030 5.83E-07 11.733 11 
NM_001498 Glutamate-cysteine ligase GCLC -2.210 -1.144 1.090 0.952 -4.091 8.56E-03 -1.550 11 
NM_022749 Retinoic acid induced 16 RAI16 -2.211 -1.145 0.952 0.822 -4.655 3.78E-03 -0.395 10 
AB023204 Erythrocyte membrane protein band 4.1-
like 3 
EPB41L3 -2.222 -1.152 0.719 0.652 -5.594 1.00E-03 1.432 9 
AK001478 Wnt-1 responsive Cdc42 homolog WRCH1 -2.230 -1.157 1.008 0.870 -4.462 5.00E-03 -0.814 11 
NM_013989 Deiodinase DIO2 -2.231 -1.158 0.562 0.550 -6.134 4.75E-04 2.300 11 
BC000268 Proteasome PSMB2 -2.255 -1.173 0.699 0.719 -4.650 3.82E-03 -0.445 10 
NM_019088 Hypothetical protein F23149_1 PD2 -2.256 -1.174 0.572 0.464 -6.291 3.84E-04 2.687 9 
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NM_002491 NADH dehydrogenase (ubiquinone) 1 
beta subcomplex, 3, 12kDa 
NDUFB3 -2.259 -1.176 0.902 0.767 -5.015 2.23E-03 0.227 12 
AL136924 RAB5 interacting protein 2 RIN2 -2.261 -1.177 0.724 0.608 -6.094 5.02E-04 2.263 11 
BC005847 Hypothetical protein DKFZp667O116  -2.277 -1.187 0.620 0.604 -5.674 8.96E-04 1.502 10 
NM_002351 SH2 domain protein 1A SH2D1A -2.283 -1.191 1.118 0.928 -4.211 7.22E-03 -1.229 9 
AL359931 Ras protein-specfic guanine nucleotide-
releasing factor 1 
RASGRF1 -2.286 -1.193 0.485 0.348 -6.008 7.23E-04 1.933 8 
AK057176 Hypothetical protein 669  -2.288 -1.194 0.990 0.822 -4.686 3.61E-03 -0.336 10 
AY027862 Upregulated in colorectal cancer gene 1 UCC1 -2.291 -1.196 0.417 0.344 -9.502 1.04E-05 7.571 11 
NM_015544 DKFZP564K1964 protein DKFZP56
4K1964 
-2.302 -1.203 0.745 0.616 -5.937 7.96E-04 1.771 10 
NM_031461 CocoaCrisp CRISPLD1 -2.317 -1.212 0.931 0.764 -5.136 1.88E-03 0.618 8 
NM_020397 CamKI-like protein kinase CKLiK -2.320 -1.214 0.357 0.270 -8.721 2.29E-05 6.454 11 
AK023942 Homo sapiens cDNA FLJ13880 fis  -2.320 -1.214 0.739 0.609 -6.281 3.90E-04 2.629 10 
NM_006667 Progesterone receptor membrane 
component 
PGRMC1 -2.325 -1.217 0.844 0.694 -5.522 1.11E-03 1.186 12 
NM_022159 EGF-TM7-latrophilin-related protein ELTD1 -2.329 -1.220 0.916 0.739 -4.974 2.80E-03 0.097 9 
NM_001375 Deoxyribonuclease II DNASE2 -2.336 -1.224 0.524 0.490 -6.339 3.60E-04 2.663 11 
NM_014062 ART-4 protein NOB1P -2.338 -1.225 0.941 0.740 -4.762 3.22E-03 -0.146 9 
NM_017908 Hypothetical protein FLJ20626  -2.338 -1.225 1.001 0.818 -4.833 2.91E-03 -0.009 9 
AK025326 Hypothetical protein FLJ21673  -2.341 -1.227 0.935 0.755 -5.149 1.85E-03 0.599 9 
NM_015906 Tripartite motif-containing 33 TRIM33 -2.349 -1.232 0.537 0.374 -5.392 1.33E-03 0.944 11 
AB058693 Hypothetical protein FLJ23119  -2.355 -1.236 0.522 0.528 -5.021 2.21E-03 0.274 10 
AK025007 Homo sapiens cDNA: FLJ21354 fis FLJ38771 -2.357 -1.237 1.073 0.860 -4.519 4.60E-03 -0.663 10 
BC008191 Pleckstrin homology, Sec7 and coiled-
coil domains 3 
PSCD3 -2.365 -1.242 1.001 0.818 -4.760 3.23E-03 -0.105 8 
NM_015400 DKFZP586N0721 protein DKFZP58
6N0721 
-2.370 -1.245 0.519 0.536 -4.482 4.86E-03 -0.811 11 
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AK026883 Homo sapiens cDNA: FLJ23230 fis  -2.373 -1.247 0.969 1.392 -6.705 2.26E-04 3.362 16 
NM_004425 Extracellular matrix protein 1 ECM1 -2.375 -1.248 0.765 0.503 -4.524 4.57E-03 -0.654 9 
NM_009587 Lectin LGALS9 -2.378 -1.250 0.759 0.600 -6.172 4.54E-04 2.401 11 
NM_031437 Hypothetical protein MGC10823 RASSF5 -2.378 -1.250 0.692 0.556 -6.749 2.15E-04 3.515 8 
AL122043 Hypothetical protein DKFZp566G1424 C20orf112 -2.390 -1.257 0.560 0.443 -8.340 3.46E-05 5.958 10 
BC013082 Seven in absentia homolog 2 
(Drosophila) 
SIAH2 -2.398 -1.262 0.501 0.362 -6.414 3.28E-04 2.826 10 
NM_016048 CGI-111 protein CGI-111 -2.400 -1.263 0.724 0.571 -6.665 2.39E-04 3.332 9 
NM_020401 Nuclear pore complex protein NUP107 -2.407 -1.267 0.953 0.752 -5.120 1.92E-03 0.429 12 
NM_000358 Transforming growth factor TGFBI -2.410 -1.269 0.784 0.638 -5.541 1.08E-03 1.334 9 
NM_004566 6-phosphofructo-2-kinase/fructose-2 PFKFB3 -2.415 -1.272 1.041 0.826 -4.724 3.41E-03 -0.300 11 
NM_017875 Hypothetical protein FLJ20551 FLJ20551 -2.422 -1.276 1.175 0.892 -4.117 8.25E-03 -1.459 10 
NM_024960 Chromosome 20 open reading frame 48 PANK2 -2.439 -1.286 0.753 0.586 -6.501 2.91E-04 2.944 12 
AF417165 5'-nucleotidase, cytosolic IB NT5C1B -2.444 -1.289 0.857 0.656 -5.770 7.91E-04 1.715 10 
AK024911 Heterogeneous nuclear 
ribonucleoprotein  
HNRPM -2.452 -1.294 0.981 0.757 -5.118 1.93E-03 0.460 11 
NM_002689 Polymerase (DNA-directed) POLA2 -2.452 -1.294 0.778 0.575 -5.943 6.18E-04 2.068 9 
NM_003426 Zinc finger protein 74 (Cos52) ZNF74 -2.455 -1.296 0.852 0.644 -5.725 8.37E-04 1.634 10 
NM_013312 Hook2 protein HOOK2 -2.462 -1.300 0.950 0.601 -5.541 1.08E-03 1.222 22 
NM_032640 Hypothetical protein MGC10526 MGC1052
6 
-2.467 -1.303 0.988 0.778 -4.866 2.76E-03 0.015 10 
NM_003054 Solute carrier family 18 (vesicular 
monoamine), member 2 
SLC18A2 -2.467 -1.303 0.677 0.422 -4.780 3.13E-03 -0.110 8 
AK024192 Homo sapiens cDNA FLJ14130 fis  -2.469 -1.304 0.727 0.558 -6.841 1.92E-04 3.557 11 
AK021643 Homo sapiens cDNA FLJ11581 fis  -2.471 -1.305 0.533 0.411 -8.951 1.82E-05 6.810 11 
NM_001788 CDC10 cell division cycle 10 homolog 
(S. cerevisiae) 
CDC10 -2.481 -1.311 0.823 0.809 -4.154 8.72E-03 -1.446 8 
NM_052859 Putative endoplasmic reticulum 
multispan transmembrane protein 
RFT1 -2.491 -1.317 0.494 0.375 -9.755 8.21E-06 7.936 10 
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NM_032626 Retinoblastoma binding protein 6, 
transcript variant 3 
RBBP6 -2.497 -1.320 0.764 1.099 -4.539 4.47E-03 -0.663 20 
NM_006007 Zinc finger protein 216 ZNF216 -2.500 -1.322 0.861 0.637 -5.764 7.97E-04 1.743 9 
AF029729 Neuralized-like (Drosophila) NEURL -2.507 -1.326 1.110 0.839 -4.661 3.75E-03 -0.423 11 
AK057278 Contactin 4 CNTN4 -2.519 -1.333 0.834 0.629 -6.025 5.52E-04 2.215 9 
NM_002447 Macrophage stimulating 1 receptor (c-
met-related tyrosine kinase) 
MST1R -2.521 -1.334 1.110 0.819 -4.744 3.31E-03 -0.181 9 
NM_012080 DNA segment FAM16AX -2.535 -1.342 1.218 0.868 -4.216 7.19E-03 -1.220 9 
NM_032982 Caspase 2 CASP2 -2.537 -1.343 0.596 0.438 -7.554 8.14E-05 4.827 8 
AJ000503 Dopachrome tautomerase (dopachrome 
delta-isomerase, tyrosine-related protein 
2) 
DCT -2.558 -1.355 1.114 0.807 -4.701 3.53E-03 -0.307 10 
AK024127 Homo sapiens cDNA FLJ14065 fis SNRP70 -2.558 -1.355 1.090 0.825 -4.421 5.33E-03 -0.768 8 
NM_001664 Ras homolog gene family ARHA -2.562 -1.357 0.803 0.709 -4.814 2.99E-03 -0.161 11 
NM_013380 Zinc finger protein 228 ZNF228 -2.562 -1.357 0.957 0.720 -5.055 2.50E-03 0.292 8 
U14383 Mucin 8 MUC8 -2.578 -1.366 0.248 0.193 -12.640 7.30E-07 11.358 8 
L19267 Dystrophia myotonica-containing WD 
repeat motif 
DMWD -2.588 -1.372 0.932 0.681 -5.696 8.69E-04 1.542 11 
NM_024954 Hypothetical protein FLJ11807 FLJ11807 -2.597 -1.377 0.250 0.171 -12.620 7.30E-07 11.287 11 
NM_002655 Pleiomorphic adenoma gene 1 PLAG1 -2.599 -1.378 0.967 0.702 -5.491 1.16E-03 1.129 12 
NM_003809 Tumor necrosis factor (ligand) 
superfamily, member 12 
TNFSF12 -2.604 -1.381 0.450 0.325 -11.000 2.56E-06 9.476 11 
NM_005582 Lymphocyte antigen 64 homolog LY64 -2.606 -1.382 1.008 0.751 -4.908 2.60E-03 0.056 11 
BC011808 Chromosome 1 open reading frame 28  -2.606 -1.382 1.083 0.784 -4.939 2.49E-03 0.081 12 
NM_022154 Up-regulated by BCG-CWS BIGM103 -2.608 -1.383 0.545 0.394 -9.372 1.19E-05 7.367 12 
NM_024640 Hypothetical protein FLJ23476 FLJ23476 -2.610 -1.384 0.442 0.357 -8.036 4.86E-05 5.535 8 
NM_014371 Neighbor of A-kinase anchoring protein 
9 
NAKAP95 -2.621 -1.390 0.551 0.461 -6.212 4.29E-04 2.438 11 
NM_014766 KIAA0193 gene product KIAA0193 -2.624 -1.392 0.627 0.429 -7.496 8.74E-05 4.736 8 
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AB058773 KIAA1870 protein COL27A1 -2.630 -1.395 0.573 0.395 -7.562 8.08E-05 4.801 9 
NM_030578 Hypothetical protein MGC4093 MGC4093 -2.643 -1.402 0.767 0.555 -6.752 2.14E-04 3.479 16 
AK021427 Homo sapiens cDNA FLJ11365 fis  -2.657 -1.410 1.153 0.801 -4.699 3.54E-03 -0.311 10 
AK057456 Homo sapiens cDNA FLJ32894 fis  -2.657 -1.410 1.259 0.899 -4.407 5.42E-03 -0.883 10 
AK025706 Adenosine monophosphate deaminase 2 
(isoform L) 
AMPD2 -2.659 -1.411 0.492 0.351 -9.431 1.13E-05 7.503 10 
NM_031426 Hypothetical protein FLJ12783 IBA2 -2.661 -1.412 0.706 0.500 -7.547 8.20E-05 4.743 10 
BC017907 Homo sapiens  -2.665 -1.414 0.784 0.745 -5.622 9.66E-04 1.407 21 
AK001279 Homo sapiens cDNA FLJ10417 fis  -2.674 -1.419 0.694 0.489 -7.731 6.74E-05 4.968 12 
AK055877 Homo sapiens cDNA FLJ31315 fis  -2.678 -1.421 0.640 0.537 -5.365 1.38E-03 0.928 10 
NM_003684 MAP kinase-interacting serine/threonine  MKNK1 -2.689 -1.427 0.725 0.503 -7.361 1.03E-04 4.412 11 
NM_001150 Alanyl (membrane) aminopeptidase 
(aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, 
p150) 
ANPEP -2.693 -1.429 1.324 0.915 -4.294 6.40E-03 -1.064 9 
NM_024770 Hypothetical protein FLJ13984 FLJ13984 -2.696 -1.431 0.489 0.331 -9.710 8.62E-06 7.935 8 
NM_002855 Poliovirus receptor-related 1 
(herpesvirus entry mediator C; nectin) 
PVRL1 -2.700 -1.433 0.880 0.582 -5.895 6.64E-04 2.024 8 
AB058755 Hypothetical protein FLJ14260  -2.702 -1.434 0.525 0.330 -6.961 1.65E-04 3.828 8 
AB023210 KIAA0993 protein  -2.704 -1.435 1.221 0.852 -4.599 4.10E-03 -0.544 11 
AK022928 Helicase, lympoid-specific HELLS -2.715 -1.441 0.690 0.479 -7.900 5.57E-05 5.231 12 
AK055808 Homo sapiens  -2.717 -1.442 0.984 0.679 -5.712 8.51E-04 1.608 10 
NM_005573 Lamin B1 LMNB1 -2.721 -1.444 0.833 0.580 -6.706 2.26E-04 3.364 10 
AB038651 K562 cell-derived leucine-zipper-like 
protein 1 
KLP1 -2.723 -1.445 1.106 0.975 -4.017 9.57E-03 -1.698 21 
AL512731 Homo sapiens mRNA  -2.725 -1.446 1.337 0.915 -4.206 7.27E-03 -1.321 11 
AK026717 Selenoprotein W, 1 SEPW1 -2.734 -1.451 1.141 0.786 -4.931 2.51E-03 0.066 12 
NM_018222 Parvin PARVA -2.738 -1.453 1.422 0.972 -4.011 9.65E-03 -1.628 9 
98
 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
NM_013438 Ubiquilin 1 UBQLN1 -2.742 -1.455 0.664 0.448 -7.994 5.07E-05 5.437 10 
AK023151 Hypothetical protein FLJ13089  -2.743 -1.456 0.570 0.387 -8.866 2.98E-05 6.226 10 
NM_014723 Syntaphilin SNPH -2.753 -1.461 0.301 0.226 -8.969 1.80E-05 6.897 8 
NM_032816 Hypothetical protein FLJ14640  -2.757 -1.463 0.762 0.532 -6.805 2.01E-04 3.609 8 
AK056965 Homo sapiens cDNA FLJ32403 fis MGC2744 -2.759 -1.464 1.041 0.700 -5.431 1.26E-03 1.090 10 
NM_014599 EH-domain containing 4 MAGED2 -2.770 -1.470 1.170 0.796 -4.875 2.73E-03 -0.042 12 
AK000757 Homo sapiens cDNA FLJ20750 fis SORT1 -2.778 -1.474 1.299 0.863 -4.453 5.08E-03 -0.750 9 
NM_002160 Hexabrachion (tenascin C TNC -2.788 -1.479 0.986 0.645 -5.300 1.50E-03 0.844 10 
AF055018 Homo sapiens clone 24442 mRNA 
sequence 
 -2.795 -1.483 0.851 0.500 -5.354 1.40E-03 0.906 10 
BC013113 Homo sapiens MGC3321
2 
-2.803 -1.487 0.950 0.624 -5.700 1.08E-03 1.401 9 
X95097 Vasoactive intestinal peptide receptor 2 VIPR2 -2.803 -1.487 0.804 0.537 -7.173 1.30E-04 4.216 8 
AJ414564 Homo sapiens mRNA for connexin40.1 
(CX40.1 gene) 
 -2.809 -1.490 0.404 0.244 -7.626 7.58E-05 4.902 8 
NM_001966 Enoyl-Coenzyme A EHHADH -2.832 -1.502 0.552 0.361 -9.806 7.80E-06 8.031 9 
BC001043 Hypothetical protein DKFZp434E2216 SF4 -2.840 -1.506 0.750 0.579 -5.611 9.84E-04 1.387 10 
NM_024567 Hypothetical protein FLJ21616 FLJ21616 -2.844 -1.508 0.770 0.508 -7.458 9.17E-05 4.567 11 
AL359954 TAR DNA binding protein-like TARDBPL -2.846 -1.509 1.199 0.787 -4.984 2.33E-03 0.283 9 
NM_000900 Matrix Gla protein MGP -2.852 -1.512 0.963 0.637 -6.052 5.30E-04 2.154 12 
BC002770 Homo sapiens LOC92154 -2.860 -1.516 0.461 0.283 -9.546 1.02E-05 7.604 11 
NM_002268 Karyopherin alpha 4 (importin alpha 3) KPNA4 -2.864 -1.518 0.919 0.771 -4.553 4.38E-03 -0.597 9 
NM_001033 Ribonucleotide reductase M1 
polypeptide 
RRM1 -2.882 -1.527 0.452 0.298 -11.920 1.24E-06 10.562 10 
NM_012142 Cyclin D-type binding-protein 1 CCNDBP1 -2.900 -1.536 0.935 0.604 -6.371 3.45E-04 2.788 10 
AK056622 Homo sapiens cDNA FLJ32060 fis PPHLN1 -2.918 -1.545 1.276 0.816 -4.848 2.84E-03 0.067 8 
BC001698 Lipase protein ABHD6 -2.936 -1.554 0.596 0.380 -9.214 2.14E-05 6.684 10 
NM_001558 Interleukin 10 receptor IL10RA -2.938 -1.555 0.727 0.470 -7.981 5.13E-05 5.488 8 
NM_002378 Megakaryocyte-associated tyrosine MATK -2.938 -1.555 1.264 0.816 -4.786 3.11E-03 -0.140 10 
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AL122055 KIAA1028 protein  -2.951 -1.561 0.854 0.542 -6.927 1.72E-04 3.701 11 
NM_000582 Secreted phosphoprotein 1 (osteopontin, 
bone sialoprotein I, early T-lymphocyte 
activation 1) 
SPP1 -2.965 -1.568 1.196 0.922 -4.142 7.98E-03 -1.486 11 
NM_000609 Stromal cell-derived factor 1 CXCL12 -2.977 -1.574 1.330 0.830 -4.610 4.03E-03 -0.397 8 
NM_001275 Chromogranin A (parathyroid secretory 
protein 1) 
CHGA -2.998 -1.584 0.564 0.409 -7.324 1.08E-04 4.423 8 
AB067491 KIAA1904 protein KIAA1904 -3.042 -1.605 0.453 0.331 -6.835 1.94E-04 3.581 9 
AK022190 Homo sapiens cDNA FLJ12128 fis  -3.059 -1.613 1.095 0.682 -5.728 8.36E-04 1.602 11 
AF261091 ATP-binding cassette ABCF2 -3.067 -1.617 0.599 0.430 -7.036 1.51E-04 3.916 9 
NM_004688 N-myc (and STAT) interactor NMI -3.072 -1.619 0.872 0.539 -7.119 1.38E-04 3.987 12 
AK023345 Homo sapiens cDNA FLJ13283 fis DIAPH1 -3.089 -1.627 1.042 0.637 -6.055 5.28E-04 2.193 11 
NM_020634 Growth differentiation factor 3 GDF3 -3.093 -1.629 1.217 0.733 -5.266 1.58E-03 0.864 8 
AK057556 Homo sapiens cDNA FLJ32994 fis  -3.093 -1.629 1.392 0.856 -4.594 4.13E-03 -0.554 11 
NM_016022 CGI-78 protein APH-1A -3.095 -1.630 0.726 0.544 -5.427 1.26E-03 1.045 10 
AK058118 Homo sapiens cDNA FLJ25389 fis  -3.095 -1.630 0.641 0.397 -9.526 1.03E-05 7.690 8 
AK056022 Homo sapiens cDNA FLJ31460 fis UXS1 -3.097 -1.631 1.095 0.667 -5.836 7.19E-04 1.835 10 
NM_004772 P311 protein C5orf13 -3.110 -1.637 0.965 0.589 -6.536 2.79E-04 3.004 12 
AK057169 Small acidic protein  -3.110 -1.637 1.100 0.654 -5.862 6.93E-04 1.964 8 
AK055600 Popeye protein 3  -3.112 -1.638 0.501 0.307 -11.990 1.18E-06 10.676 8 
NM_001618 ADP-ribosyltransferase NAD(+) ADPRT -3.117 -1.640 0.494 0.293 -11.110 2.36E-06 9.671 8 
NM_006144 Granzyme A (granzyme 1, cytotoxic T-
lymphocyte-associated serine esterase 3) 
GZMA -3.134 -1.648 0.750 0.383 -5.504 1.14E-03 1.225 9 
AP001753 Homo sapiens genomic DNA  -3.145 -1.653 1.402 0.832 -4.604 4.07E-03 -0.496 10 
NM_003910 Maternal G10 transcript G10 -3.156 -1.658 0.885 0.667 -4.313 6.23E-03 -1.069 9 
AF368463 Carboxypeptidase M CPM -3.176 -1.667 1.071 0.642 -6.021 5.55E-04 2.098 12 
AB026156 Homo sapiens mRNA for TCAM-1  -3.187 -1.672 0.584 0.345 -10.040 6.09E-06 8.285 11 
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NM_003576 Serine/threonine kinase 24 (STE20 
homolog, yeast) 
STK24 -3.187 -1.672 1.314 0.770 -5.033 2.18E-03 0.262 24 
NM_024903 Hypothetical protein FLJ14297 FLJ14297 -3.193 -1.675 0.601 0.352 -10.010 6.28E-06 8.301 9 
AF056490 Phosphodiesterase 8A PDE8A -3.215 -1.685 1.514 0.885 -4.381 5.60E-03 -0.935 10 
AK021648 Homo sapiens cDNA FLJ11586 fis  -3.220 -1.687 0.461 0.252 -9.922 1.14E-05 7.577 9 
NM_012261 Chromosome 20 open reading frame 103 C20orf103 -3.224 -1.689 0.770 0.456 -8.145 6.23E-05 5.301 8 
L36861 Guanylate cyclase activator 1A (retina) GUCA1A -3.229 -1.691 0.931 0.540 -6.951 1.67E-04 3.813 9 
NM_000129 Coagulation factor XIII F13A1 -3.238 -1.695 1.324 0.761 -4.582 4.83E-03 -0.586 8 
NM_004651 Ubiquitin specific protease 11 USP11 -3.242 -1.697 0.701 0.442 -7.767 6.52E-05 5.122 18 
AK056432 Homo sapiens cDNA FLJ31870 fis  -3.242 -1.697 0.817 0.481 -7.942 5.32E-05 5.296 12 
AK021706 Homo sapiens cDNA FLJ11644 fis  -3.242 -1.697 0.362 0.194 -10.140 9.47E-06 7.845 9 
NM_002700 POU domain, class 4, transcription 
factor 3 
POU4F3 -3.249 -1.700 1.085 0.628 -6.131 4.77E-04 2.403 9 
NM_024741 Hypothetical protein FLJ12827 ZNF408 -3.256 -1.703 1.347 0.781 -4.955 2.43E-03 0.186 10 
AB033058 KIAA1232 protein DLG3 -3.263 -1.706 1.105 0.643 -6.022 5.54E-04 2.171 10 
NM_002449 Msh homeo box homolog 2 (Drosophila) MSX2 -3.276 -1.712 1.517 0.876 -4.393 6.28E-03 -0.944 8 
NM_013421 Gamma-glutamyltransferase 1 GGT1 -3.297 -1.721 0.904 0.524 -7.360 1.03E-04 4.410 11 
NM_033419 Hypothetical gene MGC9753 CAB2 -3.324 -1.733 1.090 0.621 -6.057 5.27E-04 2.197 11 
NM_005748 YY1 associated factor 2 YAF2 -3.326 -1.734 1.507 0.857 -4.513 4.63E-03 -0.586 8 
AK021640 Homo sapiens cDNA FLJ11578 fis  -3.336 -1.738 0.378 0.204 -11.710 1.43E-06 10.301 10 
NM_016231 Nemo-like kinase NLK -3.340 -1.740 1.477 0.838 -4.645 3.84E-03 -0.416 10 
NM_003468 Frizzled homolog 5 (Drosophila) FZD5 -3.366 -1.751 1.716 0.965 -4.083 8.68E-03 -1.438 8 
AK025311 Homo sapiens cDNA: FLJ21658 fis  -3.418 -1.773 0.377 0.230 -11.150 2.30E-06 9.677 9 
NM_005463 Heterogeneous nuclear 
ribonucleoprotein  
HNRPDL -3.434 -1.780 0.951 0.674 -6.747 2.15E-04 3.399 20 
BC011684 GATA zinc finger domain containing 
2A 
GATAD2
A 
-3.439 -1.782 0.989 0.672 -5.193 1.74E-03 0.640 9 
AF305616 Transmembrane, prostate androgen 
induced RNA 
TMEPAI -3.465 -1.793 0.624 0.345 -10.400 4.28E-06 8.745 11 
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NM_021197 WAP four-disulfide core domain 1 WFDC1 -3.468 -1.794 1.064 0.576 -5.961 6.05E-04 2.100 9 
Z98751 Human DNA sequence from PAC 
560B9 on chromosome 1q24-25 
 -3.468 -1.794 0.927 0.517 -7.451 9.23E-05 4.525 12 
NM_006447 Ubiquitin specific protease 16 USP16 -3.473 -1.796 1.385 0.769 -5.138 1.88E-03 0.537 10 
NM_002541 Oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 
OGDH -3.473 -1.796 1.134 0.714 -6.623 2.50E-04 3.222 19 
AK054771 Homo sapiens cDNA FLJ30209 fis  -3.482 -1.800 0.500 0.305 -9.307 1.26E-05 7.306 10 
NM_007240 Dual specificity phosphatase 12 DUSP12 -3.485 -1.801 1.587 0.862 -4.415 5.37E-03 -0.825 9 
NM_002427 Matrix metalloproteinase 13 
(collagenase 3) 
MMP13 -3.506 -1.810 0.897 0.501 -7.754 6.60E-05 5.103 9 
NM_014456 Programmed cell death 4 (neoplastic 
transformation inhibitor) 
PDCD4 -3.506 -1.810 0.442 0.265 -10.520 3.87E-06 8.860 11 
AF161383 Homo sapiens LOC15446
7 
-3.509 -1.811 0.401 0.207 -11.940 1.22E-06 10.561 10 
AK023375 Homo sapiens cDNA FLJ13313 fis  -3.521 -1.816 0.353 0.177 -11.080 2.39E-06 9.596 9 
NM_030570 Hypothetical protein MGC10902 UPK3B -3.523 -1.817 0.562 0.307 -11.710 1.43E-06 10.347 9 
BC002821 Homo sapiens CBX1 -3.531 -1.820 1.084 0.588 -6.550 2.74E-04 3.135 9 
NM_016816 2',5'-oligoadenylate synthetase 1, 
40/46kDa 
OAS1 -3.536 -1.822 0.494 0.272 -11.790 1.38E-06 10.455 8 
Z84479 RAR (RAS like GTPASE) like RARL -3.568 -1.835 0.987 0.579 -7.630 7.56E-05 4.841 20 
NM_005954 Metallothionein 3 (growth inhibitory 
factor (neurotrophic)) 
MT3 -3.570 -1.836 0.638 0.347 -10.810 3.07E-06 9.227 12 
AK022028 Homo sapiens cDNA FLJ11966 fis  -3.578 -1.839 1.015 0.554 -7.167 1.31E-04 4.168 9 
NM_018356 Hypothetical protein FLJ11193  -3.585 -1.842 1.717 0.926 -4.261 6.74E-03 -1.173 10 
AK027328 Homo sapiens cDNA FLJ14422 fis  -3.585 -1.842 0.421 0.225 -14.630 1.93E-07 13.314 8 
NM_000151 Glucose-6-phosphatase, catalytic 
(glycogen storage disease type I, von 
Gierke disease) 
G6PC -3.603 -1.849 0.511 0.296 -10.630 3.56E-06 9.023 10 
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NM_018964 Solute carrier family 37 (glycerol-3-
phosphate transporter), member 1 
SLC37A1 -3.633 -1.861 0.566 0.273 -8.553 2.73E-05 6.270 9 
NM_032349 Hypothetical protein MGC11275 SDOS -3.635 -1.862 1.508 0.803 -4.920 2.56E-03 0.160 9 
AB040893 KIAA1460 protein  -3.635 -1.862 1.068 0.574 -6.747 2.15E-04 3.365 12 
BC001255 Nuclear cap binding protein subunit 2 NCBP2 -3.645 -1.866 0.831 0.424 -7.187 1.72E-04 3.886 8 
NM_006245 Protein phosphatase 2 PPP2R5D -3.648 -1.867 0.640 0.379 -8.236 3.90E-05 5.741 11 
L40392 S164 protein  -3.673 -1.877 1.381 0.736 -5.296 1.51E-03 0.763 12 
AK057628 Homo sapiens cDNA FLJ33066 fis  -3.673 -1.877 1.265 0.670 -5.598 1.24E-03 1.181 10 
AK056153 Deleted in esophageal cancer 1 1-Dec -3.676 -1.878 0.904 0.553 -6.067 5.20E-04 2.215 10 
NM_024018 Butyrophilin BTN2A3 -3.686 -1.882 1.247 0.663 -5.868 6.88E-04 1.822 12 
NM_000086 Ceroid-lipofuscinosis CLN3 -3.704 -1.889 1.680 0.889 -4.395 5.52E-03 -0.983 12 
NM_018046 Hypothetical protein FLJ10283 FLJ10283 -3.727 -1.898 0.561 0.295 -12.320 8.99E-07 10.999 10 
AK056574 Homo sapiens cDNA FLJ32012 fis  -3.737 -1.902 0.465 0.243 -14.230 2.47E-07 12.933 10 
NM_003090 Small nuclear ribonucleoprotein 
polypeptide A' 
SNRPA1 -3.784 -1.920 1.781 0.887 -4.092 8.56E-03 -1.420 8 
AB051461 KIAA1674 KIAA1674 -3.789 -1.922 1.167 0.610 -6.416 3.27E-04 2.830 11 
NM_052818 Hypothetical gene CG018 CG018 -3.803 -1.927 1.821 0.941 -4.260 6.75E-03 -1.133 9 
AK021495 Homo sapiens cDNA FLJ11433 fis  -3.805 -1.928 0.414 0.199 -11.590 1.57E-06 10.164 10 
AK023870 Homo sapiens cDNA FLJ13808 fis  -3.837 -1.940 0.914 0.471 -8.082 6.62E-05 5.212 8 
AL136752 Hypothetical protein FLJ12716 FLJ12716 -3.842 -1.942 1.478 0.763 -4.879 3.82E-03 -0.203 8 
AK022035 Homo sapiens cDNA FLJ11973 fis  -3.853 -1.946 0.888 0.531 -5.850 7.05E-04 1.824 10 
AK057607 Homo sapiens cDNA FLJ33045 fis  -3.907 -1.966 0.980 0.484 -7.728 6.76E-05 5.100 8 
NM_015701 Homo sapiens chromosome 2 open 
reading frame 30 
C2orf30 -3.931 -1.975 1.373 0.860 -4.211 7.22E-03 -1.311 10 
AJ420564 Homo sapiens cDNA: FLJ22314 fis  -3.950 -1.982 1.141 0.561 -6.513 2.86E-04 3.072 9 
NM_019110 Hypothetical protein P1 p373c6 P1P373C6 -3.967 -1.988 0.592 0.276 -9.958 6.67E-06 8.175 10 
NM_033105 Beta cysteine string protein CSP-beta -3.975 -1.991 1.470 0.738 -5.364 1.38E-03 0.964 10 
NM_003648 Diacylglycerol kinase DGKD -3.981 -1.993 1.288 0.631 -5.868 6.88E-04 1.894 10 
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AL137340 Hypothetical protein DKFZp761C1711  -3.986 -1.995 0.723 0.360 -10.500 3.92E-06 8.914 9 
AK023330 Homo sapiens cDNA FLJ13268 fis  -3.989 -1.996 0.278 0.139 -11.070 2.40E-06 9.556 9 
NM_032013 NDRG family member 3 NDRG3 -3.997 -1.999 1.630 0.802 -4.821 2.96E-03 -0.072 10 
NM_012119 Cell cycle related kinase CCRK -4.017 -2.006 1.474 0.741 -5.309 1.48E-03 0.823 11 
AK058080 Homo sapiens cDNA FLJ25351 fis  -4.025 -2.009 0.951 0.541 -6.199 4.37E-04 2.485 9 
NM_005566 Lactate dehydrogenase A LDHA -4.081 -2.029 0.690 4.312 -14.710 1.93E-07 13.390 142 
BC017595 Homo sapiens  -4.124 -2.044 1.700 0.820 -4.795 3.08E-03 -0.082 9 
AK021636 Homo sapiens cDNA FLJ11574 fis C14orf111 -4.141 -2.050 0.240 0.111 -15.710 1.04E-07 14.265 8 
NM_005741 Zinc finger protein 263 ZNF263 -4.161 -2.057 1.472 0.717 -5.490 1.16E-03 1.161 11 
NM_002557 Oviductal glycoprotein 1 OVGP1 -4.190 -2.067 1.563 0.761 -5.223 1.67E-03 0.697 10 
NM_032307 Hypothetical protein MGC10999 MGC1099
9 
-4.208 -2.073 0.944 0.518 -6.731 2.20E-04 3.370 10 
AK021524 Homo sapiens cDNA FLJ11462 fis PRPF18 -4.208 -2.073 0.429 0.190 -11.100 2.36E-06 9.590 10 
AK023300 Homo sapiens cDNA FLJ13238 fis  -4.225 -2.079 0.381 0.171 -12.840 6.28E-07 11.547 9 
AL157773 Human DNA sequence from clone 
RP11-345L2 
 -4.234 -2.082 0.801 0.385 -9.643 1.44E-05 7.231 10 
NM_025005 Hypothetical protein FLJ13315 FLJ13315 -4.243 -2.085 0.251 0.113 -15.040 1.53E-07 13.680 8 
AK054573 Homo sapiens cDNA FLJ30011 fis  -4.272 -2.095 1.406 0.668 -5.719 8.43E-04 1.704 8 
AF350881 Transient receptor potential cation 
channel, subfamily M, member 6 
TRPM6 -4.293 -2.102 0.841 0.363 -7.139 1.35E-04 4.052 10 
AK023112 Homo sapiens cDNA FLJ13050 fis  -4.359 -2.124 1.162 0.545 -7.158 1.32E-04 4.117 10 
AF130085 Homo sapiens clone FLB8503 PRO2286 
mRNA 
CTNNB1 -4.365 -2.126 0.759 0.356 -10.650 3.48E-06 9.054 11 
AK056459 Hypothetical protein FLJ22938  -4.374 -2.129 1.332 0.620 -6.205 4.33E-04 2.461 11 
NM_015898 HIV-1 inducer of short transcripts 
binding protein 
FBI1 -4.411 -2.141 1.176 0.540 -6.943 1.69E-04 3.761 10 
AK023058 Homo sapiens cDNA FLJ12996 fis  -4.411 -2.141 1.037 0.497 -6.855 2.51E-04 3.290 10 
NM_014882 KIAA0053 gene product KIAA0053 -4.438 -2.150 0.660 0.303 -11.750 1.42E-06 10.371 10 
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NM_004434 Echinoderm microtubule-associated 
protein like 1 
EML1 -4.451 -2.154 1.024 0.471 -7.953 5.25E-05 5.409 9 
NM_004237 Thyroid hormone receptor interactor 13 TRIP13 -4.466 -2.159 0.623 0.287 -12.850 6.23E-07 11.581 9 
NM_012341 G protein-binding protein CRFG GTPBP4 -4.494 -2.168 0.500 0.204 -8.141 4.32E-05 5.628 10 
AK022859 Homo sapiens cDNA FLJ12797 fis UNC5B -4.506 -2.172 1.810 0.819 -4.779 3.14E-03 -0.113 9 
NM_018294 Hypothetical protein FLJ10998 FLJ10998 -4.513 -2.174 0.707 0.388 -6.720 2.23E-04 3.425 8 
NM_017597 Hypothetical protein DKFZp761K1824 AMSH-LP -4.528 -2.179 1.512 0.687 -5.604 9.92E-04 1.373 11 
NM_032315 Hypothetical protein MGC4399 MGC4399 -4.538 -2.182 1.668 0.762 -4.989 2.73E-03 0.085 10 
AB020626 KIAA0819 protein KIAA0819 -4.547 -2.185 0.658 0.298 -11.820 1.37E-06 10.426 11 
NM_007117 Thyrotropin-releasing hormone TRH -4.560 -2.189 1.118 0.506 -7.509 8.63E-05 4.649 11 
NM_005432 X-ray repair complementing defective 
repair in Chinese hamster cells 3 
XRCC3 -4.582 -2.196 1.388 0.630 -6.100 4.99E-04 2.390 8 
NM_024999 Hypothetical protein FLJ12988 FLJ12988 -4.611 -2.205 0.708 0.321 -11.790 1.38E-06 10.379 12 
BC011941 Homo sapiens  -4.624 -2.209 0.831 0.316 -5.161 1.82E-03 0.542 10 
AB051448 KIAA1661 protein KIAA1661 -4.640 -2.214 1.081 0.488 -7.924 5.44E-05 5.268 12 
NM_014887 Hypothetical protein from BCRA2 
region 
CG005 -4.665 -2.222 1.581 0.693 -5.599 9.97E-04 1.486 8 
NM_006080 Sema domain SEMA3A -4.665 -2.222 0.660 0.294 -12.320 8.99E-07 11.037 8 
AK022930 Homo sapiens cDNA FLJ12868 fis YME1L1 -4.672 -2.224 0.518 0.220 -12.620 7.30E-07 11.288 11 
NM_001200 Bone morphogenetic protein 2 BMP2 -4.691 -2.230 1.198 0.632 -5.441 1.24E-03 1.071 10 
NM_006518 Small proline-rich protein 2C SPRR2C -4.708 -2.235 0.582 0.257 -13.320 4.76E-07 12.045 10 
NM_004217 Serine/threonine kinase 12 AURKB -4.724 -2.240 0.770 0.377 -8.170 4.17E-05 5.671 10 
NM_001878 Cellular retinoic acid binding protein 2 CRABP2 -4.740 -2.245 1.757 0.783 -4.997 2.28E-03 0.193 12 
AK024419 Homo sapiens mRNA for FLJ00008 
protein 
 -4.744 -2.246 0.765 0.378 -8.170 4.17E-05 5.643 11 
BC010642 Zinc finger protein 22 (KOX 15) ZNF22 -4.763 -2.252 0.837 0.473 -4.813 2.99E-03 -0.127 10 
AK000893 Homo sapiens cDNA FLJ10031 fis  -4.800 -2.263 1.421 0.615 -6.262 4.00E-04 2.635 9 
NM_025004 Hypothetical protein FLJ13215 FLJ13215 -4.803 -2.264 0.313 0.131 -16.860 5.39E-08 15.214 9 
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NM_006621 S-adenosylhomocysteine hydrolase-like 
1 
AHCYL1 -4.817 -2.268 1.247 0.545 -6.897 1.79E-04 3.686 10 
NM_006749 Solute carrier family 20 (phosphate 
transporter), member 2 
SLC20A2 -4.820 -2.269 1.122 0.494 -7.388 9.96E-05 4.490 10 
AL133269 Human DNA sequence from clone RP3-
468K3  
 -4.820 -2.269 1.035 0.450 -8.122 6.39E-05 5.233 9 
NM_024810 Hypothetical protein FLJ23018 FLJ23018 -4.847 -2.277 1.237 0.551 -7.097 1.41E-04 4.017 20 
AK026809 Homo sapiens cDNA: FLJ23156 fis  -4.911 -2.296 1.798 0.782 -5.035 2.17E-03 0.302 11 
AL137398 Homo sapiens mRNA  -4.918 -2.298 1.258 0.692 -5.431 1.26E-03 1.090 17 
NM_030964 Sprouty homolog 4 (Drosophila) SPRY4 -4.952 -2.308 0.446 0.180 -12.940 6.07E-07 11.642 10 
AF176707 F-box only protein 29 FBX29 -4.986 -2.318 0.346 0.141 -15.180 1.40E-07 13.794 10 
AB040950 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 37 
DHX37 -4.990 -2.319 1.187 0.498 -7.419 9.60E-05 4.575 9 
NM_024324 Cysteine-rich with EGF-like domains 2 CRELD2 -5.004 -2.323 1.526 0.621 -6.519 2.84E-04 3.008 21 
AK055159 Homo sapiens cDNA FLJ30597 fis  -5.004 -2.323 1.725 0.724 -5.279 1.55E-03 0.844 9 
AK022094 Homo sapiens cDNA FLJ12032 fis  -5.018 -2.327 0.963 0.400 -8.944 1.83E-05 6.894 8 
NM_003149 Src homology three (SH3) and cysteine 
rich domain 
STAC -5.021 -2.328 1.192 0.509 -7.660 7.29E-05 4.921 10 
AK021481 Homo sapiens cDNA FLJ11419 fis  -5.074 -2.343 0.302 0.121 -14.670 1.93E-07 13.330 10 
AK021501 Homo sapiens cDNA FLJ11439 fis LOC92482 -5.134 -2.360 0.701 0.298 -12.770 6.64E-07 11.466 11 
AK056438 Kruppel-like factor 4 (gut)  -5.152 -2.365 0.498 0.197 -12.530 7.81E-07 11.212 10 
NM_012254 Very long-chain acyl-CoA synthetase 
homolog 2 
SLC27A5 -5.177 -2.372 0.939 0.441 -7.740 6.67E-05 5.012 10 
NM_020660 Connexin-36 CX36 -5.216 -2.383 1.774 0.734 -5.232 1.97E-03 0.613 8 
NM_001063 Transferrin TF -5.260 -2.395 0.630 0.261 -13.820 3.31E-07 12.540 10 
NM_003170 Suppressor of Ty 6 homolog (S. 
cerevisiae) 
SUPT6H -5.267 -2.397 0.788 0.329 -11.600 1.57E-06 10.157 12 
NM_005056 Retinoblastoma binding protein 2 RBBP2 -5.329 -2.414 1.566 0.645 -6.139 4.73E-04 2.419 9 
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NM_005471 Glucosamine-6-phosphate isomerase GNPI -5.389 -2.430 1.362 0.567 -6.827 1.96E-04 3.533 11 
NM_003182 Tachykinin TAC1 -5.441 -2.444 1.031 0.418 -9.012 1.71E-05 6.897 11 
NM_016548 Golgi phosphoprotein 2 GOLPH2 -5.457 -2.448 0.992 0.401 -9.337 1.22E-05 7.375 10 
AK022010 Homo sapiens cDNA FLJ11948 fis  -5.479 -2.454 0.632 0.258 -13.500 1.42E-06 10.529 10 
NM_032951 Williams Beuren syndrome chromosome 
region 14 
WBSCR14 -5.521 -2.465 0.747 0.303 -12.550 7.77E-07 11.214 12 
AK024939 Homo sapiens cDNA: FLJ21286 fis  -5.552 -2.473 1.708 0.692 -5.872 6.85E-04 1.982 8 
NM_015904 Translation initiation factor IF2 IF2 -5.571 -2.478 1.209 0.488 -7.962 5.19E-05 5.325 12 
AK024873 Homo sapiens cDNA: FLJ21220 fis NF1 -5.598 -2.485 0.559 0.224 -15.830 9.78E-08 14.363 10 
NM_032164 Hypothetical protein FLJ12298 FLJ12298 -5.606 -2.487 0.893 0.359 -10.900 2.83E-06 9.397 9 
NM_016623 Hypothetical protein BM-009 -5.633 -2.494 1.103 0.535 -5.318 1.47E-03 0.804 11 
AL359941 Homo sapiens mRNA  -5.641 -2.496 0.916 0.360 -9.251 1.33E-05 7.258 10 
AK025558 3-hydroxyisobutyrate dehydrogenase HIBADH -5.696 -2.510 0.777 0.276 -8.274 5.44E-05 5.447 8 
AK056437 Homo sapiens cDNA FLJ31875 fis FLJ31875 -5.700 -2.511 1.693 0.684 -5.872 6.85E-04 1.982 8 
AK055100 Homo sapiens cDNA FLJ30538 fis  -5.700 -2.511 1.754 0.677 -5.396 1.59E-03 0.909 8 
NM_016592 GNAS complex locus GNAS -5.724 -2.517 1.424 0.561 -6.862 1.87E-04 3.593 11 
NM_018649 H2A histone family H2AFY2 -5.796 -2.535 0.702 0.274 -12.860 6.23E-07 11.552 11 
AB040968 KIAA1535 protein PKLR -5.812 -2.539 0.748 0.295 -12.900 6.07E-07 11.585 12 
NM_001718 Bone morphogenetic protein 6 BMP6 -5.918 -2.565 0.613 0.241 -15.160 1.40E-07 13.783 10 
NM_001967 Eukaryotic translation initiation factor EIF4A2 -5.950 -2.573 0.476 3.111 -11.080 2.39E-06 9.616 175 
AK055143 Homo sapiens cDNA FLJ30581 fis  -6.169 -2.625 1.013 0.387 -10.040 6.13E-06 8.276 11 
AK057142 Homo sapiens cDNA FLJ32580 fis  -6.251 -2.644 0.719 0.271 -13.310 4.76E-07 12.056 8 
NM_016539 Sirtuin (silent mating type information 
regulation 2 homolog) 6 (S.cerevisiae) 
SIRT6 -6.329 -2.662 1.276 0.479 -8.113 4.46E-05 5.556 12 
AK055070 Homo sapiens cDNA FLJ20167 fis  -6.662 -2.736 1.802 0.648 -5.946 6.16E-04 2.115 8 
AK057447 Homo sapiens cDNA FLJ32885 fis  -6.864 -2.779 1.459 0.516 -7.311 1.09E-04 4.365 10 
AK021970 Homo sapiens cDNA FLJ11908 fis  -6.888 -2.784 1.654 0.598 -6.509 2.88E-04 3.065 9 
NM_018111 Hypothetical protein FLJ10490 FLJ10490 -6.931 -2.793 1.862 0.666 -5.975 5.93E-04 2.086 10 
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NM_013317 Lung type-I cell membrane-associated 
glycoprotein, transcript variant 1 
T1A-2 -6.960 -2.799 0.789 0.278 -11.730 1.42E-06 10.331 11 
NM_006495 Ecotropic viral integration site 2B EVI2B -6.984 -2.804 0.444 0.156 -18.620 1.98E-08 16.510 8 
NM_024998 Hypothetical protein FLJ12704 FLJ12704 -7.126 -2.833 0.595 0.205 -15.640 1.06E-07 14.201 8 
AK026729 Homo sapiens cDNA: FLJ23076 fis  -7.135 -2.835 1.138 0.395 -9.380 1.19E-05 7.434 10 
U06711 Mucin 5, subtypes A and C, 
tracheobronchial/gastric 
MUC5AC -7.230 -2.854 1.606 0.562 -6.774 2.75E-04 3.161 10 
NM_032325 Hypothetical protein MGC11102 MGC1110
2 
-7.280 -2.864 1.338 0.464 -8.247 3.85E-05 5.852 9 
NM_018656 Bladder cancer overexpressed protein SLC35E3 -7.346 -2.877 1.108 0.380 -9.927 6.86E-06 8.161 10 
BC007323 NADH dehydrogenase (ubiquinone) 1, 
subcomplex unknown, 2, 14.5kDa 
NDUFC2 -7.454 -2.898 1.758 0.604 -6.625 2.50E-04 3.263 9 
NM_003620 Protein phosphatase 1D magnesium-
dependent, delta isoform 
PPM1D -7.485 -2.904 1.737 0.601 -6.609 2.54E-04 3.236 9 
AK025812 Homo sapiens cDNA: FLJ22159 fis RAI17 -7.501 -2.907 0.966 0.330 -10.910 2.78E-06 9.395 10 
NM_001949 E2F transcription factor 3 E2F3 -7.558 -2.918 1.130 0.390 -9.881 7.25E-06 8.102 10 
AK021802 Homo sapiens cDNA FLJ11740 fis SEMA3D -7.717 -2.948 1.312 0.440 -8.346 5.07E-05 5.548 9 
AF334588 Homo sapiens P25 mRNA  -7.765 -2.957 1.488 0.500 -7.752 6.62E-05 5.031 11 
NM_017831 Ring finger protein 125 RNF125 -7.923 -2.986 1.778 0.583 -6.613 2.53E-04 3.242 9 
NM_005940 Matrix metalloproteinase 11 
(stromelysin 3) 
MMP11 -8.095 -3.017 1.642 0.531 -6.777 2.07E-04 3.484 10 
NM_052842 BCL2-like 12 (proline rich) BCL2L12 -8.112 -3.020 1.331 0.441 -8.902 1.89E-05 6.741 11 
BC014111 Homo sapiens  -8.123 -3.022 0.654 0.214 -15.740 1.95E-07 13.325 9 
BC000549 Homo sapiens clone 24758 mRNA 
sequence 
 -8.271 -3.048 1.828 0.608 -6.522 2.83E-04 3.087 9 
AL136781 Hypothetical protein DKFZp434N1817 DKFZP43
4N1817 
-8.415 -3.073 1.214 0.398 -9.546 1.02E-05 7.687 9 
AL049280 Homo sapiens mRNA CYorf15B -8.480 -3.084 0.486 0.158 -21.540 5.35E-09 18.442 9 
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S72422 Dihydrolipoamide S-succinyltransferase 
(E2 component of 2-oxo-glutarate 
complex) 
DLST -8.521 -3.091 1.502 0.486 -8.094 4.55E-05 5.557 11 
NM_025057 Hypothetical protein FLJ23189 C14orf45 -8.586 -3.102 1.027 0.333 -10.770 5.38E-06 8.628 8 
AK000006 Hypothetical protein  -8.664 -3.115 1.131 0.363 -10.160 5.49E-06 8.458 10 
NM_014083 PRO0767 protein PRO0767 -8.803 -3.138 0.936 0.297 -12.910 6.07E-07 11.628 10 
NM_000518 Hemoglobin, beta HBB -8.840 -3.144 1.049 0.334 -11.590 1.57E-06 10.150 12 
AK026280 Homo sapiens cDNA: FLJ22627 fis  -8.938 -3.160 1.397 0.449 -8.859 1.97E-05 6.774 8 
NM_024515 Hypothetical protein MGC4645 MGC4645 -9.145 -3.193 0.862 0.292 -9.234 1.35E-05 7.234 9 
NM_020359 Phospholipid scramblase 2 PLSCR2 -9.209 -3.203 1.154 0.356 -10.660 3.48E-06 9.108 9 
NM_014392 Neuron-specific protein D4S234E -9.292 -3.216 1.012 0.312 -12.040 1.15E-06 10.714 9 
AK021678 Homo sapiens cDNA FLJ11616 fis  -9.337 -3.223 1.729 0.521 -7.334 1.06E-04 4.477 8 
NM_032810 Hypothetical protein FLJ14600 FLJ14600 -9.383 -3.230 1.231 0.343 -7.588 7.85E-05 4.807 9 
AK022239 Homo sapiens cDNA FLJ12177 fis  -9.567 -3.258 1.168 0.355 -10.450 4.14E-06 8.801 11 
NM_019066 MAGE-like 2 MAGEL2 -10.063 -3.331 1.126 0.372 -8.589 2.62E-05 6.262 11 
AK057237 Homo sapiens cDNA FLJ32675 fis  -10.711 -3.421 1.023 0.270 -9.417 1.14E-05 7.484 9 
NM_014968 Pitrilysin metalloproteinase 1 PITRM1 -10.785 -3.431 0.930 0.271 -14.260 2.43E-07 12.950 11 
AL109714 Homo sapiens mRNA full length insert 
cDNA clone 
LOC28368
7 
-11.066 -3.468 1.709 0.492 -7.902 5.57E-05 5.368 8 
AJ001403 Mucin 5, subtypes A and C, 
tracheobronchial/gastric 
MUC5AC -11.173 -3.482 1.320 0.357 -7.635 7.51E-05 4.953 8 
AL050078 Homo sapiens cDNA FLJ10784 fis  -11.448 -3.517 1.503 0.426 -9.294 1.28E-05 7.346 9 
NM_020120 UDP-glucose ceramide 
glucosyltransferase 
UGCGL1 -11.519 -3.526 1.363 0.387 -10.080 5.92E-06 8.303 12 
AB037761 KIAA1340 protein KIAA1340 -11.819 -3.563 2.130 0.596 -6.822 1.97E-04 3.637 8 
AB037781 Hypothetical protein FLJ10074 FLJ10074 -12.009 -3.586 1.475 0.409 -9.069 2.46E-05 6.558 8 
AK055084 Homo sapiens cDNA FLJ30522 fis  -12.329 -3.624 1.824 0.500 -7.976 5.15E-05 5.443 9 
AL109691 Homo sapiens mRNA full length insert 
cDNA clone 
 -13.343 -3.738 1.700 0.448 -8.322 5.17E-05 5.550 8 
109
 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
used 
AK054962 Homo sapiens cDNA FLJ30400 fis  -13.352 -3.739 1.652 0.435 -9.066 1.61E-05 7.064 8 
AF086735 Microsomal NAD+-dependent retinol 
dehydrogenase 4 
RODH-4 -13.852 -3.792 1.479 0.387 -9.834 7.62E-06 8.012 11 
D21262 Nucleolar and coiled-body 
phosphprotein  
NOLC1 -13.938 -3.801 1.206 0.314 -12.080 1.11E-06 10.741 10 
BC011969 Homo sapiens  -14.836 -3.891 1.040 0.266 -14.000 2.87E-07 12.726 9 
NM_013355 Protein kinase PKNbeta PKN3 -14.949 -3.902 1.224 0.311 -11.800 1.37E-06 10.408 11 
AK055809 Homo sapiens cDNA FLJ31247 fis  -14.970 -3.904 1.527 0.450 -10.220 8.75E-06 8.022 16 
AK023182 CGI-145 protein  -15.012 -3.908 0.979 0.250 -15.400 1.26E-07 13.980 12 
AK022334 Homo sapiens cDNA FLJ12272 fis  -17.606 -4.138 1.507 0.364 -10.790 3.12E-06 9.222 11 
AK002078 Homo sapiens cDNA FLJ11216 fis  -18.507 -4.210 1.628 0.396 -10.760 3.18E-06 9.181 17 
NM_000844 Glutamate receptor GRM7 -20.294 -4.343 1.559 0.364 -10.730 3.28E-06 9.219 8 
AK057806 Homo sapiens cDNA FLJ25077 fis  -22.254 -4.476 1.153 0.256 -15.350 1.29E-07 13.955 8 
AF003738 Homo sapiens chromosome 21q22.1 
anonymous mRNA sequence 
 -22.596 -4.498 1.035 0.230 -16.940 5.22E-08 15.274 10 
AK024863 Homo sapiens cDNA: FLJ21210 fis DNCLI2 -24.864 -4.636 0.511 0.106 -23.760 1.63E-09 19.786 10 
AB028953 KIAA1030 protein KIAA1030 -31.363 -4.971 1.101 0.219 -16.000 9.24E-08 14.507 9 
NM_015369 TP53TG3 protein TP53TG3 -33.382 -5.061 1.418 0.277 -12.660 7.25E-07 11.398 8 
AJ301580 DMRT-like family A2 DMRTA2 -47.308 -5.564 1.370 0.247 -15.850 9.78E-08 14.381 10 
AK024871 Homo sapiens cDNA: FLJ21218 fis APBB2 -55.599 -5.797 0.833 0.144 -26.150 5.91E-10 20.907 9 
BC006317 Homo sapiens solute carrier family 18 
(vesicular monoamine), member 1 
SLC18A1 -61.393 -5.940 0.739 0.124 -29.460 5.91E-10 20.961 11 
BC009393 Homo sapiens HIV-1 Rev binding 
protein-like 
HRBL -113.300 -6.824 0.935 0.137 -28.070 4.35E-10 21.857 10 
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Differential Gene Expression Studies of Normal Pelvic Peritoneum in Women with and 
without Endometriosis 
 
 
 202 genes were found to be significantly up- or down-regulated in the normal 
pelvic peritoneum of women with endometriosis versus those without (Table IV).  115  
genes were up-regulated greater than 2-fold with a p-value <0.01, and 87 were down-
regulated greater than two-fold.  The most up-regulated gene was A20-binding inhibitor 
of NF-kappa B activation 2 (NM_024309) with a fold change of +24.268 (log2 ratio 
4.601, SD 0.799).  Eight replicates were utilized in the analysis, with a p-value of 8.98 x 
10-7.  The gene most down-regulated, with a fold-change of -43.441 (log2 ratio -5.441, 
SD 0.578) was Troponin T type 3 (skeletal, fast) (NM_006757).  Seven replicates were 
utilized in its analysis, rendering a p-value of 4.20 x 10-8.
 Table IV. Log Ratio Changes of Gene Expression in Normal Pelvic Peritoneum of Women with Endometriosis versus Without. 
 
Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
Used 
NM_024309 A20-binding inhibitor of NF-kappaB 
activation 2 
TNIP2 24.268 4.601 0.799 0.174 19.290 8.98E-07 12.667 8 
AJ420589 Homo sapiens mRNA full length insert 
cDNA clone 
 19.495 4.285 1.050 0.245 13.850 1.23E-05 9.234 8 
AK025643 Homo sapiens cDNA: FLJ21990 fis  18.817 4.234 0.926 0.217 15.010 6.54E-06 10.090 7 
NM_017765 PQ loop repeat containing 2 PQLC2 14.400 3.848 1.498 0.381 8.661 2.95E-04 4.522 6 
NM_003215 Tec protein tyrosine kinase TEC 14.182 3.826 1.047 0.269 10.800 7.24E-05 6.698 7 
AL049650 Transglutaminase 3-like TGM3L 13.288 3.732 1.150 0.304 11.020 6.57E-05 6.937 6 
BC014396 Copine IV CPNE4 12.799 3.678 1.017 0.272 11.080 6.36E-05 6.994 6 
NM_001249 Ectonucleoside triphosphate 
diphosphohydrolase 5 
ENTPD5 12.799 3.678 0.802 0.217 15.120 6.14E-06 10.169 7 
AK055061 Homo sapiens cDNA FLJ30499 fis  12.441 3.637 0.684 0.209 10.220 1.02E-04 6.091 7 
NM_003083 Small nuclear RNA activating complex, 
polypeptide 2 
SNAPC2 11.802 3.561 0.895 0.251 13.420 1.49E-05 8.905 8 
NM_015887 Putative peroxisome microbody protein 
175.1 
 10.718 3.422 1.436 0.418 8.359 3.64E-04 4.173 6 
AK021930 Homo sapiens cDNA FLJ11868 fis  10.440 3.384 1.343 0.394 8.632 2.97E-04 4.439 7 
NM_032293 GTPase activating Rap/RanGAP domain-
like 3 
GARNL3 10.239 3.356 1.225 0.365 9.354 1.83E-04 5.195 8 
AK055705 Homo sapiens cDNA FLJ31143 fis  10.077 3.333 1.054 0.310 10.430 9.01E-05 6.377 6 
AK026942 Homo sapiens cDNA: FLJ23289 fis  10.070 3.332 0.677 0.204 16.020 3.70E-06 10.765 7 
AL050175 Homo sapiens mRNA  10.028 3.326 1.380 0.415 8.267 3.88E-04 3.967 8 
NM_000583 Group-specific component (vitamin D 
binding protein) 
GC 10.000 3.322 0.509 0.152 19.720 8.14E-07 12.883 7 
NM_022496 ARP6 actin-related protein 6 homolog 
(yeast) 
ACTR6 9.673 3.274 0.996 0.303 11.280 5.62E-05 7.137 7 
AK023446 Aminoadipate-semialdehyde synthase AASS 9.000 3.170 1.278 0.389 7.626 6.49E-04 3.286 6 
NM_032447 Fibrillin 3 FBN3 8.706 3.122 1.261 0.405 8.586 3.04E-04 4.385 7 
NM_005701 RNA, U transporter I RNUT1 8.282 3.050 1.220 0.396 8.744 2.78E-04 4.616 6 
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AB033104 Serine/threonine kinase 36  STK36 8.271 3.048 0.910 0.297 11.620 4.40E-05 7.479 6 
NM_005738 ADP-ribosylation factor-like 4A ARL4 7.857 2.974 1.273 0.428 8.005 4.83E-04 3.652 8 
AK021831 Homo sapiens cDNA FLJ11769 fis  7.749 2.954 1.027 0.346 9.798 1.37E-04 5.705 7 
AB067501 KIAA1914 KIAA1914 7.413 2.890 1.121 0.384 8.653 2.95E-04 4.463 7 
AB051514 KIAA1727 protein  7.301 2.868 0.954 0.326 9.833 1.33E-04 5.786 6 
NM_004388 Chitobiase CTBS 7.180 2.844 0.893 0.314 10.750 7.39E-05 6.612 8 
AL080077 Homo sapiens genomic DNA  7.047 2.817 1.464 0.519 6.779 1.33E-03 2.179 6 
NM_016932 Sine oculis homeobox homolog 2 
(Drosophila) 
SIX2 6.964 2.800 1.151 0.405 8.386 3.59E-04 4.204 6 
NM_024636 STEAP family member 4 STEAP4 6.945 2.796 1.748 0.743 6.219 3.07E-03 1.116 6 
AB037715 KIAA1294 protein  6.816 2.769 0.971 0.348 9.661 1.50E-04 5.563 7 
NM_014810 Centrosome-associated protein 350kDa CAP350 6.797 2.765 1.225 0.436 7.435 7.66E-04 2.989 7 
AB014542 Trinucleotide repeat containing 15 TNRC15 6.530 2.707 0.701 0.258 12.280 6.15E-05 7.179 6 
NM_006174 Neuropeptide Y receptor Y5 NPY5R 6.516 2.704 1.043 0.376 8.003 4.83E-04 3.749 6 
S66666 P53  6.467 2.693 0.821 0.305 11.020 6.57E-05 6.865 8 
AL359599 Homo sapiens genomic DNA  6.369 2.671 1.284 0.479 7.209 9.18E-04 2.696 7 
AK025527 Homo sapiens cDNA: FLJ21874 fis INSR 6.251 2.644 1.002 0.376 8.940 2.49E-04 4.786 7 
BC012458 Sec1 family domain containing 2 SCFD2 5.959 2.575 0.897 0.347 9.778 1.39E-04 5.684 7 
NM_001677 ATPase, Na+/K+ transporting, beta 1 
polypeptide 
ATP1B1 5.905 2.562 1.401 0.533 6.270 2.17E-03 1.469 6 
BC008613 Homo sapiens  5.760 2.526 1.213 0.481 7.108 9.89E-04 2.514 8 
AK021484 Homo sapiens cDNA FLJ11422 fis  5.438 2.443 1.310 0.666 6.267 2.17E-03 1.464 13 
AK056642 Hypothetical LOC552889  5.400 2.433 1.055 0.428 7.660 6.32E-04 3.274 7 
NM_006739 MCM5 minichromosome maintenance 
deficient 5, cell division cycle 46 
MCM5 5.141 2.362 0.996 0.417 8.106 4.43E-04 3.873 6 
NM_004964 Histone deacetylase 1 HDAC1 5.102 2.351 1.163 0.498 6.968 1.13E-03 2.378 7 
NM_005442 Eomesodermin homolog (Xenopus 
laevis) 
EOMES 5.095 2.349 0.376 0.189 8.361 3.64E-04 4.124 6 
NM_005201 Chemokine (C-C motif) receptor 8 CCR8 5.088 2.347 0.814 0.338 8.947 2.48E-04 4.843 6 
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AF016903 Agrin AGRN 5.021 2.328 0.980 0.410 7.749 5.96E-04 3.438 6 
NM_014725 START domain containing 8 STARD8 4.969 2.313 1.111 0.479 7.321 8.35E-04 2.897 6 
AK054969 Ubiquitin protein ligase E3 component n-
recognin 1 
UBR1 4.931 2.302 0.716 0.319 10.340 9.44E-05 6.253 13 
NM_003379 Villin 2 (ezrin) VIL2 4.820 2.269 1.136 0.497 6.892 1.21E-03 2.332 6 
AK023730 Chromosome 6 open reading frame 188 C6orf188 4.790 2.260 0.933 0.406 8.181 4.15E-04 3.963 6 
AK055644 Zinc finger protein 138 ZNF138 4.754 2.249 0.736 0.323 9.988 1.20E-04 5.943 6 
AK056177 Chromosome 20 open reading frame 102 C20orf102 4.717 2.238 1.043 0.463 7.366 8.09E-04 2.900 7 
NM_024724 Hypothetical protein FLJ22332 FLJ22332 4.588 2.198 0.852 0.388 8.667 2.95E-04 4.433 8 
Y11918 H.sapiens IMAGE cDNA clone 26881  4.547 2.185 0.678 0.310 10.860 7.08E-05 6.789 6 
AJ420568 Coiled-coil domain containing 28A CCDC28A 4.547 2.185 1.087 0.494 6.909 1.19E-03 2.298 7 
BC018078 Homo sapiens cDNA clone 
IMAGE:4793871 
 4.519 2.176 0.462 0.210 14.000 1.13E-05 9.372 7 
AK057215 Homo sapiens cDNA FLJ32653 fis  4.451 2.154 1.085 0.504 6.863 1.24E-03 2.236 7 
U72518 Human destrin-2 pseudogene mRNA  4.326 2.113 1.008 0.469 7.221 9.09E-04 2.768 6 
BC013114 aarF domain containing kinase 4 ADCK4 4.320 2.111 1.082 0.509 6.804 1.30E-03 2.212 6 
NM_024594 Pantothenate kinase 3 PANK3 4.260 2.091 0.648 0.310 10.630 8.05E-05 6.489 8 
AB051552 Doublecortin and CaM kinase-like 3 DCAMKL3 4.187 2.066 0.970 0.465 7.199 9.22E-04 2.684 7 
AK021840 Homo sapiens cDNA FLJ11778 fis  4.138 2.049 1.047 0.507 6.677 1.46E-03 1.983 7 
NM_014465 Sulfotransferase family, cytosolic, 1B, 
member 1 
SULT1B1 4.112 2.040 0.851 0.419 8.020 4.77E-04 3.770 6 
NM_006182 Discoidin domain receptor family, 
member 2 
DDR2 4.064 2.023 0.950 0.463 7.091 1.01E-03 2.541 7 
AL117574 Homo sapiens mRNA C20orf80 3.997 1.999 0.848 0.413 7.687 6.22E-04 3.361 6 
NM_004334 Bone marrow stromal cell antigen 1 BST1 3.972 1.990 0.503 0.261 14.160 1.02E-05 9.512 13 
NM_022829 Solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 3 
SLC13A3 3.939 1.978 0.514 0.256 12.040 3.39E-05 7.847 6 
AB011153 Phospholipase C, beta 1 
(phosphoinositide-specific) 
PLCB1 3.907 1.966 1.072 0.545 6.252 2.20E-03 1.332 8 
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AK024867 Homo sapiens cDNA: FLJ21214 fis  3.795 1.924 0.959 0.495 6.847 1.25E-03 2.271 6 
NM_004483 Glycine cleavage system protein H 
(aminomethyl carrier) 
GCSH 3.792 1.923 0.658 0.342 9.650 1.50E-04 5.509 8 
NM_058188 Homo sapiens chromosome 21 open 
reading frame 67 
C21orf67 3.763 1.912 0.671 0.340 7.485 7.33E-04 3.053 7 
NM_007281 Scrapie responsive protein 1 SCRG1 3.735 1.901 0.900 0.473 7.227 9.05E-04 2.720 7 
NM_021624 Histamine receptor H4 HRH4 3.678 1.879 0.982 0.514 6.577 1.60E-03 1.901 6 
NM_007112 Thrombospondin 3 THBS3 3.487 1.802 0.536 0.289 10.560 8.35E-05 6.507 12 
AB002331 Death associated transcription factor 1 DATF1 3.461 1.791 0.834 0.461 7.367 8.09E-04 2.957 6 
NM_016299 Heat shock 70kDa protein 14 HSPA14 3.320 1.731 0.866 0.498 6.815 1.29E-03 2.171 7 
AF334710 Homo sapiens pyruvate dehydrogenase 
kinase, isozyme 4 
PDK4 3.274 1.711 0.570 0.329 9.318 1.86E-04 5.199 7 
AK055220 Homo sapiens cDNA FLJ30658 fis  3.269 1.709 0.568 0.335 8.930 2.49E-04 4.824 6 
NM_018440 Phosphoprotein associated with 
glycosphingolipid microdomains 1  
PAG1 3.184 1.671 0.489 0.284 9.693 1.48E-04 5.642 6 
AK023371 Homo sapiens cDNA FLJ13309 fis  3.173 1.666 0.585 0.345 8.523 3.23E-04 4.363 6 
NM_006327 Translocase of inner mitochondrial 
membrane 23 homolog (yeast) 
TIMM23 3.080 1.623 0.755 0.463 7.218 9.09E-04 2.709 7 
AK025346 Homo sapiens cDNA: FLJ21693 fis  3.074 1.620 0.412 0.226 7.847 5.46E-04 3.458 7 
NM_033439 DVS27-related protein DVS27 3.061 1.614 0.769 0.476 7.010 1.09E-03 2.383 8 
BC010942 Acetyl-Coenzyme A acetyltransferase 1      
(acetoacetyl Coenzyme A thiolase) 
ACAT1 3.004 1.587 0.863 0.535 6.226 2.23E-03 1.406 6 
AB033114 AT2 receptor-interacting protein 1 MTSG1 2.959 1.565 0.893 0.571 5.985 2.85E-03 0.996 7 
NM_015474 SAM domain and HD domain 1 SAMHD1 2.894 1.533 0.767 0.500 6.671 1.47E-03 1.922 8 
AK055770 Spermatogenesis associated 13 SPATA13 2.878 1.525 0.753 0.487 6.657 1.49E-03 1.955 7 
NM_003226 Trefoil factor 3 (intestinal) TFF3 2.864 1.518 0.518 0.341 9.436 1.73E-04 5.326 7 
BC010099 Homo sapiens chromosome 16 open 
reading frame 57 
C16orf57 2.842 1.507 0.301 0.203 12.020 3.39E-05 7.792 7 
NM_003657 Breast carcinoma amplified sequence 1 BCAS1 2.795 1.483 0.377 0.249 10.760 7.38E-05 6.699 6 
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NM_001881 cAMP responsive element modulator CREM 2.786 1.478 0.744 0.500 6.646 1.51E-03 1.939 7 
NM_015665 Achalasia, adrenocortical insufficiency, 
alacrimia (Allgrove, triple-A) 
AAAS 2.782 1.476 0.663 0.444 7.232 9.04E-04 2.726 7 
NM_032638 GATA binding protein 2 GATA2 2.778 1.474 0.772 0.524 6.374 1.96E-03 1.507 8 
NM_025080 Asparaginase like 1 ASRGL1 2.747 1.458 0.740 0.510 6.452 1.80E-03 1.727 6 
NM_005033 Polymyositis/scleroderma autoantigen 1 
(75kD) 
PMSCL1 2.728 1.448 0.742 0.512 6.508 1.72E-03 1.696 8 
AF339829 Homo sapiens clone IMAGE:609847  2.661 1.412 0.756 0.536 6.229 2.23E-03 1.299 8 
NM_032764 Homo sapiens chromosome 9 open 
reading frame 70 
C9orf70 2.617 1.388 0.630 0.454 7.232 9.04E-04 2.677 8 
NM_003375 Voltage-dependent anion channel 2 VDAC2 2.569 1.361 0.721 0.528 6.345 2.02E-03 1.518 7 
NM_006435 Interferon induced transmembrane 
protein 2 (1-8D) 
IFITM2 2.546 1.348 0.642 0.482 6.836 1.26E-03 2.200 7 
AL117477 PHD finger protein 19 PHF19 2.535 1.342 0.643 0.479 6.871 1.23E-03 2.195 8 
NM_004893 H2A histone family, member Y H2AFY 2.466 1.302 0.506 0.389 8.191 4.12E-04 3.876 8 
NM_014574 Cell cycle S/G2 nuclear autoantigen STRN3 2.452 1.294 0.704 0.542 6.150 2.41E-03 1.237 7 
M55536 Human glucose transporter pseudogene GLUT6 2.450 1.293 0.500 0.387 8.230 4.00E-04 3.923 8 
NM_052960 Retinoid binding protein 7 CRBPIV 2.400 1.263 0.479 0.380 8.320 3.72E-04 4.029 8 
AB020691 KIAA0884 protein, GTPase activating 
Rap/RanGAP domain-like 1 
GARNL1 2.367 1.243 0.536 0.419 7.063 1.04E-03 2.559 6 
L20860 Glycoprotein Ib (platelet), beta 
polypeptide 
GP1BB 2.362 1.240 0.494 0.389 7.609 6.56E-04 3.264 6 
NM_001681 ATPase, Ca++ transporting, cardiac 
muscle, slow twitch 2 
ATP2A2 2.291 1.196 0.590 0.492 6.638 1.51E-03 1.928 7 
NM_001937 Dermatopontin DPT 2.274 1.185 0.353 0.301 9.603 1.55E-04 5.503 7 
BC012899 Homo sapiens sialidase 4, mRNA  2.250 1.170 0.431 0.366 8.321 3.72E-04 4.129 6 
AB011539 EGF-like-domain, multiple 3 EGFL3 2.202 1.139 0.327 0.284 9.569 1.60E-04 5.466 7 
NM_001773 CD34 antigen CD34 2.141 1.098 0.446 0.406 7.672 6.26E-04 3.240 8 
AL390172 Branched chain aminotransferase 1, 
cytosolic 
BCAT1 2.116 1.081 0.294 0.316 6.828 1.27E-03 2.138 7 
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NM_021023 Complement factor H-related 3 FHR-3 2.076 1.054 0.459 0.439 7.163 9.45E-04 2.692 6 
NM_016651 Heptacellular carcinoma novel gene 3  DACT1 2.025 1.018 0.486 0.477 6.640 1.51E-03 1.880 8 
AF064238 Smoothelin SMTN -2.010 -1.007 0.279 0.277 -9.903 1.28E-04 5.771 8 
AK056438 Homo sapiens cDNA FLJ31876 fis  -2.020 -1.014 0.469 0.462 -6.459 1.79E-03 1.736 6 
NM_030964 Sprouty homolog 4 (Drosophila) SPRY4 -2.029 -1.021 0.324 0.317 -9.085 2.22E-04 4.902 8 
NM_005418 Suppression of tumorigenicity 5 ST5 -2.031 -1.022 0.264 0.258 -10.400 9.09E-05 6.267 8 
NM_005271 Glutamate dehydrogenase 1 GLUD1 -2.035 -1.025 0.439 0.431 -7.234 9.04E-04 2.728 7 
AK021643 Homo sapiens cDNA FLJ11581 fis  -2.066 -1.047 0.221 0.205 -8.466 3.41E-04 4.246 7 
AL049471 Homo sapiens mRNA  -2.086 -1.061 0.469 0.447 -6.984 1.11E-03 2.399 7 
AK023496 Homo sapiens cDNA FLJ13434 fis  -2.092 -1.065 0.497 0.470 -6.215 2.26E-03 1.390 6 
NM_001614 Actin, gamma 1 ACTG1 -2.110 -1.077 0.392 0.364 -8.346 3.66E-04 4.060 8 
AL157773 Human DNA sequence from clone RP11-
345L2 on chromosome 6 
 -2.117 -1.082 0.411 0.378 -7.683 6.22E-04 3.356 6 
AK056574 Homo sapiens cDNA FLJ32012 fis  -2.144 -1.100 0.399 0.362 -8.413 3.55E-04 4.139 8 
NM_003877 STAT induced STAT inhibitor-2 SOCS2 -2.155 -1.108 0.495 0.433 -6.708 1.42E-03 2.081 6 
BG178211 Homo sapiens mesenchymal stem cell 
protein 
 -2.155 -1.108 0.582 0.511 -5.969 2.89E-03 1.032 6 
AL137547 Homo sapiens mRNA  -2.155 -1.108 0.527 0.473 -6.776 1.33E-03 2.174 6 
AK057363 Homo sapiens cDNA FLJ32801 fis  -2.166 -1.115 0.427 0.389 -7.912 5.21E-04 3.639 6 
AB020626 KIAA0819 protein KIAA0819 -2.173 -1.120 0.435 0.385 -7.876 5.40E-04 3.542 7 
AK023300 Homo sapiens cDNA FLJ13238 fis  -2.215 -1.147 0.404 0.352 -8.691 2.90E-04 4.460 8 
AL137798 Human DNA sequence from clone RP5-
1182A14          on chromosome 1 
 -2.225 -1.154 0.465 0.403 -7.806 5.65E-04 3.408 8 
NM_001375 Deoxyribonuclease II, lysosomal DNASE2 -2.236 -1.161 0.385 0.334 -8.917 2.50E-04 4.809 6 
NM_022154 Up-regulated by BCG-CWS BIGM103 -2.241 -1.164 0.412 0.354 -8.659 2.95E-04 4.423 8 
NM_025004 Homo sapiens coiled-coil domain 
containing 15 
CCDC15 -2.245 -1.167 0.452 0.382 -7.548 6.95E-04 3.187 6 
NM_016224 Sorting nexin 9 SNX9 -2.256 -1.174 0.525 0.450 -7.168 9.43E-04 2.643 7 
NM_001102 Actinin, alpha 1 ACTN1 -2.261 -1.177 0.229 0.176 -8.819 2.62E-04 4.605 7 
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AK022930 Homo sapiens cDNA FLJ12868 fis YME1L1 -2.267 -1.181 0.546 0.462 -6.992 1.11E-03 2.359 8 
AK023302 Homo sapiens cDNA FLJ13240 fis  -2.270 -1.183 0.395 0.324 -8.212 4.04E-04 4.000 6 
AL137340 Hypothetical protein DKFZp761C1711  -2.277 -1.187 0.452 0.376 -8.155 4.24E-04 3.932 6 
AB029031 TBC1 (tre-2/USP6, BUB2, cdc16) 
domain family,  member 1 
TBC1D1 -2.294 -1.198 0.582 0.487 -6.731 1.40E-03 2.057 7 
NM_003289 Tropomyosin 2 (beta) TPM2 -2.313 -1.210 0.452 0.374 -8.362 3.64E-04 4.078 8 
NM_017668 LIS1-interacting protein NUDE1 NDE1 -2.344 -1.229 0.522 0.425 -7.546 6.95E-04 3.082 8 
NM_000191 3-hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase 
HMGCL -2.397 -1.261 0.650 0.529 -6.258 2.18E-03 1.452 6 
NM_024999 Hypothetical protein FLJ12988 FLJ12988 -2.398 -1.262 0.492 0.390 -8.162 4.22E-04 3.842 8 
AB026156 Homo sapiens TCAM-1 pseudogene 
mRNA for testicular cell adhesion 
molecule 1 
 -2.452 -1.294 0.693 0.535 -6.251 2.20E-03 1.383 7 
NM_024018 Butyrophilin, subfamily 2, member A3 BTN2A3 -2.466 -1.302 0.517 0.396 -8.119 4.38E-04 3.889 6 
NM_003135 Signal recognition particle 19kDa SRP19 -2.486 -1.314 0.469 0.356 -8.853 2.58E-04 4.689 7 
AK021501 Homo sapiens cDNA FLJ11439 fis LOC92482 -2.512 -1.329 0.486 0.365 -8.668 2.95E-04 4.434 8 
NM_001718 Bone morphogenetic protein 6 BMP6 -2.528 -1.338 0.509 0.384 -8.279 3.84E-04 4.079 6 
AK021481 Homo sapiens cDNA FLJ11419 fis  -2.528 -1.338 0.371 0.277 -10.810 7.24E-05 6.666 8 
AF109681 Integrin, alpha 11 ITGA11 -2.569 -1.361 0.630 0.459 -6.958 1.14E-03 2.421 6 
NM_030570 Uroplakin 3B UPK3B -2.594 -1.375 0.725 0.527 -6.310 2.09E-03 1.415 8 
AB027233 19A24 protein SLAMF7 -2.614 -1.386 0.336 0.242 -12.020 3.39E-05 7.759 8 
NM_015906 Tripartite motif-containing 33 TRIM33 -2.621 -1.390 0.257 0.185 -14.330 9.46E-06 9.585 8 
AF176707 F-box only protein 29 FBXO29 -2.757 -1.463 0.506 0.346 -9.236 1.99E-04 5.067 8 
NM_022873 Interferon, alpha-inducible protein (clone 
IFI-6-16) 
G1P3 -2.789 -1.480 0.646 0.436 -7.547 6.95E-04 3.082 8 
NM_005877 Splicing factor 3a, subunit 1, 120kDa SF3A1 -2.797 -1.484 0.504 0.334 -8.995 2.36E-04 4.896 6 
AK055600 Popeye protein 3, Homo sapiens cDNA 
FLJ31038 fis 
 -2.825 -1.498 0.659 0.439 -7.511 7.17E-04 3.037 8 
NM_024998 Hypothetical protein FLJ12704 FLJ12704 -2.856 -1.514 0.823 0.546 -6.235 2.23E-03 1.360 7 
AB040968 KIAA1535 protein KIAA1535 -2.870 -1.521 0.281 0.166 -8.029 4.76E-04 3.729 6 
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NM_021238 TERA protein, Family with sequence 
similarity 60, member A 
TERA -2.965 -1.568 0.427 0.278 -9.695 1.48E-04 5.644 6 
NM_016564 BM88 antigen BM88 -2.969 -1.570 0.642 0.405 -7.870 5.41E-04 3.534 7 
BC002770 Homo sapiens, clone IMAGE:3616574 LOC92154 -3.008 -1.589 0.759 0.478 -6.986 1.11E-03 2.351 8 
AL080232 Homo sapiens genomic DNA  -3.276 -1.712 0.660 0.387 -8.598 3.02E-04 4.399 7 
NM_001610 Acid phosphatase 2, lysosomal ACP2 -3.437 -1.781 0.879 0.506 -6.700 1.43E-03 2.071 6 
NM_003809 Tumor necrosis factor (ligand) 
superfamily, member 12 
TNFSF12 -3.568 -1.835 0.923 0.503 -6.728 1.41E-03 2.001 8 
NM_001276 Chitinase 3-like 1 (cartilage 
glycoprotein-39) 
CHI3L1 -3.590 -1.844 0.574 0.315 -9.304 1.88E-04 5.232 6 
NM_005855 Receptor (calcitonin) activity modifying 
protein 1 
RAMP1 -3.613 -1.853 0.535 0.289 -11.190 5.94E-05 7.057 7 
NM_003186 Transgelin TAGLN -3.625 -1.858 0.360 0.216 -9.696 1.48E-04 5.557 7 
NM_030765 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 4 
B3GNT4 -3.655 -1.870 0.394 0.210 -14.270 9.68E-06 9.570 7 
NM_013271 Proprotein convertase subtilisin/kexin 
type 1 inhibitor 
PCSK1N -3.655 -1.870 0.637 0.341 -9.654 1.50E-04 5.513 8 
AL110248 Homo sapiens mRNA  -3.789 -1.922 0.279 0.164 -9.398 1.79E-04 5.242 7 
NM_030655 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 11 (CHL-1 like helicase 
homolog, S. cerevisiae) 
DDX11 -4.003 -2.001 1.024 0.512 -6.634 1.52E-03 1.872 8 
NM_001299 Calponin 1, basic, smooth muscle CNN1 -4.441 -2.151 0.924 0.424 -7.428 1.11E-03 2.570 6 
NM_032454 Serine/threonine kinase 19 STK19 -4.604 -2.203 0.735 0.333 -10.060 1.14E-04 5.976 7 
NM_053025 Myosin, light polypeptide kinase MYLK -4.617 -2.207 0.593 0.269 -12.110 3.35E-05 7.834 8 
NM_001613 Actin, alpha 2, smooth muscle, aorta ACTA2 -4.807 -2.265 1.093 0.475 -6.893 1.21E-03 2.276 7 
AB051448 KIAA1661 protein KIAA1661 -4.928 -2.301 0.338 0.170 -8.930 2.49E-04 4.775 6 
AK025094 Homo sapiens cDNA: FLJ21441 fis ACTA2 -5.000 -2.322 0.897 0.392 -8.694 2.90E-04 4.559 6 
NM_013317 Lung type-I cell membrane-associated 
glycoprotein 
T1A-2 -5.021 -2.328 0.356 0.174 -9.853 1.31E-04 5.762 6 
NM_014392 Neuron-specific protein D4S234E -5.032 -2.331 0.792 0.347 -9.503 1.68E-04 5.444 6 
119
 
 Gene ID Description Symbol Fold 
Change 
Average 
log2 
ratio 
SD CV t-test P-value B-
statistic 
Replicates 
Used 
NM_017680 Asporin (LRR class 1) ASPN -5.148 -2.364 1.079 0.460 -7.459 7.51E-04 3.020 7 
AL359941 Homo sapiens mRNA  -5.864 -2.552 0.600 0.266 -8.639 2.96E-04 4.401 7 
U11058 Potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
KCNMA1 -5.905 -2.562 0.705 0.275 -12.080 3.38E-05 7.812 8 
NM_022844 Myosin, heavy polypeptide 11, smooth 
muscle 
MYH11 -5.905 -2.562 0.684 0.267 -12.380 2.87E-05 8.064 8 
NM_000300 Phospholipase A2, group IIA (platelets, 
synovial fluid) 
PLA2G2A -5.971 -2.578 0.530 0.206 -15.600 4.79E-06 10.469 8 
NM_002923 Regulator of G-protein signalling 2, 
24kDa 
RGS2 -6.285 -2.652 0.932 0.356 -9.213 2.02E-04 5.086 7 
NM_000867 5-hydroxytryptamine (serotonin) receptor 
2B 
HTR2B -6.360 -2.669 0.655 0.246 -13.600 1.40E-05 9.097 6 
NM_001901 Connective tissue growth factor CTGF -6.998 -2.807 0.459 0.163 -19.180 9.28E-07 12.608 8 
NM_005909 Microtubule-associated protein 1B MAP1B -7.003 -2.808 0.787 0.281 -12.010 3.39E-05 7.786 7 
NM_018649 H2A histone family, member Y2 H2AFY2 -7.140 -2.836 0.299 0.114 -15.250 5.84E-06 10.255 6 
AK055872 Haptoglobin HP -7.428 -2.893 0.835 0.289 -11.650 4.34E-05 7.438 8 
NM_001615 Actin, gamma 2, smooth muscle, enteric ACTG2 -7.574 -2.921 0.986 0.334 -9.964 1.22E-04 5.919 6 
AK023182 CGI-145 protein CGI-145 -10.447 -3.385 1.073 0.317 -10.880 7.02E-05 6.771 7 
NM_006198 Purkinje cell protein 4 PCP4 -11.624 -3.539 1.596 0.453 -7.738 6.01E-04 3.371 7 
NM_014456 Programmed cell death 4 (neoplastic 
transformation inhibitor) 
PDCD4 -14.980 -3.905 0.885 0.227 -14.880 6.82E-06 9.980 8 
NM_024567 Hypothetical protein FLJ21616 FLJ21616 -20.606 -4.365 0.847 0.194 -17.680 1.63E-06 11.773 6 
NM_006495 Ecotropic viral integration site 2B EVI2B -25.246 -4.658 0.302 0.062 -23.590 2.74E-07 14.695 7 
U87460 G protein-coupled receptor 37 
(endothelin receptor type B-like protein 
mRNA) 
 -38.160 -5.254 0.654 0.125 -26.990 9.34E-08 15.879 6 
NM_006757 Troponin T type 3 (skeletal, fast) TNNT3 -43.441 -5.441 0.578 0.106 -30.430 4.20E-08 17.058 7 
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RT-PCR Validation Studies 
 
 
 RT-PCR validation of the eutopic endometrium microarrays included utilization 
of 5 individual gene primer sets and comparing the abundance of the gene of interest 
compared to GAPDH.  Three separate RT-PCR experiments were conducted with each 
cDNA for each gene.  Within the eutopic endometrium samples, the average fold-changes 
of the genes were as follows: Mammoglobin, 37.908 (Table V); Thrombospondin, 1.267 
(Table VI); GADD45B, 3.133 (Table VII); G2 & S phase expressed, 1.488 (Table VIII); 
and Homo sapiens BC009393, 0.677 (Table IX).   
 Validation studies for the normal pelvic peritoneum microarray studies included 
RT-PCR utilizing three separate gene primer sets and comparing their abundance to 
GAPDH.  Three separate experiments were conducted with each cDNA for each gene.  
The genes had the following fold-changes: SOCS2, 2.240 (Table X); MCM5, 2.877 
(Table XI); and TNIP2, 3.833 (Table XII).
 Table V. RT-PCR Studies of Mammoglobin. 
 
Sample ID GADPH Ct Mammoglobin Ct Gene/Control*1000 Average SD Fold Change 
 
Ave Fold Change 
        
Pooled EA-1 18.33 28.22 1.054 1.051 0.239  37.908 
Pooled EA-2 18.60 28.20 1.289     
Pooled EA-3 18.81 29.08 0.810     
        
E03 EA-1 16.76 27.60 0.546 0.594 0.061 0.565  
E03 EA-2 19.40 30.17 0.573     
E03 EA-3 17.24 27.80 0.662     
        
E04 EA-1 13.48 25.22 0.292 0.262 0.074 0.249  
E04 EA-2 16.26 28.72 0.177     
E04 EA-3 15.57 27.20 0.316     
        
E05 EA-1 16.53 23.17 10.027 10.407 1.778 9.904  
E05 EA-2 17.19 23.53 12.344     
E05 EA-3 16.90 23.72 8.851     
        
E11 EA-1 17.26 21.12 68.869 68.624 6.865 65.306  
E11 EA-2 16.71 20.44 75.363     
E11 EA-3 16.65 20.67 61.640     
        
E15 EA-1 16.66 22.09 23.196 40.955 16.279 38.975  
E15 EA-2 16.67 20.85 55.169     
E15 EA-3 16.40 20.89 44.502     
        
E17 EA-1 15.70 18.87 111.105 118.160 7.931 112.448  
E17 EA-2 15.71 18.81 116.629     
E17 EA-3 15.87 18.85 126.745     
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 Table VI. RT-PCR Studies of Thrombospondin 3. 
 
 
Sample ID GADPH Ct Thrombospondin Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled EA-1 18.33 25.29 8.032 7.104 0.820  1.267 
Pooled EA-2 18.60 25.80 6.801     
Pooled EA-3 18.81 26.08 6.479     
        
E03 EA-1 16.76 23.70 8.144 11.821 5.971 1.664  
E03 EA-2 19.40 25.14 18.711     
E03 EA-3 17.24 24.10 8.609     
        
E04 EA-1 13.48 24.64 0.437 3.737 3.232 0.526  
E04 EA-2 16.26 24.27 3.879     
E04 EA-3 15.57 22.75 6.896     
        
E05 EA-1 16.53 23.45 8.258 8.313 2.040 1.170  
E05 EA-2 17.19 24.50 6.302     
E05 EA-3 16.90 23.49 10.380     
        
E11 EA-1 17.26 24.05 9.037 7.004 2.498 0.986  
E11 EA-2 16.71 24.60 4.216     
E11 EA-3 16.65 23.66 7.759     
        
E15 EA-1 16.66 22.70 15.198 15.723 3.151 2.213  
E15 EA-2 16.67 22.38 19.104     
E15 EA -3 16.40 22.68 12.869     
        
E17 EA-1 15.70 22.67 7.977 7.387 0.532 1.040  
E17 EA-2 15.71 22.82 7.239     
E17 EA-3 15.87 23.04 6.944     
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 Table VII. RT-PCR Studies of Growth Arrest and DNA-Damage-Inducible, beta. 
 
 
Sample ID GADPH Ct GADD45B Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled EA-1 18.60 26.48 4.245 4.736 0.694  3.133 
Pooled EA-2 18.81 26.39 5.226     
        
E03 EA-1 16.76 22.53 18.326 22.856 3.924 4.826  
E03 EA-2 19.40 24.72 25.033     
E03 EA-3 17.24 22.55 25.208     
        
E04 EA-1 13.48 22.23 2.323 11.641 8.634 2.458  
E04 EA-2 16.26 21.95 19.370     
E04 EA-3 15.57 21.81 13.230     
        
E05 EA-1 16.53 24.09 5.299 4.993 0.918 1.054  
E05 EA-2 17.19 24.64 5.719     
E05 EA-3 16.90 24.88 3.961     
        
E11 EA-1 17.26 25.37 3.619 4.638 2.912 0.979  
E11 EA-2 16.71 23.69 7.922     
E11 EA-3 16.65 25.37 2.371     
        
E15 EA-1 16.66 21.92 26.096 20.348 5.239 4.297  
E15 EA-2 16.67 22.38 19.104     
E15 EA -3 16.40 22.38 15.843     
        
E17 EA-1 15.70 21.19 22.251 24.544 4.914 5.183  
E17 EA-2 15.71 21.27 21.197     
E17 EA-3 15.87 20.92 30.186     
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 Table VIII. RT-PCR Studies of G2 and S Phase Expressed 1. 
 
 
Sample ID GADPH Ct G2 & S Phase Expressed Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled EA-1 18.33 27.67 1.543 2.180 0.551  1.488 
Pooled EA-2 18.60 27.25 2.489     
Pooled EA-3 18.81 27.45 2.507     
        
E03 EA-1 16.76 23.78 7.705 16.090 12.280 7.382  
E03 EA-2 19.40 24.45 30.186     
E03 EA-3 17.24 23.83 10.380     
        
E04 EA-1 13.48 25.08 0.322 0.414 0.148 0.190  
E04 EA-2 16.26 27.00 0.585     
E04 EA-3 15.57 27.11 0.336     
        
E05 EA-1 16.53 26.89 0.761 0.766 0.053 0.351  
E05 EA-2 17.19 27.64 0.715     
E05 EA-3 16.90 27.15 0.821     
        
E11 EA-1 17.26 27.75 0.695 0.690 0.106 0.316  
E11 EA-2 16.71 27.46 0.581     
E11 EA-3 16.65 26.95 0.793     
        
E15 EA-1 16.66 27.40 0.585 1.037 0.422 0.476  
E15 EA-2 16.67 26.13 1.420     
E15 EA -3 16.40 26.22 1.106     
        
E17 EA-1 15.70 27.85 0.220 0.460 0.220 0.211  
E17 EA-2 15.71 26.29 0.653     
E17 EA-3 15.87 26.82 0.506     
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 Table IX. RT-PCR Studies of Homo sapiens BC009393.  
 
 
Sample ID GADPH Ct Homo BC009393 Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled EA-1 18.33 30.16 0.275 0.745 0.440  0.677 
Pooled EA-2 18.60 28.86 0.816     
Pooled EA-3 18.81 28.58 1.145     
        
E03 EA-1 16.76 25.77 1.940 1.459 1.210 1.958  
E03 EA-2 19.40 32.95 0.083     
E03 EA-3 17.24 25.97 2.355     
        
E04 EA-1 16.26 33.26 0.008 0.010 0.003 0.013  
E04 EA-2 15.57 31.97 0.012     
        
E05 EA-1 16.53 26.36 1.099 0.816 0.620 1.095  
E05 EA-2 17.19 30.40 0.106     
E05 EA-3 16.90 26.55 1.245     
        
E11 EA-1 17.26 31.66 0.046 0.415 0.338 0.557  
E11 EA-2 16.71 27.17 0.710     
E11 EA-3 16.65 27.65 0.488     
        
E15 EA-1 16.66 30.79 0.056 0.294 0.346 0.394  
E15 EA-2 16.67 27.17 0.691     
E15 EA -3 16.40 29.26 0.135     
        
E17 EA-1 15.70 30.14 0.045 0.032 0.013 0.042  
E17 EA-2 15.71 31.46 0.018     
E17 EA-3 15.87 30.81 0.032     
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 Table X. RT-PCR Studies of Suppressor of Cytokine Signaling 2.  
 
 
Sample ID GADPH Ct SOCS2 Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled NPP-1 22.68 25.98 101.532 92.287 13.073  2.240 
Pooled NPP-2 22.30 25.89 83.043     
        
E03 EA-1 24.26 25.92 316.439 359.654 56.338 3.897  
E03 EA-2 24.94 26.18 423.373     
E03 EA-3 25.44 27.00 339.151     
        
E04 EA-1 22.82 27.48 39.555 87.524 44.560 0.948  
E04 EA-2 23.29 26.26 127.627     
E04 EA-3 23.31 26.70 95.391     
        
E09 EA-1 23.32 24.90 334.482 172.884 141.340 1.873  
E09 EA-2 23.29 27.08 72.293     
E09 EA-3 22.72 25.88 111.878     
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 Table XI. RT-PCR Studies of Minichromosome Maintenance Deficient 5, Cell Division Cycle 46. 
 
 
Sample ID GADPH Ct MCM5 Ct Gene/Control*1000 Average SD Fold Change Ave Fold Change 
        
Pooled NPP-1 22.68 28.52 17.458 18.686 1.738  2.877 
Pooled NPP-3 24.29 29.94 19.915     
        
E03 EA-1 24.26 27.96 76.947 80.709 25.684 4.319  
E03 EA-2 24.94 29.07 57.114     
E03 EA-3 25.44 28.65 108.067     
        
E04 EA-1 22.82 28.66 17.458 34.921 15.316 1.869  
E04 EA-2 23.29 27.89 41.235     
E04 EA-3 23.31 27.75 46.071     
        
E09 EA-1 23.32 27.14 70.805 45.628 21.815 2.442  
E09 EA-2 23.29 28.18 33.726     
E09 EA-3 22.72 27.67 32.352     
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 Table XII. RT-PCR Studies of A20-Binding Inhibitor of NF-kappaB Activation 2. 
 
 
Sample ID GADPH Ct TNIP2 Ct Gene/Control*1000 Average SD Fold Change Average Fold Change 
        
Pooled NPP-1 22.68 25.85 111.105 197.398 166.725  3.833 
Pooled NPP-2 22.30 25.75 91.505     
Pooled NPP-3 24.29 25.65 389.582     
        
E03 EA-1 24.94 24.07 1827.663 1760.577 94.874 8.919  
E03 EA-2 25.44 24.68 1693.491     
        
E04 EA-1 22.82 25.13 201.660 240.597 36.325 1.219  
E04 EA-2 23.29 25.31 246.558     
E04 EA-3 23.31 25.18 273.573     
        
E09 EA-1 23.32 25.33 248.273 268.828 160.190 1.362  
E09 EA-2 23.29 24.48 438.303     
E09 EA-3 22.72 25.78 119.908     
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CHAPTER V 
 
 
DISCUSSION 
 
 
 In keeping with Sampson’s theory of retrograde menstruation as the source for the 
cells that make up endometriotic lesions, it would be expected that the eutopic 
endometrial cells and/or the pelvic peritoneum of women with endometriosis would 
display properties of increased adhesion.  In addition, cell growth and apoptotic pathways 
would be altered to allow for the continued presence of these cells in the peritoneal cavity 
rather than their destruction.  Cells involved in inflammatory response and cytotoxicity, 
such as macrophages, would be expected to be deficient in their capability to carry out 
phagocytosis and cytolysis in the peritoneal environment.   
 
Pathway Involvement 
 
 
 Importing of genes from the eutopic endometrium data set into the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) rendered involvement of differentially 
expressed genes in 103 pathways.  The pathways in which differentially expressed genes 
were most involved included: Cell Communication; MAPK Signaling Pathway; 
Cytokine-Cytokine Receptor Interaction; Cell Cycle; TGF-beta Signaling Pathway; Focal 
Adhesion; ECM-Receptor Interaction; Cell Adhesion Molecules; Adherens, Tight, and 
Gap Junctions; and Leukocyte Transendothelial Migration.  
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 Differentially expressed genes in the normal pelvic peritoneum data set were 
involved in 59 KEGG Pathways.  The pathways with the greatest representation of genes 
included: Calcium Signaling Pathway; Cytokine-Cytokine Receptor Interaction; Cell 
Cycle; TGF-beta Signaling Pathway; Focal Adhesion; Leukocyte Transendothelial 
Migration; Regulation of Actin Cytoskeleton; ECM-Receptor Interaction; and Adherens, 
Tight, and Gap Junctions. 
 Several genes involved in cell adhesion were found to be up-regulated in the 
eutopic endometrium of women with endometriosis.  These include junctional adhesion 
molecule I (F11R) and thrombospondin 3 (THBS3 or TSP3).  F11R was up-regulated 
3.782-fold (p=5.12 x 10-7) and is involved in the following KEGG pathways: Cell 
Adhesion Molecules, Tight Junctions, and Leukocyte Transendothelial Migration.  F11R 
is found on the surface of human platelets and has been suggested to play a role in the 
adhesion of platelets to cytokine-inflamed endothelial cells.  It is also an important 
regulator of tight junction assembly in epithelial cells and is involved in platelet 
aggregation, secretion, adhesion, and spreading (111).  This might aid in the adhesion of 
endometrial cells to the pelvic peritoneum, as well as participate in vasculogenesis with 
implanting endometriotic lesions. 
 THBS3, which was up-regulated 3.422-fold (p=5.48 x 10-4) in the eutopic 
endometrium of women with endometriosis, was also found to be up-regulated in the 
normal pelvic peritoneum of women with endometriosis (+3.487, p=8.35 x 10-5).  In both 
studies, THBS3 was involved in the Cell Communication, TGF-beta Signaling, Focal 
Adhesion, ECM-Receptor Interaction KEGG pathways.  THBS3 is a member of a family 
of extracellular matrix glycoproteins that mediate interactions between cells and the 
132 
extracellular matrix.  It is located at chromosome 1q21-24.  THBS3 has been found in 
high abundance in endocrine tissues (pituitary, testis, thyroid, adrenal, thymus, and 
stomach), muscle (uterus, colon, prostate, and bladder), and fetal tissues (kidney and 
lung).  In addition, high levels of THBS3 have been found in placenta and mammary 
gland tissue, while the expression of THBS3 mRNA has been characterized as low in the 
ovary and fetal thymus.  Other members of the thrombospondin family, including TSP1 
and TSP4, have shown expression in connective tissue and been found to bind to 
extracellular matrix proteins including heparin sulfate proteoglycan, collagen, 
fibronectin, and laminin.  In addition, TSP1 binds to TGF-β1 (112). 
 Other genes involved in cell adhesion were found to be down-regulated in the 
eutopic endometrium of women with endometriosis, including β-catenin, GNAS complex 
locus, Connexin-36, and Phosphatase and tensin homolog.  Interestingly, down-regulated 
expression of β-catenin decreases TGF-β induced apoptosis (113).  This may be one way 
in which endometrial cells in women with endometriosis are able to survive longer in the 
intrauterine environment, and then have a greater chance of being refluxed and 
subsequently involved in attachment to the peritoneal lining and generation of an 
endometriotic implant. 
 Tumor necrosis factor (ligand) superfamily, member 12 (TNFSF12), was found to 
be down-regulated 2.604-fold (p=2.56 x 10-6) in the eutopic endometrium of women with 
endometriosis; it was down-regulated in normal pelvic peritoneum as well (-3.568, 
p=1.41 x 10-3).  TNFSF12 is implicated in the cytokine-cytokine receptor interaction 
KEGG pathway, alongside bone morphogenetic protein 2, chemokine ligands, and 
interleukin receptors.  TNFSF12, also known as TWEAK (TNF-related weak inducer of 
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apoptosis), has been found in various tissues and cells and has been associated with 
endothelial cell proliferation and angiogenesis.  It has been shown to lead to cell death via 
interactions with caspases leading to apoptosis, as well as with cathepsin B, leading to 
cell necrosis (114).  Its down-regulation in both the eutopic endometrium and normal 
pelvic peritoneum of women with endometriosis may allow for continued growth of cells 
that would typically undergo death via a TWEAK-induced pathway.  Although an 
increase in TWEAK could be proposed to aid in proliferation of endometriotic cells and 
vasculature, TWEAK’s role in endometriosis appears to be more associated with cell 
viability.  In addition, TWEAK is located at chromosome 17p13, a region that has been 
found to have loss of heterozygosity in late-stage endometriosis (91) and to contain the 
gene for TP53 (87). 
 Only one study involving microarray analysis and gene expression in 
endometriosis has incorporated KEGG pathways into the data analysis.  Wu et al. 
compared expression of eutopic endometrium versus ovarian and nonovarian 
endometriosis utilizing cDNA microarrays imprinted with 9600 genes.  Over 900 genes 
were differentially expressed and were involved in 79 KEGG pathways.  The pathways 
represented were: Purine Metabolism; Glutathione Metabolism; Starch and Sucrose 
Metabolism; MAPK Signaling Pathway; Calcium Signaling Pathway; Cytokine-Cytokine 
Receptor Interaction; Cell Cycle; Apoptosis; Wnt Signaling Pathway; TGF-beta 
Signaling Pathway; Focal Adhesion; Tight Junction; Toll-like Receptor Signaling 
Pathway; Jak-STAT Signaling Pathway; and Regulation of Actin Cytoskeleton.  In 
comparing the results of the present study with those of Wu et al., differentially expressed 
genes in the eutopic endometrium portion of this study were present in all of the 
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aforementioned pathways.  In addition, the proportion of genes involved were similar.  
However, the microarrays contained only two genes that were identical and were 
differentially expressed in both studies: MKNK1 in the MAPK Signaling Pathway and 
BMP6 in the TGF-beta Signaling Pathway.  The lack of overlap could be for several 
reasons, most likely due to the utilization of different arrays with a different number and 
selection of genes.  In addition, the Wu study was a comparison of eutopic versus ectopic 
endometrium in women with endometriosis, whereas this study compared eutopic 
endometrium in women with and without endometriosis.  Lastly, despite the 
aforementioned reasons for differences, it is promising that both studies show differential 
expression of genes in many of the same metabolic pathways.   
   
Comparison of Results to Prior Microarray Studies 
 
 The most appropriate studies to compare the results of the present study to are 
those examining differences in gene expression of eutopic endometrium in women with 
and without endometriosis.  In regard to the study by Chen et al., there were similarities 
in differential gene expression involving transforming growth factor-β, neuropeptide Y 
receptor, ras-related genes, and keratin-associated proteins.  However, the results from 
the Chen study were not reported in a formal research paper; therefore, it is difficult to 
compare gene-to-gene.  In addition, whether genes were up-regulated or down-regulated 
was not specified (6). 
 Differential expression of heat shock proteins and tyrosine-related genes was 
demonstrated in this study and that of Ezeh et al.  Heat shock 70kD protein 1B had a 
significantly higher expression in the endometrium of women with endometriosis in the 
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Ezeh study.  In the present study, another heat shock 70kDa protein, 9B, was found to be 
down-regulated 2.205-fold (p=3.35 x 10-4) in endometrium, while in the normal pelvic 
peritoneum, heat shock 70kDa protein 14 was up-regulated 3.320-fold (p-value=1.29 x 
10-3).  Tyrosine 3-monooxygenase was significantly down-regulated in women with 
endometriosis in the Ezeh study (106).  Several tyrosine kinase genes were differentially 
expressed in the present study; however, none of them were tyrosine monooxygenase 
genes.   
 The most comprehensive study of eutopic endometrium gene expression was 
conducted by Kao et al. (107) and compared expression in women with and without 
endometriosis during the window of implantation.  These results were compared with a 
prior study by Kao et al. (109) which examined differences in eutopic endometrial gene 
expression in nonpregnant women between 28 and 39 yr of age with regular menstrual 
cycles (26–35 days) and with no history of endometriosis.  Endometrial biopsies obtained 
during the window of implantation timed to the lutenizing hormone surge were compared 
with biopsies collected during the late proliferative phase (109).  Genes found to be 
differentially expressed by Kao et al. that were also differentially expressed in this study 
included members of the interleukin family, proline-rich proteins, and genes related to the 
progesterone receptor. 
 Oviductal glycoprotein 1 (OVGP1), found by Arimoto et al. (102) to be down-
regulated  in ovarian endometriotic tissue throughout the menstrual cycle, was down-
regulated 4.190-fold (p=1.67 x 10-3) in the eutopic endometrium of women with 
endometriosis in this study.  This gene is involved in protecting the early embryo and 
fallopian tube from noxious extracellular environments.  It is secreted from non-ciliated 
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oviductal epithelial cells and is expressed greatest during ovulation, and decreased 
expression is speculated to be associated with infertility in women with endometriosis 
(115).  Its decreased expression in the eutopic endometrium of women with 
endometriosis may play an even greater role in endometriosis-associated infertility, by 
making the endometrium less capable of protecting an embryo during and after 
implantation. 
 
RT-PCR Validation of Microarray Studies 
 
 The average fold-change of each gene utilized in the validation studies of the 
eutopic endometrium microarrays corresponded to the array results with regard to up-
regulation or down-regulation.  However, the magnitude of expression was not always 
similar.  This was especially true in the case of mammaglobin, with an average fold-
change of 37.908 via RT-PCR and 4.469 via microarray analysis.  GADD45B, on the 
other hand, demonstrated excellent correlation in expression direction and magnitude 
between the microarray and RT-PCR results, with an average fold-change of 3.133 via 
the RT-PCR analysis, concurrent with the microarray fold-change of 3.17.   
 What is the significance of the increase in mammaglobin expression?  Could this 
be a potential marker for endometriotic disease?  Despite its dramatic up-regulation in 
four of the six women with endometriosis (per RT-PCR), it was actually down-regulated 
via RT-PCR validation in the other two samples.  Knowing the phase of the menstrual 
cycle for each participant would have been helpful in clarifying if this dramatic change in 
expression was due to endometriosis or to changes in the uterine hormonal environment.  
Mammaglobin was one of the genes found to be differentially regulated in the study of 
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Kao et al. comparing gene expression in the window of implantation versus the late 
proliferative phase (109).  It was up-regulated 12.4-fold (p=0.0255) during the window of 
implantation.  Mammaglobin is considered to be a breast-specific uteroglobin, and is 
most noted for its expression in breast cancer.  It is also a member of the secretory 
lipophilin family of proteins prominent in glandular secretions and hormone responsive 
tissues.  Its role in human endometrium during the window of implantation has not been 
determined (109).  It would be interesting to look further into the differential expression 
of this gene to determine whether its up-regulation is associated with the menstrual cycle 
phase or whether it plays a role in endometriotic disease.  Of note, mammaglobin was not 
found to be differentially expressed in Kao’s subsequent study of differential gene 
expression in women with endometriosis (107). 
 In the case of the G2 and S Phase Expressed gene, although the average fold 
change did show an increase in expression in the endometriosis participants via RT-PCR 
(1.488), only one of six endometriosis subjects rendered an increase in gene expression 
(E03), with a fold change of 7.382.  The other five subjects actually showed decreased 
expression versus the normal pool, with all fold changes less than one.  When the 
microarray results for this gene were examined by individuals rather than by the average, 
it was found that all individuals showed an up-regulation of gene expression.  The most 
likely reason for this discrepancy involves the selection of primers utilized to validate the 
expression of this gene.  An independent primer set was created for this gene utilizing 
OligoPerfect Designer versus utilizing the sequence on the array.  Therefore, the primer 
set utilized for the RT-PCR validation studies may have amplified a different portion of 
the gene or an isomer of the gene, instead of the region imprinted on the arrays.   
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 In the same fashion, the SOCS2 transcript was found by RT-PCR to be in greater 
abundance in the normal pelvic peritoneum of women with endometriosis versus the 
normal participant pool (average fold change of 2.240).  Microarray analysis had 
rendered this gene down-regulated at with an average fold change of -2.15.  The other 
two genes transcripts examined in normal pelvic peritoneum, TNIP2 and MCM5, were 
both found to be in greater abundance in the endometriosis participants via RT-PCR 
(3.833 and 2.877, respectively), which corresponded to the microarray results of +24.3 
and +5.14, respectively. 
   
Future Directions 
 
 The primary research direction should be an expansion of the normal pelvic 
peritoneum studies.  No other studies have examined this tissue utilizing microarray 
analysis.  It would be beneficial to study larger samples of normal pelvic peritoneum in 
women with versus those without endometriosis, as well as to compare peritoneal tissue 
that is adjacent to endometriotic lesions versus peritoneum in areas where endometriosis 
is not present within the same patient.  A necessity for such a study would be the 
procurement of a surgical instrument that is able to collect a sufficient quantity of tissue.  
In most laparoscopies for tubal ligation, only two trocars are placed, one for the camera 
and one for the instrument that is to either cauterize or place a band around the fallopian 
tube.  The use of only one instrument makes the collection of a tissue biopsy difficult; 
however, the placement of a third trocar would be extraneous for this surgical procedure.  
In contrast, the majority of diagnostic laparoscopies have greater than two trocars in 
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place, which allows for one instrument to grasp the peritoneum and a second instrument 
for biopsying. 
 Microarray analysis of peritoneal macrophages in women with and without 
endometriosis is another area of research in which there has been a lack of publications.  
For such a study, ideally peritoneal cells should be collected through washings during 
laparoscopy and the macrophages isolated via negative selection to inflict the least 
amount of trauma and reduce the likelihood of changes in gene expression.  Total RNA 
isolated from these cells could be hybridized to microarrays specific for inflammatory 
and cytotoxic pathways to determine if peritoneal macrophages in women with 
endometriosis demonstrate a decreased ability to remove “foreign” cells from the 
peritoneal environment.  The first studies could be conducted on whole populations of 
peritoneal cells, with RNA extraction occurring immediately after collection, to 
determine the gene expression of the peritoneal environment globally.  This analysis 
could be further extrapolated throughout different stages of endometriosis to examine if 
the characteristics of macrophages change as the disease progresses.  
 Laser capture microdissection (LCM) is a technique that has allowed microarray 
analysis of individual cell types from harvested human tissues.  It has been utilized in a 
recent microarray study of deep endometriosis (116).  LCM would allow selection for 
endometrial cells with or without examining stromal cell gene expression as well.  This 
technology is also necessary for examining endometriotic lesions in the peritoneal cavity 
to ensure that peritoneal or ovarian cells are not included in the analysis.     
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Recommendations for Similar Studies 
 
 
 Certain elements would enhance the results of a study similar to this one.  First of 
all, access to a larger patient population would enable recruitment at more surgeries and 
more opportunities for adequate sample collection.  In addition, a larger patient 
population would likely allow for the recruitment of more women with endometriosis of 
all stages and studies to be performed examining gene expression throughout disease 
progression.   
 Depending upon the type of hospital and clinic system, recruitment of participants 
might be possible prior to the day of surgery, as was the case with this study.  If the 
potential subjects are direct patients of the principal investigator, an introduction to the 
idea of participation in a research study could be made at the time of surgery scheduling, 
and a research packet sent home with the patient to look over prior to consideration.  This 
would save time on the day of surgery as well and prevent any delays in the surgery 
schedule.  This also might help on reliability of a patient showing up for their scheduled 
surgery, which was often an impediment to participant recruitment in this study. 
 Recruitment during a specific phase of the menstrual cycle might also be able to 
be coordinated in a research situation where the participants were direct patients of the 
principal investigator.  In the current research study, most of the patients were not 
utilizing any form of hormonal contraception and/or were not compliant with use.  In 
addition, by approaching participants the day of surgery, it was not possible to schedule 
or reschedule a participant based upon their menstrual cycle phase.  Throughout the 
analysis of this study’s data, alteration of gene expression based upon phase of the 
menstrual cycle has definitely been a great consideration.  As mentioned previously, 
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several of the genes found to be significantly up- or down-regulated could be due to the 
presence of endometriotic disease or whether the participants were in the proliferative or 
secretory phase.  Therefore, it would be necessary to determine the menstrual phase of 
recruited participants and to coordinate collection of samples during the same portion of 
the cycle.  
  
Limitations to Analysis 
 
 Microarrays are an inherently difficult medium with which to work.  There are 
many opportunities for error, particularly in the initial printing of the arrays, as well as in 
subsequent handling during analysis.  One of the greatest difficulties involves proper 
washing and drying of the arrays following hybridizations.  If the slide is allowed to dry, 
even briefly, throughout the washing process, it can result in residual salts on the array 
and interfere with scanning.  In addition, care must be taken to never touch the array 
without gloves on to prevent fingerprints and to remove of all dust particles that could 
render one or more genes unusable.  As a result, throughout the image analysis and spot 
quantification individual genes, and in some instances entire blocks of genes, had to be 
flagged from analysis due to the presence of background or a dust particle.  In addition, 
some printing errors became evident through scanning, where one spot overlapped with 
another or alignment of an entire row was “off,” and therefore both had to be flagged and 
removed from analysis.    
 This study was not able to look at gene expression of the entire genome or sample 
every endometriosis patient.  The arrays utilized allow examination of just over 21,000 of 
the 30,000 known human genes, and therefore, did not provide a complete examination of 
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every possible gene that could be involved in pathogenesis of the disease.  In addition, 
the participants enrolled were women from the Tulsa metropolitan area, and within that 
population, only those whose surgery was conducted at Tulsa Regional Medical Center.  
Other variables that were not controlled for, including menstrual cycle phase, race, 
ethnicity, method of hormonal contraception, and body mass index, affect the 
generalizablility of this study’s results. 
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APPENDIX I 
 
The following documents are the IRB approval letters from the Oklahoma State 
University Center for Health Sciences Institutional Review Board. 
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APPENDIX II 
 
The following documents are the most recent versions of the informed consent letters for 
both the normal participants and the endometriosis participants. 
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OKLAHOMA STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE 
PATIENT INFORMATION AND CONSENT FORM 
 
Title of Project: DNA Microarray Analysis of Endometriosis:  A Comparison of Gene Expression in 
Normal Endometrium versus Four Stages of Endometriotic Lesions 
 
Principal Investigator:  Melanie Y. McKean, D.O./Ph.D. Student 
 
Sub-Investigators: Marty Beal, D.O., Sheila Carnett, D.O. 
 
You are being asked to take part in a research study. If this consent form contains any words you do not 
understand, please ask your doctor or the staff to explain these words so that you understand them.  This 
consent form contains important facts to help you decide if it is in your best interest to take part in this 
study. 
 
Your participation in this research study is voluntary.  You are free to refuse to participate in any procedure 
and to refuse to answer any question at any time, and are free to withdraw your consent, and to withdraw 
from the research at any time without penalty. 
 
This research study involves the disease endometriosis.  Endometriosis is a common disease among women 
of reproductive age, and it involves the presence and growth of endometrial tissue (the tissue lining the 
inside of the uterus that is eliminated each month by a menstrual period) on the outside of uterus.  Common 
symptoms include menstrual cramping, pain during sexual intercourse, and infertility or the inability to 
become pregnant.  Many research studies have shown that endometriosis may have a genetic or heritable 
basis.  A woman with endometriosis often has a mother or sister with endometriosis too.  However, 
endometriosis can also develop in women without a family history of the disease.   
One type of cell, the macrophage, may become stimulated or activated in response to foreign materials.  
Macrophages play an important role in killing foreign substances in the body, and they release substances 
that stimulate other cells.  Women with endometriosis have been found to have more macrophages and 
more active macrophages in the fluid surrounding the uterus than women without endometriosis.  However, 
the direct effects of these differences have not been determined.  
The purpose of this study, therefore, is to gain knowledge regarding how and why endometriosis develops 
in some women and not others.  By examining tissue from women both with and without endometriosis, 
heritable units or genes can be studied to see if they are active in normal tissue or diseased tissue or both.  
Those genes active in diseased tissue can then be further studied to determine their specific role in 
endometriosis development and progression. 
 
The Study Design: 
• In this study, we are asking women who are already undergoing surgery to participate.   
• For the participants without endometriosis, women undergoing tubal ligation (getting your tubes 
tied) will be asked to participate.   
• Other women who present with pelvic pain and/or infertility, and are planning to undergo surgery, 
will be asked to participate as a potential endometriosis participant should disease be found when 
visually inspected by their physician during the surgical procedure. 
• If you agree to participate, you will be assigned a number and asked to complete a short medical 
history form discussing your personal medical history and family history, surgical history, 
infertility, prescribed and herbal medication use, and pain history.  The information linking your 
name with your study number will be kept in a confidential file during the study that will only be 
accessed by Dr. Beal or Dr. Carnett.  At the completion of this study, this information will be 
destroyed. 
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• Three samples will be taken:  (1) an endometrial biopsy, (2) a peritoneal biopsy, and (3) peritoneal 
fluid.   
o An endometrial biopsy is a sample of the tissue lining the inside of the uterus.  A thin 
instrument called a "pipelle" that looks like a narrow drinking straw is inserted through 
the opening in your cervix and into the uterus.  It is pushed forward several inches.  A 
small wire is pulled out of this pipelle once it is inserted.  Pulling out the wire makes the 
pipelle hollow and also creates suction, which draws some of the cells in the lining of 
your uterus into the pipelle through a hole at its end.  Your doctor will move the pipelle 
forwards and backwards a few times to get a good sample before pulling it out. 
o A peritoneal biopsy is a sample of the tissue lining the inside wall of the abdomen.  It is 
often the site of endometriosis tissue. 
o Peritoneal fluid is fluid found inside of the body around and behind the uterus.  It is 
typically removed during surgeries involving the pelvic region of the body. 
• The samples will be taken while you are under anesthesia during the surgery.   
• An analysis will then be performed on the tissue samples.  Genes, or heritable units, will be  
• examined to determine which ones are active in normal tissue, which are active in endometriotic 
tissue, and how this activity is different in women with endometriosis versus women without 
endometriosis. 
 
Participation in this study will not cost you anything.  The samples will be taken as part of the normal 
surgical procedure that you are planning to undergo for either tubal ligation or pain evaluation.  Refusal to 
participate in this study WILL NOT affect the timing or care involved in your planned surgical procedure.   
 
Risks: 
As with any surgical procedure, there are risks such as infection, delayed wound healing, hematoma 
formation (a collection of blood inside the body in and around where the incision is made), bleeding, 
and possible reactions from anesthesia.  These complications are uncommon.  You may also experience 
some pain after the surgical procedure, as your incisions heal.  Your physician will explain the amount and 
type of pain to be experienced.   
 
Infection can result from any surgery and produce swelling, tenderness, pain, and fever.  Almost all 
infections appear within a few days of the operation but on rare occasions may appear at any time after  
your surgery.  Small hematomas should be absorbed by your body, like any bruise, but large ones may have 
to be drained surgically to permit proper healing.  Any incision in the skin will leave a scar.  Surgical 
techniques, under most circumstances, can minimize, though not eliminate, scars. 
 
Benefits: 
You will derive no direct benefits from your participation in this study.  The indirect benefits of  
participating in this study may include assisting in an investigation for the genes responsible for the 
development of a disease that affects 5-15% of normal women and up to 60-80% of women with pelvic  
pain and/or infertility.  This information could lead to more specific treatments, including refined surgical 
procedures, drug treatments, and other therapies designed for patients suffering from endometriosis. 
 
The records of this study will be kept confidential and you will not be identifiable by name or description in 
any reports or publications.  Reviews may be required for research or monitoring purposes by Dr. Marty 
Beal, the Oklahoma State University Center for Health Sciences Institutional Review Board or its agents, 
and other government agencies or as required by law. 
 
NOTICE TO PATIENTS: Information in your medical record that you have a communicable or venereal 
disease is made confidential by law and cannot be released without your permission except in limited 
circumstances including release to persons who have risk exposures, release pursuant to an order of the  
court or the Department of Health, release among health care providers or release for statistical or 
epidemiological purposes. When such information is released, it cannot contain information from which  
you could be identified unless release of that identifying information is authorized by you, by an order of 
the court or the Department of Health or by law. 
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I understand this authorization is subject to revocation by me at any time except to the extent that action has 
already been taken in reliance on it. I UNDERSTAND THAT MY MEDICAL RECORDS MAY 
CONTAIN INFORMATION THAT INDICATES THAT I HAVE A COMMUNICABLE OR 
VENEREAL DISEASE WHICH MAY INCLUDE, BUT IS NOT LIMITED TO, DISEASES SUCH AS 
HEPATITIS, SYPHILIS, GONORRHEA OR THE HUMAN IMMUNODEFICIENCY VIRUS, ALSO 
KNOWN AS ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). With this knowledge I give 
my consent to the release of all information in my medical records including any information concerning 
my identity and release Oklahoma State University-College of Osteopathic Medicine, its agents and 
employees from any liability in connection with the release of the information relating to a communicable 
or venereal disease contained therein. 
 
I understand that Oklahoma State University-Center for Health Sciences will not provide compensation and 
will not provide medical treatment without charge for any injury as a result of and during the course of this 
research investigation. 
 
By agreeing to participate in this research and signing this form, you do not waive any of your legal rights, 
nor are the investigators, the institutions, or their agents free from liability or negligence. 
 
If you have any questions about your rights as a study participant, you may contact Dr. Stephen Eddy at 
Oklahoma State University-Center for Health Sciences, (918) 561-8287. 
 
If you have any questions about this study or research procedures, please contact the principal investigator, 
Melanie Y. McKean at (918) 852-7270, 1111 W. 17th Street, Tulsa, OK, 74017, at any time (day or night or 
on the weekends).  If you need to report any adverse effects from the research procedures, you will need to 
contact Dr. Marty Beal, (918) 584-5355, 802 S. Jackson, Suite 420, Tulsa, OK, 74127, at any time. 
 
Voluntary Participation 
 
I have read this consent document or it has been read and clearly explained in the language I understand.  
My questions have been answered to my satisfaction.  I freely consent to participate in this study under the 
conditions described.  I agree to the release of records for review as described under the above conditions.  
I understand that this consent may be canceled at any time.  I have been told of the potential risks and I 
agree to participate in this research.  I will receive a copy of this completed, signed consent form. 
 
_________________________________ 
Participant's Name (printed) 
 
 
_________________________________ ________________ 
Participant's Signature   Date 
 
 
_________________________________ ________________ 
Witness's Signature   Date 
 
 
_________________________________ ________________ 
Principal Investigator's Signature  Date 
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OKLAHOMA STATE UNIVERSITY 
CENTER FOR HEALTH SCIENCES 
 
AUTHORIZATION TO PERMIT THE USE AND DISCLOSURE OF 
PROTECTED HEALTH INFORMATION FOR RESEARCH PURPOSES 
ADDENDUM TO RESEARCH CONSENT FORM 
 
TITLE: DNA Microarray Analysis of Endometriosis:  A Comparison of Gene Expression  
 in Normal Endometrium versus Four Stages of Endometriotic Lesions   
PRINCIPAL INVESTIGATOR: Melanie Y. McKean, D.O./Ph.D. student    
PRINCIPAL INVESTIGATOR’S ADDRESS:1111 W. 17th Street, Graduate Room 336   
   Tulsa, OK 74107     
PRINCIPAL INVESTIGATOR’S TELEPHONE NUMBER: (918) 852-7270   
OTHER INVESTIGATORS: J. Martin Beal, D.O., Sheila Carnett, D.O.    
 
 
You have given or will give consent to participate in the above-named research study.  
The purpose of this additional form is to provide you with specific information regarding 
the use and disclosure of your protected health information, that is information about 
your health care that has a way that you can be identified with it, for the purpose of this 
research study.  While much of this information was provided to you in the consent form, 
recently enacted laws, focused on the privacy of medical information, require that this 
information be addressed in a certain manner.  Through the use of this additional form, 
we are seeking your authorization for the use and disclosure of your medical information 
for the purpose of this research study as required in these recently enacted laws. 
 
This research study will involve the recording of current and/or future protected health 
information from your hospital and/or physician office records.  The information that will 
be recorded will be limited to information concerning the stage of endometriosis that was 
observed during the laparoscopic surgery (Stage I, II, III, or IV) by the physician.  This 
information will be used for the purpose of categorizing the samples obtained during the 
surgery. 
 
Authorized representatives of the Institutional Review Board that reviewed and approved 
the performance of this study may review your protected health information for the 
purpose of monitoring the appropriate conduct of this research study. 
 
Staff of your hospital, the OSU-CHS clinics or other affiliated health care providers will 
have access to your protected health information as needed for the purpose of (1) 
following treatment orders made by the investigators for health care services (e.g., 
laboratory tests, diagnostic procedures) related to your participation in the research study; 
(2) billing for tests and procedures ordered by the investigators; and (3) for internal 
hospital operations (i.e. quality assurance). 
 
In unusual cases, the investigators may be required to release your protected research 
information in response to an order from a court of law.  If the investigators learn that 
you or someone with whom you are involved is in serious danger or potential harm, they 
will need to inform the appropriate agencies as required by Oklahoma law.  
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Although the researchers may report their findings about this research study in scientific 
journals or meetings, you will not be identified in their reports or articles.   
 
The researchers, OSU-CHS, and other health care providers affiliated with OSU-CHS 
will try to keep all information about your participation in this research study 
confidential, but absolute confidentiality cannot be guaranteed. 
 
In accordance with the OSU-CHS Notice of Privacy Practices document which you have 
been provided, or will be provided when you present for services at the OSU Clinic, OSU 
Physicians Building, or Tulsa Regional Medical Center, you are permitted to see the 
information contained in your medical records and kept by your health care provider 
unless otherwise specifically stated below. 
 
Your authorization (permission) to use and disclose your protected health information for 
the purpose of this research study is completely voluntary.  However, if you do not 
provide your written authorization for the use and disclosure of your protected health 
information, you will not be allowed to participate or continue to participate in the 
research study. 
 
Whether or not you provide your authorization for the research use and disclosure of your 
medical information will have no affect on your current or future medical care at the 
OSU-CHS-affiliated clinic or hospitals where you receive care or your current or future 
relationship with a health insurance carrier.  Whether or not you provide this 
authorization will have no affect on your relationship with OSU-CHS. 
 
You may withdraw, at any time, your authorization for the use and disclosure of your 
protected health information for the purpose of this research study.  However, if you 
withdraw your authorization for the use and disclosure of your protected health 
information, you will also be withdrawn from further participation in this research study.  
Any protected health information recorded for, or resulting from, your participation in 
this research study prior to the date that you formally withdrew your authorization may 
continue to be used and disclosed by the investigators for the purposes described above. 
 
To formally withdraw your authorization you should notify the principal investigator of 
this research study.  Contact information is listed on the first page of this form.  The 
investigator will ask you to sign a document with the date you asked to withdraw. 
 
Your decision to withdraw your authorization for the research use and disclosure of your 
medical information will have no affect on your current or future medical care at the 
OSU-CHS-affiliated clinic or hospitals or your current or future relationship with a health 
insurance provider.  Your decision to withdraw this authorization will have no affect on 
your current or future relationship with the OSU-CHS.  
 
The investigators may continue to use and disclose your protected health information for 
the purposed described above for an indefinite period of time. 
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Voluntary Consent 
 
All of the above has been explained to me and all of my current questions have been 
answered.  Throughout my participation in this research study, I have been encouraged to 
ask any additional questions I may have about the research use and disclosure of my 
protected health information.  Such future questions will be answered by the investigators 
listed on the first page of this form.   
 
Any questions I have about my rights associated with the research use and disclosure of 
my medical information will be answered by Teri Bycroft at (918) 699-8643. 
 
By signing this form, I agree to allow the use and disclosure of my medical information 
for the purposes described above.  With this knowledge, I give my authorization and 
consent to the use and disclosure as described in this document to the people identified in 
this form.  A copy of this authorization form will be given to me. 
 
           
Participant’s Signature    Date 
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OKLAHOMA STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE 
PATIENT INFORMATION AND CONSENT FORM 
 
Title of Project: DNA Microarray Analysis of Endometriosis:  A Comparison of Gene Expression in 
Normal Endometrium versus Four Stages of Endometriotic Lesions 
 
Principal Investigator:  Melanie Y. McKean, D.O./Ph.D. Student 
 
Sub-Investigators: Marty Beal, D.O., Sheila Carnett, D.O. 
 
You are being asked to take part in a research study. If this consent form contains any words you do not 
understand, please ask your doctor or the staff to explain these words so that you understand them.  This 
consent form contains important facts to help you decide if it is in your best interest to take part in this 
study. 
 
Your participation in this research study is voluntary.  You are free to refuse to participate in any procedure 
and to refuse to answer any question at any time, and are free to withdraw your consent, and to withdraw 
from the research at any time without penalty. 
 
This research study involves the disease endometriosis.  Endometriosis is a common disease among women 
of reproductive age, and it involves the presence and growth of endometrial tissue (the tissue lining the 
inside of the uterus that is eliminated each month by a menstrual period) on the outside of uterus.  Common 
symptoms include menstrual cramping, pain during sexual intercourse, and infertility or the inability to 
become pregnant.  Many research studies have shown that endometriosis may have a genetic or heritable 
basis.  A woman with endometriosis often has a mother or sister with endometriosis too.  However, 
endometriosis can also develop in women without a family history of the disease.   
One type of cell, the macrophage, may become stimulated or activated in response to foreign materials.  
Macrophages play an important role in killing foreign substances in the body, and they release substances 
that stimulate other cells.  Women with endometriosis have been found to have more macrophages and 
more active macrophages in the fluid surrounding the uterus than women without endometriosis.  However, 
the direct effects of these differences have not been determined.  
The purpose of this study, therefore, is to gain knowledge regarding how and why endometriosis develops 
in some women and not others.  By examining tissue from women both with and without endometriosis, 
heritable units or genes can be studied to see if they are active in normal tissue or diseased tissue or both.  
Those genes active in diseased tissue can then be further studied to determine their specific role in 
endometriosis development and progression. 
 
The Study Design: 
• In this study, we are asking women who are already undergoing surgery to participate.   
• For the participants without endometriosis, women undergoing tubal ligation (getting your tubes 
tied) will be asked to participate.   
• Other women who present with pelvic pain and/or infertility, and are planning to undergo surgery, 
will be asked to participate as a potential endometriosis participant should disease be found when 
visually inspected by their physician during the surgical procedure. 
• If you agree to participate, you will be assigned a number and asked to complete a short medical 
history form discussing your personal medical history and family history, surgical history, 
infertility, prescribed and herbal medication use, and pain history.  The information linking your 
name with your study number will be kept in a confidential file during the study that will only be 
accessed by Dr. Beal or Dr. Carnett.  At the completion of this study, this information will be 
destroyed. 
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• Five samples will be taken:  (1) a blood sample, (2) an endometrial biopsy, (3) a peritoneal biopsy 
of normal pelvic peritoneum, (4) a peritoneal biopsy of endometriotic tissue, and (5) peritoneal 
fluid.   
o The blood sample collected will be approximately 2-3 tablespoons. 
o An endometrial biopsy is a sample of the tissue lining the inside of the uterus.  A thin 
instrument called a "pipelle" that looks like a narrow drinking straw is inserted through 
the opening in your cervix and into the uterus.  It is pushed forward several inches.  A 
small wire is pulled out of this pipelle once it is inserted.  Pulling out the wire makes the 
pipelle hollow and also creates suction, which draws some of the cells in the lining of 
your uterus into the pipelle through a hole at its end.  Your doctor will move the pipelle 
forwards and backwards a few times to get a good sample before pulling it out. 
o A peritoneal biopsy is a sample of the tissue lining the inside wall of the abdomen.  It is 
often the site of endometriosis tissue.  One biopsy will be taken from normal pelvic 
peritoneum.  A second biopsy will be taken from endometriotic tissue. 
o Peritoneal fluid is fluid found inside of the body around and behind the uterus.  It is 
typically removed during surgeries involving the pelvic region of the body. 
• All biopsies will be taken while you are under anesthesia during the surgery.   
• An analysis will then be performed on the tissue samples.  Genes, or heritable units, will be 
examined to determine which ones are active in normal tissue, which are active in endometriotic 
tissue, and how this activity is different in women with endometriosis versus women without 
endometriosis. 
 
Participation in this study will not cost you anything.  The samples will be taken as part of the normal 
surgical procedure that you are planning to undergo for either tubal ligation or pain evaluation.  Refusal to 
participate in this study WILL NOT affect the timing or care involved in your planned surgical procedure.   
 
Risks: 
As with any surgical procedure, there are risks such as infection, delayed wound healing, hematoma 
formation (a collection of blood inside the body in and around where the incision is made), bleeding, 
and possible reactions from anesthesia.  These complications are uncommon.  You may also experience 
some pain after the surgical procedure, as your incisions heal.  Your physician will explain the amount and 
type of pain to be experienced.   
 
Infection can result from any surgery and produce swelling, tenderness, pain, and fever.  Almost all 
infections appear within a few days of the operation but on rare occasions may appear at any time after  
your surgery.  Small hematomas should be absorbed by your body, like any bruise, but large ones may have 
to be drained surgically to permit proper healing.  Any incision in the skin will leave a scar.  Surgical 
techniques, under most circumstances, can minimize, though not eliminate, scars. 
 
The risks from obtaining a blood sample include bruising, or small hematoma formation, as well as 
tenderness or pain. 
 
Benefits: 
You will derive no direct benefits from your participation in this study.  The indirect benefits of  
participating in this study may include assisting in an investigation for the genes responsible for the 
development of a disease that affects 5-15% of normal women and up to 60-80% of women with pelvic  
pain and/or infertility.  This information could lead to more specific treatments, including refined surgical 
procedures, drug treatments, and other therapies designed for patients suffering from endometriosis. 
 
The records of this study will be kept confidential and you will not be identifiable by name or description in 
any reports or publications.  Reviews may be required for research or monitoring purposes by Dr. Marty 
Beal, the Oklahoma State University Center for Health Sciences Institutional Review Board or its agents, 
and other government agencies or as required by law. 
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NOTICE TO PATIENTS: Information in your medical record that you have a communicable or venereal 
disease is made confidential by law and cannot be released without your permission except in limited 
circumstances including release to persons who have risk exposures, release pursuant to an order of the  
court or the Department of Health, release among health care providers or release for statistical or 
epidemiological purposes. When such information is released, it cannot contain information from which  
you could be identified unless release of that identifying information is authorized by you, by an order of 
the court or the Department of Health or by law. 
 
I understand this authorization is subject to revocation by me at any time except to the extent that action has 
already been taken in reliance on it. I UNDERSTAND THAT MY MEDICAL RECORDS MAY  
CONTAIN INFORMATION THAT INDICATES THAT I HAVE A COMMUNICABLE OR  
VENEREAL DISEASE WHICH MAY INCLUDE, BUT IS NOT LIMITED TO, DISEASES SUCH AS 
HEPATITIS, SYPHILIS, GONORRHEA OR THE HUMAN IMMUNODEFICIENCY VIRUS, ALSO 
KNOWN AS ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). With this knowledge I give  
my consent to the release of all information in my medical records including any information concerning  
my identity and release Oklahoma State University-College of Osteopathic Medicine, its agents and 
employees from any liability in connection with the release of the information relating to a communicable  
or venereal disease contained therein. 
 
I understand that Oklahoma State University-Center for Health Sciences will not provide compensation and 
will not provide medical treatment without charge for any injury as a result of and during the course of this 
research investigation. 
 
By agreeing to participate in this research and signing this form, you do not waive any of your legal rights, 
nor are the investigators, the institutions, or their agents free from liability or negligence. 
 
If you have any questions about your rights as a study participant, you may contact Dr. Stephen Eddy at 
Oklahoma State University-Center for Health Sciences, (918) 561-8287. 
 
If you have any questions about this study or research procedures, please contact the principal investigator, 
Melanie Y. McKean at (918) 852-7270, 1111 W. 17th Street, Tulsa, OK, 74017, at any time (day or night or 
on the weekends).  If you need to report any adverse effects from the research procedures, you will need to 
contact Dr. Marty Beal, (918) 584-5355, 802 S. Jackson, Suite 420, Tulsa, OK, 74127, at any time. 
 
 
Voluntary Participation 
 
I have read this consent document or it has been read and clearly explained in the language I understand.  
My questions have been answered to my satisfaction.  I freely consent to participate in this study under the 
conditions described.  I agree to the release of records for review as described under the above conditions.  
I understand that this consent may be canceled at any time.  I have been told of the potential risks and I 
agree to participate in this research.  I will receive a copy of this completed, signed consent form. 
 
_________________________________ 
Participant's Name (printed) 
 
 
_________________________________ ________________ 
Participant's Signature   Date 
 
 
_________________________________ ________________ 
Witness's Signature   Date 
 
 
_________________________________ ________________ 
Principal Investigator's Signature  Date  
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OKLAHOMA STATE UNIVERSITY 
CENTER FOR HEALTH SCIENCES 
 
AUTHORIZATION TO PERMIT THE USE AND DISCLOSURE OF 
PROTECTED HEALTH INFORMATION FOR RESEARCH PURPOSES 
ADDENDUM TO RESEARCH CONSENT FORM 
 
TITLE: DNA Microarray Analysis of Endometriosis:  A Comparison of Gene Expression  
 in Normal Endometrium versus Four Stages of Endometriotic Lesions   
PRINCIPAL INVESTIGATOR: Melanie Y. McKean, D.O./Ph.D. student    
PRINCIPAL INVESTIGATOR’S ADDRESS:1111 W. 17th Street, Graduate Room 336   
   Tulsa, OK 74107     
PRINCIPAL INVESTIGATOR’S TELEPHONE NUMBER: (918) 852-7270   
OTHER INVESTIGATORS: J. Martin Beal, D.O., Sheila Carnett, D.O.    
 
 
You have given or will give consent to participate in the above-named research study.  
The purpose of this additional form is to provide you with specific information regarding 
the use and disclosure of your protected health information, that is information about 
your health care that has a way that you can be identified with it, for the purpose of this 
research study.  While much of this information was provided to you in the consent form, 
recently enacted laws, focused on the privacy of medical information, require that this 
information be addressed in a certain manner.  Through the use of this additional form, 
we are seeking your authorization for the use and disclosure of your medical information 
for the purpose of this research study as required in these recently enacted laws. 
 
This research study will involve the recording of current and/or future protected health 
information from your hospital and/or physician office records.  The information that will 
be recorded will be limited to information concerning the stage of endometriosis that was 
observed during the laparoscopic surgery (Stage I, II, III, or IV) by the physician.  This 
information will be used for the purpose of categorizing the samples obtained during the 
surgery. 
 
Authorized representatives of the Institutional Review Board that reviewed and approved 
the performance of this study may review your protected health information for the 
purpose of monitoring the appropriate conduct of this research study. 
 
Staff of your hospital, the OSU-CHS clinics or other affiliated health care providers will 
have access to your protected health information as needed for the purpose of (1) 
following treatment orders made by the investigators for health care services (e.g., 
laboratory tests, diagnostic procedures) related to your participation in the research study; 
(2) billing for tests and procedures ordered by the investigators; and (3) for internal 
hospital operations (i.e. quality assurance). 
 
In unusual cases, the investigators may be required to release your protected research 
information in response to an order from a court of law.  If the investigators learn that 
you or someone with whom you are involved is in serious danger or potential harm, they 
will need to inform the appropriate agencies as required by Oklahoma law.  
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Although the researchers may report their findings about this research study in scientific 
journals or meetings, you will not be identified in their reports or articles.   
 
The researchers, OSU-CHS, and other health care providers affiliated with OSU-CHS 
will try to keep all information about your participation in this research study 
confidential, but absolute confidentiality cannot be guaranteed. 
 
In accordance with the OSU-CHS Notice of Privacy Practices document which you have 
been provided, or will be provided when you present for services at the OSU Clinic, OSU 
Physicians Building, or Tulsa Regional Medical Center, you are permitted to see the 
information contained in your medical records and kept by your health care provider 
unless otherwise specifically stated below. 
 
Your authorization (permission) to use and disclose your protected health information for 
the purpose of this research study is completely voluntary.  However, if you do not 
provide your written authorization for the use and disclosure of your protected health 
information, you will not be allowed to participate or continue to participate in the 
research study. 
 
Whether or not you provide your authorization for the research use and disclosure of your 
medical information will have no affect on your current or future medical care at the 
OSU-CHS-affiliated clinic or hospitals where you receive care or your current or future 
relationship with a health insurance carrier.  Whether or not you provide this 
authorization will have no affect on your relationship with OSU-CHS. 
 
You may withdraw, at any time, your authorization for the use and disclosure of your 
protected health information for the purpose of this research study.  However, if you 
withdraw your authorization for the use and disclosure of your protected health 
information, you will also be withdrawn from further participation in this research study.  
Any protected health information recorded for, or resulting from, your participation in 
this research study prior to the date that you formally withdrew your authorization may 
continue to be used and disclosed by the investigators for the purposes described above. 
 
To formally withdraw your authorization you should notify the principal investigator of 
this research study.  Contact information is listed on the first page of this form.  The 
investigator will ask you to sign a document with the date you asked to withdraw. 
 
Your decision to withdraw your authorization for the research use and disclosure of your 
medical information will have no affect on your current or future medical care at the 
OSU-CHS-affiliated clinic or hospitals or your current or future relationship with a health 
insurance provider.  Your decision to withdraw this authorization will have no affect on 
your current or future relationship with the OSU-CHS.  
 
The investigators may continue to use and disclose your protected health information for 
the purposed described above for an indefinite period of time. 
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Voluntary Consent 
 
All of the above has been explained to me and all of my current questions have been 
answered.  Throughout my participation in this research study, I have been encouraged to 
ask any additional questions I may have about the research use and disclosure of my 
protected health information.  Such future questions will be answered by the investigators 
listed on the first page of this form.   
 
Any questions I have about my rights associated with the research use and disclosure of 
my medical information will be answered by Teri Bycroft at (918) 699-8643. 
 
By signing this form, I agree to allow the use and disclosure of my medical information 
for the purposes described above.  With this knowledge, I give my authorization and 
consent to the use and disclosure as described in this document to the people identified in 
this form.  A copy of this authorization form will be given to me. 
 
           
Participant’s Signature    Date 
   
VITA 
 
Melanie Ann Yuracko McKean 
 
Candidate for the Degree of 
 
Doctor of Philosophy 
 
 
Thesis:    DIFFERENTIAL GENE EXPRESSION OF EUTOPIC ENDOMETRIUM 
AND NORMAL PELVIC PERITONEUM IN WOMEN WITH AND 
WITHOUT ENDOMETRIOSIS 
 
Major Field:  Biomedical Science 
 
Biographical: 
 
Personal Data:  Born in St. Clair, Missouri, May 22, 1977, the daughter of Betty 
V. and John D. Yuracko.  Married to Christopher James McKean on July 
8, 2000.  Expecting first child in May, 2006. 
   
Education:  Received a Bachelor of Science in Biology and a minor in Women’s 
Studies from Truman State University, Kirksville, MO, in 1999; Doctor 
of Osteopathy degree to be conferred at Oklahoma State University 
Center for Health Sciences, Tulsa, Oklahoma in May, 2006.  Completed 
the requirements for the Doctor of Philosophy degree at Oklahoma State 
University Center for Health Sciences, Tulsa, Oklahoma in May, 2006. 
 
Professional Memberships:  Alpha Phi International Fraternity Alumnae 
 Association, American Medical Women’s Association, American 
 Osteopathic Association, Student Osteopathic Medical Association, Sigma 
 Sigma Phi National Osteopathic Service Honor Society, Oklahoma 
 Osteopathic Association, American College of Physicians, American 
 Psychiatric Association.  
   
Name: Melanie Ann Yuracko McKean                         Date of Degree: May 2006 
 
Institution: Oklahoma State University Center for Health Sciences         
 
Location: Tulsa, Oklahoma 
 
Title of Study: DIFFERENTIAL GENE EXPRESSION OF EUTOPIC    
  ENDOMETRIUM AND NORMAL PELVIC PERITONEUM IN   
  WOMEN WITH AND WITHOUT ENDOMETRIOSIS 
 
Pages in Study: 165                 Candidate for the Degree of Doctor of Philosophy 
Major Field: Biomedical Science 
 
Scope and Method of Study: To investigate differential gene expression in women with 
and without endometriosis.  Women already undergoing laparoscopic surgery 
were recruited as normal and potential endometriosis participants.  The normal 
participants were those women undergoing laparoscopic bilateral tubal ligation, 
and the endometriosis participants were those undergoing diagnostic laparoscopy 
to evaluate chronic pelvic pain.  Sample collection included an endometrial 
aspiration, normal pelvic peritoneum, peritoneal fluid, and endometriotic lesion 
(in those with endometriosis).  Total RNA was extracted from tissue samples and 
put through one round of amplification in the normal pelvic peritoneum studies.  
Human oligo microarrays with over 21,000 genes were utilized in the analysis.  
Pooled RNA from normal participants was hybridized against RNA from each 
endometriosis participant.  Microarray analysis was performed utilizing GenePix 
Pro and GenePix Auto Processor.  Microarray results were validated utilizing RT-
PCR. 
   
Findings and Conclusions:  Seven women with and seven women without endometriosis 
were utilized in the microarray studies.  In the comparison of gene expression in 
eutopic endometrium, 756 genes were found to be significantly up-regulated or 
down-regulated in the women with endometriosis versus a normal pool.  KEGG 
pathway analysis revealed genes involved in the following pathways: cell 
communication, MAPK signaling, cytokine-cytokine receptor interaction, cell 
cycle, TGF-beta signaling, focal adhesion, cell adhesion, and ECM-receptor 
interaction.  In the comparison of gene expression in normal pelvic peritoneum, 
202 genes were found to be significantly up-regulated or down-regulated in 
women with endometriosis versus those without.  These genes are involved in the 
following pathways: cytokine-cytokine receptor, cell cycle, focal adhesion, 
regulation of actin cytoskeleton, and leukocyte transendothelial migration. 
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